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Abstract 
Mechanistic target of rapamycin (mTOR) functions within a complex signalling 
cascade, through its activity in two unique complexes mTORC1 and mTORC2, to 
promote a multitude of different cellular functions including autophagy, protein 
synthesis and survival. The exact role of these complexes during leukaemia 
initiation/maintenance remains to be elucidated. Here, using transgenic 
knockout (KO) mouse models, we determine the individual roles of mTORC1 
(targeting Raptor) and mTORC2 (targeting Rictor) in normal haemopoiesis and in 
CLL initiation/maintenance. 
Our results demonstrate that mice carrying a targeted KO of Raptor at the 
haemopoietic stem cell (HSC) stage (Vav-Raptor KO) do not survive post birth. 
This is due to anaemia resulting from a significant decrease in Ter119+ 
population, a significant decrease in Klf1 and Klf2 gene expression, and a 
significant increase in the megakaryocyte-erythroid progenitor (MEP) population, 
suggesting a block at the MEP stage in Vav-Raptor KO foetal liver (FL). While 
mTORC1 plays a fundamental role in RBC development, we show that mTORC2 
plays a potential role in RBC regulation, as Rictor-deficient HSPCs exhibit an 
increase in RBC colony formation ex vivo. Conditional KO (cKO) of Raptor (Mx1-
Raptor cKO) in adult mice results in splenomegaly accompanied by increased 
spleen organ cellularity. Furthermore, there is a significant decrease in B cell 
lineage commitment, with a block in B cell development at the Lin-Sca-1+CD117+ 
(LSK) stage in the BM. mTORC2, on the other hand regulates late B cell 
maintenance as indicated by a significant decrease in transitional B cells 
(T1/T2), marginal zone progenitor (MZP), and follicular 1 (fol1) cells in Vav-
Rictor KO mice compared to controls. 
To address the role of mTORC1 and mTORC2 in CLL initiation/maintenance in 
vitro, BM-derived haemopoietic progenitor cells (HPCs) isolated from control 
(cre-), Raptor-deficient (Mx1-Raptor cKO) or Rictor-deficient (Vav-Rictor KO) 
mice were retrovirally-transduced with a kinase dead PKCα (PKCαKR) construct 
to induce an aggressive CLL-like disease. Raptor-deficient BM progenitors 
exhibited reduced proliferation and failed to generate a CLL-like disease, due to 
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a block in B cell lineage commitment in vitro. However, there was an increase in 
cell cycling and migration in PKCαKR CLL-like cells with Rictor-deficiency 
suggesting a role of mTORC2 in disease maintenance.  
To determine a role for mTORC1 in disease maintenance in vivo, NSG mice were 
transplanted with Mx1-Raptor control or Mx1-Raptor cKO PKCαKR transduced BM 
cells. Once disease was established in vivo, cKO was induced and disease load 
and progression was monitored. Our data demonstrate a decrease in disease load 
with Raptor cKO, together with a significant increase in survival. Additionally, 
host mice transplanted with CD19-Raptor KO PKCαKR cells exhibited a significant 
increase in survival. However, these mice eventually died of disease due to 
limitations of the KO model. 
Lastly, to test the translational capacity of mTOR inhibitors, efficiency of 
AZD2014 (dual mTOR inhibitor), ibrutinib and a combination of the two drugs 
was assessed in reducing PKCαKR CLL-like disease load in host mice. AZD2014 
was as efficient at reducing disease load as ibrutinib, however combination 
therapy of these drugs was not as efficient compared to single agents. 
Interestingly, we demonstrate that a more aggressive PKCαKR CLL-like disease 
(in secondary transplants) is more mTORC1 dependent than in primary 
transplants, as indicated by the superiority of rapamycin (allosteric mTORC1 
inhibitor) in markedly decreasing disease load as compared to AZD2014 in host 
mice. 
Taken together, mTORC1 plays an essential role in haemopoiesis, with Raptor-
deficiency causing a block in RBC and B cell development at the MEP and LSK 
stage respectively. In comparison, Rictor-deficiency regulates later B cell 
lineages and promotes RBC colony formation, potentially through mTORC1 
activation. Importantly, CLL-like cells lacking mTORC2 have increased cell 
cycling and migration whereas mTORC1 deficiency causes a decrease in disease 
load. Therefore, mTORC1 and mTORC2 play distinct/complementary roles in 
haemopoietic development and leukaemia initiation/progression. These studies 
provide a strong foundation for further studies testing novel mTOR inhibitors for 
CLL in our models. 
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1 Introduction 
1.1 Early Haemopoiesis: 
Murine haemopoiesis initially occurs in the yolk sac and in two waves, the first of 
which is known as ‘primitive’ haemopoiesis. At this stage de novo 
haemangioblasts are generated and produce large quantities of erythrocytes to 
promote increased oxygenation, accommodating rapid growth. During the second 
wave of haemopoiesis or ‘definitive’ haemopoiesis, haemopoietic stem cells 
(HSCs) appear in the aorta-gonad-mesonenphros (AGM) region around embryonic 
day 10 (E10)(1). From E11, HSCs migrate to and colonise the foetal liver (FL) and 
subsequently the bone marrow (BM) with waves of repopulating HSCs that 
provide a continuous source of mature haemopoietic lineage cells during the 
adult life span. The nature of the HSCs differ depending on the 
microenvironmental niche, with HSCs in the BM being more quiescent than those 
in the FL(2,3). HSC differentiation into multipotent progenitor (MPP) cells occurs 
mainly in the FL prior to migration into specific haemopoietic organs, such as the 
thymus, for further lineage differentiation. Conventionally, MPPs give rise to 
oligopotent common myeloid or lymphoid progenitors (CMPs or CLPs). CMPs 
further give rise to megakaryocyte-erythroid progenitors (MEP) and granulocyte-
macrophage progenitors (GMP), while CLPs give rise to lymphoid lineage cells(4). 
Nevertheless, there exists an alternate hierarchical model of haemopoiesis 
where MPPs give rise to lymphoid-primed multipotent progenitors (LMPPs) which 
have also been shown to develop into GMP myeloid progenitors but carry a 
lymphoid generation bias(5,6). It has previously been demonstrated, that the 
Lin-Sca1+cKit+ (LSK) HSC compartment of cells express high levels of CD34, Flt3 
and IL7, are able to sustain the granulocyte, monocyte, B and T cell lineages. 
However, they lose megakaryocyte and erythrocyte potential (7,8). It is the 
further expression of C/EBPα and EBF1 which supports a myeloid and B cell 
lineage fate respectively (9).  
As they get primed towards a lymphoid lineage, they lose the myeloid lineage 
generation capacity and develop into CLPs (Figure 1.1). 
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Figure 1.1 Diagram showing the hierarchy of haemopoietic cell differentiation.  
Haemopoietic stem cells (HSCs) give rise to multipotent progenitors (MPPs) which either develop 
into common lymphoid progenitors (CLPs) or common myeloid progenitors (CMPs). Literature also 
alludes to a lymphoid-primed multipotent progenitor (LMPP) population which is lymphoid primed 
(gives rise to CLPs) but capable of generating megakaryocyte-erythrocyte progenitors (MEPs) and 
granulocyte-macrophage progenitors (GMPs) giving rise to myeloid and erythroid lineages. CMPs 
further give rise to MEPs and GMPs whereas CLPs give rise to lymphoid lineages including B, T, 
and NK cells. Dashed arrows suggest alternative routes of haemopoietic differentiation. 
 
 4 
 
1.2 Erythropoiesis 
Erythropoiesis is governed by the complex regulation of key transcription factors 
(TFs), which enable a balance between erythrocyte progenitors and 
erythroblasts enabling self-renewal and differentiation. The zinc-finger TFs(4) 
Gata1 and Gata2 play critical and non-redundant roles during erythroid 
maturation. Gata2 is expressed in HSCs and early progenitor populations 
regulating the expression of self-renewal genes, in addition to genes responsible 
for initiating Gata1 expression. GATA1 plays a vital role in erythroid 
differentiation, sustaining its own expression and suppressing GATA2 expression, 
a process known as GATA factor switching(10). Gata1-deficient (Gata1-/-) mice in 
murine embryos gave rise to lymphoid cells and non-haemopoietic tissues but 
failed to give rise to a mature erythroid population, resulting from a block at the 
pro-erythroblast stage due to increased apoptosis. McIver et al., have 
demonstrated that Foxo3 and Gata1 co-operativity represses exosome complex 8 
(Exosc8) expression thereby promoting erythroid maturation. Exosc8 is a vital 
component of the exosome machinery responsible for epigenetic regulation and 
RNA surveillance(11). Recently, IKAROS, a zinc-finger protein has been shown to 
play a role in foetal and adult erythropoiesis and erythroid lineage commitment 
as Ikaros gene silencing leads to an irreversible switch to myeloid lineage(12). 
Pu.1 TF is an established master regulator in haemopoiesis as it is one of the key 
genes involved in primitive cell fate decisions. Pu.1 expression levels determine 
myeloid and lymphoid cell fates where higher expression of Pu.1 leads to 
myeloid cell fate whereas a lower expression to a lymphoid fate(13). 
Additionally, a myeloid cell fate is not solely regulated by Pu.1 expression but 
also the inhibition of Gata1(14) and the expression of Cebpα (15). Cebpa is 
considered essential for myeloid fate by binding and transcribing genes 
associated with myelopoiesis at the long-term haemopoietic stem cell stage (LT-
HSC) stage(16). 
PU.1 and GATA1 interact to regulate lineage fate where upregulation of Gata1 
inhibits Pu.1 transcription and promotes erythroid lineage(17) differentiation 
whereas expression of Pu.1 inhibits Gata1 expression promoting myeloid lineage 
fate(18). Gata1 is known to be a very potent TF as it binds to the promoter 
region of erythroid-Krüppel like factor/ Krüppel like factor 1 (e-Klf/Klf1)(19). 
Klf1 TF is vital for erythropoiesis as it regulates MEP lineage fate during 
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erythrocyte development. Klf1 expression has been shown to promote CD71 
surface expression, which leads to the development of the earliest pro-
erythroblasts (proE). These cells are nucleated and have oxygen carrying 
capacity and circulate in the embryo. These cells then develop into definitive 
erythroblasts (EryD) which is marked by enucleation. CD71, a transferrin 
receptor, is known to be expressed at all embryonic stem (ES) cells and proE 
cells(20). Nevertheless, during maturation, proE cells undergo ‘maturational 
globin switching’ leading to reduced CD71 expression and erythrocyte 
maturation. TER119, on the other hand is associated with glycophorinA (GlyA) 
and is correlated with maturing erythrocytes(21). Together, CD71 and TER119 
are widely used in flow cytometry to determine the developing stages of 
erythrocytes: EryA, EryB and EryC stages. TER119loCD71hi population is 
considered as the proE stage. Subsequent populations which express 
TER119+CD71+FSC-Ahi are considered to be in the EryA stage as these populations 
are larger as they are nucleated. Subsequent enucleation reduces the size and 
therefore the forward scatter-area (FSC-A) in flow cytometry and EryB 
populations are CD71+TER119+. Lastly, maturation of erythrocytes is marked by a 
reduction in CD71 expression which are considered TER119+ EryC cells(22).   
‘Maturational globin switching’ also involves the ‘globin switching’ from γ- to β-
Globin for the maturation of erythrocytes via Klf1 activity(23). In human 
haemopoietic development, β-GLOBIN is expressed when erythropoiesis moves to 
the BM. Initially, the yolk-sac expresses ε-GLOBIN, followed by the expression of 
γ-GLOBIN in the FL and spleen. Therefore, Klf1 mediated β-GLOBIN expression is 
vital for the development of mature erythrocytes(24). Whilst Klf1 plays a major 
role in erythropoiesis, Klf2 plays a role in endothelial growth, vascular 
remodelling and inflammation responses(25), which is vital for embryonic 
development. 
1.3 B1 B cells and B2 B cells 
B1 B cells were originally given this name as they were thought to appear earlier 
in ontogeny compared to B2 B cells. B1 B cells secrete majority of the IgM and 
play a vital role in pathogen-induced immunity. B1-a B cells express surface CD5+ 
whereas B2 cells lack CD5, a marker initially only thought to be specific for T 
cells(26). Nevertheless, there also exist CD5- B1 cells termed B1-b cells which 
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have similar phenotypes to B1-a cells. B1 B cells are thought to be ‘rarer’ and 
are not considered the ‘conventional’ B cells. B1 B cell heterogeneity is not 
restricted to CD5 expression, and different populations within B1 B cells have 
been identified, wherein increased levels of B cell receptor (BCR) signalling 
induced antigen-presenting cells (APCs) whereas other subtypes had a 
diminished BCR signalling alluding to cell quiescence(27).  
B1 B cell precursors are considered to originate in the FL, whereas B2 precursor 
cells are said to originate in FL which later moves onto the BM after birth. 
However, B1 B cell generation has been shown in other-haemopoietic regions 
such as the blood island yolk sacs in the embryo, in the FL and in the BM after 
birth. Nevertheless, these B1 B cell pools in the BM do not contribute to B1 B 
cell development after 3-6 wk of birth(28) supporting previous work highlighting 
B1 B cell lineage to be a foetal/neonatal developed population. It also suggests 
that this population is maintained by self-renewal in the BM and not by de novo 
development.  
Therefore, from hereon, B cell development and other aspects of B cells 
presented will refer to the ‘conventional’ B cell population – B2 B cells. 
1.4 B cell development 
B cells are a subtype of lymphocytes involved in the humoral immunity in the 
adaptive immune response of the body. B cell development comprises several 
phenotypic stages enabling B cell lineage commitment/maturation from HSCs 
initially in the FL during embryogenesis and then in the BM.  
1.4.1 TFs involved in B cell development 
Pu.1 is a vital TF most likely expressed during the MPP stage and is vital for 
determining lineage fate. Playing a role in lineage fate decisions between 
erythroid and myeloid lineages as seen in section 1.2, the graded expression of 
this TF has shown to determine B cell fate as high expression of Pu.1 has shown 
to bias a myeloid lineage and lower expression of Pu.1 has shown to bias to a B 
cell lineage(29). 
 7 
 
Flt3 expression is present at the MPP stage and plays an important role in 
deciding B cell fate. Nevertheless, constitutive Flt3 expression at later stages 
abrogates B cell development alluding to the importance of paired-box-protein 5 
(Pax5) mediated repression of Flt3. Indeed expression of Flt3, IL7 is essential for 
B cell development, mediated by Ikaros TF(30). Additionally, transition from the 
LMPP to the CLP phase is associated with an increase in IL7-receptor α (Il7Rα) 
expression as Il7R-deficient mice have a block in B cell development at the pre-
proB cell stage suggesting Il7R expression is vital in initiating immunoglobulin 
(Ig) rearrangement(31,32).  
IKAROS has shown vital roles for B cell development as Ikaros-deficiency has 
shown to block B cell development at the pre-proB cell stage. Ikaros-deficiency 
has also shown to regulate Il7-Rα and Flt-3 expression as Ikaros knockout (KO) 
leads to a decreased expression of these proteins suggesting the expression of 
both these proteins is vital for B cell development(33). Il7Rα has been shown to 
promote the expression of early B-cell factor 1 (Ebf1) further highlighting the 
importance of IKAROS in normal B cell development(34). 
E12 and E47 are helix-loop-helix proteins which comprise E2A. E2A TF is 
essential for lymphoid lineage development as it promotes the expression of 
Ebf1. Indeed, mice lacking Ebf1 did not undergo Ig recombination suggesting the 
importance of the expression of this gene to induce the transition from the pre-
proB to proB cell stage (35). E2A interactions with EBF1 induce Pax5 expression, 
which positively regulates Ebf1 expression along with E2A(32). Interestingly, it 
has also been shown that E2A interactions with Forkhead box O1 (Foxo1) (via the 
mTOR-AKT signalling pathway) together with E2A-Ebf1 interactions induce Pax5 
expression (36). Pax5 expression encodes various components responsible for the 
transition from pre-proB to preB cells by aiding pre-BCR expression. It also 
promotes expression of co-receptors CD19 and CD21(30). Pax5 has shown to 
negatively regulate Flt3 expression, as constitutive expression of Flt3 is 
associated with impaired B lymphopoiesis, highlighting internal mechanisms of 
regulating B cell development(37). E2A-FOXO1 interactions have been shown to 
activate Rag1 and Rag2, the main drivers of VDJ recombination and therefore Ig 
rearrangement and transition from the preB cell stage to the immature B cell 
stage(38). 
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Figure 1.2 Diagram showing the summary of B cell development.  
HSCs develop into MPPs which give rise to LMPPs which, under the appropriate signals, develop 
into CLPs, enabling B cell development. Pre-proB cells give rise to proB cells due to the 
interactions of E2A and Ebf1 and E2A and Foxo1. These TFs induce Pax5 expression, promoting 
CD19 expression and RAG1/2 expression, and subsequent IgVH re-arrangement. Functional VDJ 
re-arrangement leads to the maturation of the pre-BCR complex to a BCR complex and the 
development of preB cells into immature B cells. These cells then migrate into secondary lymphoid 
organs to further mature into different B cell subtypes via transitional 1, 2, and 3 stages (T1-3). 
These give rise to mature B cells subtypes including marginal zone (MZ) follicular 1 (fol1), fol2 B 
cells. 
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1.4.2 Developmental stages 
At the CLP stage, stem cell factor (SCF) is released from the stromal cells in the 
microenvironment, binding to its receptor CD117 on early B cell precursors (39). 
Lymphoid precursors express CD117 and IL7Rα and are capable of developing 
into B, T or natural killer (NK) cells, but not erythrocytes/myeloid lineages. 
After the CLP stage, the earliest B cell precursors express B220, along with early 
NK cells. However, these lineages can be separated using other surface markers 
such as AA4.1, which is expressed on B cells up to the immature stage (31,40). 
1.4.2.1 Early B cell development 
It is after Pax5 expression which promotes sequential recombination of the Ig 
gene segments of the heavy and light chains, forming the platform for B cell 
development. This functional rearrangement comprises the VDJ gene segments 
of the heavy chain (µ locus) and the VJ segments of the light chain (κ locus) 
initiated by recombination-activating genes 1 and 2 (Rag1 and Rag2). Functional 
rearrangement of these genes enables the cell to generate antibodies which 
recognise various cell specific antigens. The rearrangement pattern of the Ig 
heavy chain (IgH) gene segments is associated with distinct stages of B cell 
development – pre-proB cell, proB, preB cells (Figure 1.2, Figure 1.3). B 
precursors with no rearrangement are in the pre-proB cell stage. The  
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rearrangement of DJ segments in the H chain is correlated with the proB cell 
stage. Mb1 expression at the proB cell stage is vital for Ig rearrangement as Mb-1 
encodes the Ig-α subunit, deficiency of which leads to BCR deficiency(41). CD19 
expression is also expressed at the proB cell stage, under the regulation of Pax5. 
V chain addition to the DJ segment(42) marks the large preB cell stage. CD19 
expression is marked by BCR dependent and independent events. CD19 interacts 
with the BCR to enhance BCR activity. 
Figure 1.3 Diagram showing stages of early B cell development in the bone marrow along 
with table summarizing various stages of early B cell development including phenotype 
(surface markers) and events in the pre-proB cell, proB cell, preB cell and immature B cell 
stages. 
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1.4.2.2 Late B cell development 
Figure 1.4 Diagram showing stages of late B cell development in the spleen along with table 
summarizing various stages of early B cell development including phenotype (surface 
markers) and events in the transitional (T-3), marginal zone progenitor (MZP)/MZ, follicular 1 
(fol1) and fol2 B cell and B1 B cell stages. APC – antigen-presenting cells. 
 
After immature B cell development, the cells undergo one of three processes 
dependent on Ig interactions. Cells which undergo cross-linking of the BCR 
leading to high affinity interactions are associated with elimination via clonal 
deletion (negative selection). Low affinity interactions lead to non-responsive 
anergic cells which are short lived, or it could also lead to cells editing their BCR 
to become non-reactive(43). All other immature B cells, expressing surface 
bound IgM, migrate into the spleen where they mature into naïve, follicular (fol) 
or marginal zone (MZ; CD19+CD21hiCD23-IgMhi) B cells via transitional phases (T1-
T3). Cariappa et al., have shown there to be a transition from T1 
(CD19+CD21intCD23-IgMhi) to T2 (CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMhi) cells 
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which develop into fol2 B cell populations. Fol2 B cells give rise to MZ 
progenitors (MZP; CD19+CD21hiCD23+CD1dhi) and ultimately MZ B cells together 
with fol1 cells. Nevertheless, T1 cells also transition to T3 cells to give rise to 
fol1 cells (44). Association of Toll-like receptor (TLR) signalling together with 
pattern-associated molecular patterns (PAMPs) leads to MZ B cell development 
into IgM plasma cells forming the first line of innate immunity against 
pathogens(45). Fol1 B cells (CD19+AA4.1-CD21loCD23+CD1dintIgDhiIgMlo) form the 
bulk of the circulating population whereas fol2 cells (CD19+AA4.1-
CD21loCD23+CD1dintIgDhiIgMhi) form one-third of the circulating population, being 
more quiescent and considered to be more primitive(44) residing in B cell 
follicles (Figure 1.2, Figure 1.4). It is the interaction of T helper (Th) cells with 
these fol B cells which leads to the expansion of B cells comprising the germinal 
centres (GCs) in secondary lymphoid organs(45). CD19 expression is vital for the 
maintenance of peripheral B cells as CD19-null mice have shown to have 
decreased survival compared to normal B cells. This maintenance is partially via 
the BCR/B cell lymphoma-2 (Bcl-2) axis, as increasing Bcl-2 expression in CD19-
null mice rescued MZ and fol B cell generation(46). Phosphoinositide 3-kinase-
delta (PI3Kδ) expression is restricted to B and T cells and has shown to play a 
role in late B cell development. PI3Kδ-null mice show block in B cell 
development at the preB cell stage. It has been shown that PI3K expression is 
regulated by pre-BCR signalling, and PI3K isoforms, p110α and p110δ, modulate 
Pax5 expression, absence of which arrests B cell development at the preB cell 
stage(47), making PI3Kα and PI3Kδ redundant for early B cell development. 
PI3Kδ has shown to be vital for late B cell development, particularly for MZ 
cells(48,49). There is a significant reduction in MZ B cells with PI3Kδ-deficiency 
due to reduced CXCR5 mediated migration(50) as PI3Kδ-deficient mice have a 
reduction in MZ B cell homing into proliferative centres suggesting a role of 
PI3Kδ in MZ B cell maturation and homing capacity. 
1.5 mTOR signalling pathway 
The BCR signalling pathway regulated B-cell proliferation and survival and it is 
known for its crosstalk between other signalling pathways including MAPK, NFκB 
and mTOR signalling pathways. BCR engagement leads to the phosphorylation of 
tyrosine residues located on immunoreceptor tyrosine-based activation motifs 
(ITAMs) of CD79a and CD79b by protein tyrosine kinases including Lyn, Syk. 
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Through this, downstream proteins including BCAP and BLNK are activated(51). 
Additionally, CD19 engagment is vital for BCAP binding pf p85 which is essential 
for the PI3K phosphorylation(52). Moreover, CD19 is a surface protein, co-
ligation of which to the BCR, is known to modulate BCR signalling positively and 
negatively by attenuating PI3K activity(53). BLNK is responsible for PLCy1, VAV 
and BTK, whereas BCAP is responsible for the activation of PI3K, downstream 
which, is the mechanistic target of rapamycin (mTOR) signalling pathway. 
mTOR is a serine/threonine kinase, which is involved in various signalling 
pathways regulating metabolism. mTOR, as the name suggests, is targeted by 
rapamycin which is an anti-fungal macrolide first characterised in Streptomyces 
hyroscopicus. Due to the anti-proliferative properties of rapamycin, extensive 
research was carried out on this and TOR was then discovered. Its consequent 
purification in mammals also showed the vast application of TOR in mammals, 
known as the mTOR signalling pathway(54). It is involved in protein synthesis, 
mitochondrial function, autophagy, cytoskeleton organisation, and cell survival 
mechanisms. However, how mTOR signalling is regulated is not fully understood.  
The mTOR pathway is activated by a variety of signals including insulin/insulin 
growth factors (IGF), glucose, amino acid, tumour necrosis factor (TNF) and BCR 
signalling ( Figure 1.5). mTOR belongs to the PI3K family and it forms two 
different complexes – mTORC1 and mTORC2. mTORC1 comprises of 6 proteins 
and mTORC2 of 7 proteins. Of these, they share the common mTOR subunit, 
along with GβL, DEPTOR, TTI1/TEL2 complex. The subunits which make the 
respective complexes unique are RAPTOR (rapamycin TOR sensitive), PRAS40 
which are specific to mTORC1 and RICTOR (rapamycin TOR insensitive), mSIN1, 
and PROTOR1/2 specific to mTORC2(55). The complexes, RAPTOR and RICTOR 
are what make mTORC1 and mTORC2 sensitive or insensitive to rapamycin 
respectively(56).  Rapamycin is an allosteric inhibitor of mTORC1, as recent co-
crystal structures of mTOR-mLST8 show that rapamycin binds to the FKBP-
Rapamycin binding (FRB) domain thereby highly recessing the active site(57). 
Therefore, it is responsible for partial, not full mTORC1 inhibition. 
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Figure 1.5 Diagram of the AKT/mTOR signalling pathway. 
Downstream signalling from the B cell receptor (BCR) and growth factor receptors is shown. 
Activation of these receptors results in phosphorylation and activation of AKT, which leads to the 
activation of mTORC1 (PRAS40, RAPTOR), thereby initiating cell processes such as protein 
synthesis and proliferation. The downstream target of mTORC1, S6K negatively regulates 
mTORC2 (PROTOR1/2, mSIN1, RICTOR), which is responsible for the activation of AKT. This 
creates a negative feedback loop, which regulates this pathway. mTORC1 and mTORC2 share the 
subunits mTOR, GβL, DEPTOR and TTI1/TEL2 (not shown). AKT negatively phosphorylates 
FOXO1/3, which regulates cell cycle. Kinases such as AMPK are activated in stress responses and 
inhibit the mTORC1 pathway. Allosteric inhibitors such as rapamycin and other rapalogs partially 
inhibit mTORC1 activity whereas ATP competitive inhibitors such as AZD2014 are pan mTOR 
inhibitors. Abbreviations: PLC (Phospholipase C), BLNK (B-cell linker protein), BTK (Bruton’s 
tyrosine kinase), BCAP (B-cell adaptor for PI3K). 
 
Rapamycin has similar structure to FK506 which blocks Ca2+/calcineurin 
dependent signalling in T cells required for growth and proliferation. Rapamycin 
on the other hand binds to FKBP12 and inhibits mTORC1 activity by blocking the 
cytokine signalling required for growth. 
The upstream mediator of mTOR is PI3K ( Figure 1.5). PI3K can bind to Insulin 
receptor substrate proteins (IRS) and converts phosphatidylinositol-4,5-
 15 
 
phosphate (PIP2) to phosphatidylinositol-3,4,5-phosphate (PIP3). Phosphatase and 
tensin homolog (PTEN), a tumour suppressor, blocks PIP3 accumulation and PIP3 
phosphorylates and activates 3-phosphoinositide-dependent protein kinase 1 
(PDK1) and AKT. AKT then activates mTORC1 via the inhibition of the tuberous 
sclerosis proteins TSC1 and TSC2. They form a heterodimer and inhibit RHEB 
which then binds to mTORC1 causing conformational changes in the protein and 
activation(58). However, whether RHEB binds and activates mTORC2 has not 
been determined. 
1.5.1 mTOR signalling and its functions 
1.5.1.1 mTORC1 signalling:  
RAPTOR binds mTOR to enhance its’ activity, as indicated by the finding that 
RAPTOR inhibition using RNAi, leads to decreased mTOR activity(59). In a low-
energy state (low ATP:AMP ratio), AMPK, a conserved energy sensor, is activated 
leading to TSC2 phosphorylation and the subsequent inhibition of mTORC1 
activity(60). However, in a high-energy state, the mTORC1 pathway is activated, 
promoting protein synthesis, lipogenesis and mitochondrial biogenesis and 
function(8-11). Indeed, mTORC1 plays a pivotal role in mitochondrial oxidative 
function through regulation of the transcription factor yin-yang1 (YY1), which 
subsequently controls gene expression of mitochondrial transcriptional 
regulators including PGC-1(10). Additionally, mTORC1 controls mitochondrial 
biogenesis and respiration through phosphorylation/inhibition of the eukaryotic 
initiation factor 4E (eIF-4E) binding proteins (4EBPs) and regulation of the 
translation of nucleus-encoded mitochondrial-related mRNAs, which in turn 
increases ATP generation in the cell(11) ( Figure 1.5). In the absence of mTORC1 
activity, 4EBP1 is hypo-phosphorylated and interacts with the mRNA cap binding 
protein eIF-4E, inhibiting translation of cap-dependent proteins. Upon mTOR 
activation, hyper-phosphorylation of 4EBP1 releases eIF-4E, enabling its 
association with eIF-4A (RNA helicase) and the scaffolding protein eIF-4G to form 
the eIF-4F complex. The mTORC1-eIF-4E pathway is upregulated in most cancers 
and thus represents an attractive therapeutic target(61).  
mTORC1 also phosphorylates/activates S6 Kinase 1 (S6K1) at T389, which was 
initially thought to play a role in protein/ribosomal biogenesis by activating 40S 
 16 
 
ribosomal protein. However, it is now appreciated that S6K1 is important in a 
number of mechanisms, together with S6K2, including transcription, cell 
proliferation, apoptosis and potential mRNA splicing(62). S6K phosphorylates 
programmed cell death 4 protein (PDCD4) at S67 targeting it for proteosomal 
degradation(63). PDCD4 is a tumour suppressor responsible for inhibiting eIF-4E. 
Moreover, a recent study in a colorectal cancer model shows that S6K 
phosphorylates and inhibits elongation factor-2 kinase (EF2K), in turn relieving 
EF2K inhibition of EF2 and thus elongation of nascent polypeptide chains(15). 
S6K also plays a role in actin organisation by the direct binding to F-actin. A role 
in cytoskeletal rearrangement is also seen as S6K activates Rho family members 
regulating this - CDC42 and RAC1 and their downstream target PAK1. As deletion 
of S6K leads to a decrease in activation of the Rho family members, cytoskeletal 
organisation and migration in ovarian cancer cells, S6K is a promising target for 
enabling reduction of tumour progression(64). An additional target of S6K1 is 
RICTOR(65), which when phosphorylated at T1135, leads to mTORC2 inhibition, 
establishing a negative feedback loop between mTORC1 and mTORC2(66). 
1.5.1.2 mTORC2 signalling 
AKT can be considered the hub of the PI3K pathway as its downstream signalling 
leads to mechanisms controlling a multitude of diverse functions within the cell. 
AKT is only activated in response to receptor signalling via phosphorylation of 
two key sites, T308 by PDK1 and S473 by mTORC2, via growth factor (GF) 
receptor activation(67). The majority of mTORC2 functions occur through AKT 
regulation, including activation of mTORC1, placing AKT both upstream and 
downstream of mTOR regulation. During low-energy conditions, AMPK activation 
leads to an upregulation of mTORC2 and its downstream targets(68). Such 
downstream targets include the FOXO family of transcription factors, which are 
phosphorylated by AKT leading to an inhibition of their function. FOXOs play an 
important role in the repression of cell proliferation and survival, but in certain 
cell contexts are considered to play a role in tumorigenesis(69). FOXOs regulate 
apoptosis in distinct ways, repressing apoptosis through the downregulation of 
the pro-apoptotic BCL-2 family member BIM, or promoting apoptosis through 
transcriptional upregulation of FAS ligand(70). mTORC2-FOXO1 signalling also 
regulates innate immune responses as RICTOR deletion leads to attenuated AKT 
signalling, thereby increasing nuclear FOXO1, resulting in hyper-inflammatory 
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responses via TLR4(71). mTORC2 has been shown to localise at the mitochondria-
associated endoplasmic reticulum membranes (MAM) in a GF-dependent manner, 
and RICTOR deletion disrupts AKT-dependent phosphorylation of mitochondria 
associated proteins. These events lead to a reduction in mitochondrial function, 
increasing mitochondrial membrane potential and effecting energy metabolism 
and cell survival, thereby demonstrating a vital role of mTORC2 signalling in 
mitochondrial physiology(25). The importance of mTORC2 in AKT activation was 
highlighted by a recent study demonstrating that deletion of the AKT binding site 
within the mTORC2 component mSIN1 greatly reduced AKTS473 phosphorylation, 
rendering it unable to phosphorylate FOXO1/3a, while other targets such as 
glycogen synthase kinase 3 (GSK3) and mTORC1 were unaffected(72) (73). These 
findings suggest that mTORC2 activation is important for AKT-mediated cell 
survival mechanisms.   
Further downstream targets of mTORC2 include protein kinase C-alpha (PKC) as 
mTORC2 inactivation reduced PKC phosphorylation(74), which is responsible for 
functions including cell proliferation, differentiation, motility, apoptosis and 
inflammation(75). mTORC2 also regulates growth and ion transport by 
phosphorylating the hydrophobic motif of serum and glucocorticoid-induced 
protein kinase 1 (SGK1)(76). SGK1 inhibition induces autophagy, apoptosis and 
cell cycle arrest in the G2/M phase in prostate cancer cell lines, at least in part 
through an mTOR-FOXO3a-mediated pathway(31). SGK1 regulates Th2 
differentiation and negatively regulates interferon gamma (IFN) production, 
thereby highlighting the importance of mTORC2 in T cell effector function(77). 
mTORC2 has also shown to play a role in cytoskeletal organisation by activating 
RhoA GTPases(78). 
1.5.2 mTOR in embryogenesis 
The mTOR complexes are essential for cell survival and growth, and studies 
generating KO mice established that mTOR kinase and individual complexes 
mTORC1/2 were essential for normal embryogenesis(79,80). A homozygous KO of 
mTOR (mTOR-/-) resulted in the death of mouse embryos soon after implantation 
(E5.5-6.5). Despite normal blastocyst development, the embryo did not develop 
further due to limited cell proliferation and survival signalling. Nevertheless, 
mTOR+/- mice developed fertile and normal embryos. Similarly, Raptor-/- 
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embryos die during early development (E7) whereas the Rictor-/- mice survived 
slightly longer (E10.5)(80). These studies indicate mTOR function is mediated 
mainly through mTORC1 during early embryogenesis, but both mTORC1/2 play 
critical roles. 
1.5.3 mTORC1 and mTORC2 signalling in HSCs/HSPCs 
Targeted deletion of mTORC1 and/or mTORC2 in mouse models demonstrate a 
critical role for the mTOR pathway in haemopoiesis and highlight the importance 
of the individual mTOR-containing complexes at specific stages of HSC 
homeostasis and haemopoietic lineage commitment and maturation, as discussed 
below. 
1.5.3.1 HSCs 
Conditional knockout (cKO) mouse models of PTEN and TSC1, upstream negative 
regulators of mTORC1 in HSCs, revealed an increase in short-term HSC cycling 
and a concomitant decline in LT-HSC quiescence and self-renewal through 
constitutive activation of mTORC1(81,82). TSC1-/- in HSCs led to an elevation in 
mitochondrial biogenesis, resulting in increased reactive oxygen species (ROS) 
production, driving HSCs from quiescence to rapid cell cycling thereby reducing 
self-renewal capacity(83). These studies identify the importance of mTOR 
regulation in HSC quiescence through ROS regulation. Interestingly, similar 
findings were reported in mTOR cKO mice, in which BrdU labelling revealed 
rapid cell cycling in HSC leading to a loss of quiescence and defective HSC 
engraftment and repopulation upon transplantation into NSG mice(84). Recent 
studies establish crosstalk between the extracellular regulated mitogen 
activated protein kinase (ERK) and mTOR signalling pathways, with ERK activity 
regulating mTORC1 activation, thus limiting its strength to promote HSC cycling 
in favour of quiescence. Indeed, HSCs derived from MEK1 cKO mice exhibit 
exhaustion due to increased mTORC1-mediated ROS production resulting in 
increased mitochondrial damage(85). These studies identify the importance of 
precise mTOR regulation during HSC maintenance and haemopoiesis. 
The WNT signalling pathway can activate the mTOR pathway by inhibiting GSK3-
mediated phosphorylation of TSC2 independently of -catenin transcription. 
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GSK3 inhibits mTOR activation by phosphorylating TSC2 in a manner coordinated 
by AMPK (86). Knockdown (KD) of Gsk-3 disruption initially resulted in an 
increase in LSK populations due to an activation of both WNT-signalling (-
catenin dependent) and mTOR pathways. However, long-term disruption of GSK3 
expression/activity led to a depletion of HSC populations due to mTOR 
activation, which could be reversed through inhibition of mTORC1 and -
catenin(87). Inhibition of the mTOR pathway together with activation of the 
WNT--catenin pathway led to increased LT-HSC numbers and the potential to 
culture HSCs ex vivo in a cytokine free environment, highlighting the importance 
of appropriate regulation the WNT and mTOR signalling pathways in stem cell 
renewal(88). 
Reduction in signalling downstream of mTOR enhances HSC self-renewal and 
repopulating properties: mice lacking S6K1(89) or mice treated with rapamycin, 
a partial mTORC1 inhibitor(90), exhibit increased life- and health-span compared 
to controls due to an increase in repopulating LT-HSCs. Collectively, these 
findings suggest that the loss in mTOR function during haemopoiesis primarily 
represents a loss of mTORC1 activity, with mTORC2 not playing a key role in 
HSCs.  
1.5.3.2 Haemopoietic stem/progenitor cell (HSPCs):  
Assessing the role of mTOR on haemopoietic lineage commitment using an mTOR 
cKO model in adult mice revealed significant aberrations in the development of 
haemopoietic lineage populations, resulting in a reduction of splenic weight and 
size. Closer analysis revealed that mTOR disruption led to pancytopenia, 
including a block in erythrocyte development at the pro-erythroblast stage, and 
anaemia(84). The decline in haemopoietic lineage commitment was 
accompanied by increased apoptosis and decreased myeloid cell leukaemia 1 
(MCL-1) expression. Within BM HPC populations, there was a skew towards CMPs 
and a decrease in CLPs in mTOR-deficient mice. While there was an increase in 
the LSK population, the colony forming ability of these LSKs was impaired. There 
was also an attenuation in S6K and 4EBP1 phosphorylation/ activation and 
increased phosphorylation of AKT, implicating an aberration in the S6K-mediated 
negative feedback loop regulation of mTORC2 activity(66,84).  
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The mTORC1 cKO model (Mx1-cre+Raptorfl/fl; Mx1-Raptor cKO) exhibited an 
increased LSK population in the spleen in addition to the BM, suggesting 
extramedullary haemopoiesis. The LSKs were arrested at the G1 phase of cell 
cycle compared to controls, suggesting a reduction in cell division(91). 
Metabolite analysis of LSKs revealed an increase in intermediates used in lipid 
metabolism, and in AMP and NADP+ involved in redox homeostasis, and a 
decrease in nitrogen metabolism(91). LSK-CD48−CD150+ cells derived from the 
Mx1-Raptor cKO BM failed to engraft into recipient mice. While these cells were 
able to home to the BM, they localized further from osteoblast cells, indicating a 
role for mTORC1 in the integration of niche signals. Mx1-Raptor cKO HSCs also 
possessed regenerative and self-renewal aberrations compared to controls and 
those cells that ‘escaped deletion’. A compound Rictor/Raptor cKO in adult 
mice exhibited similar results as Mx1-Raptor cKO mice in haemopoiesis, however 
this mouse model did not develop BM failure and retained the deletion of alleles 
of Raptor and Rictor for almost one year after KO induction(91). These results 
suggest that the mTOR pathway is not essential for survival and haemopoietic 
maintenance in adult mice but is essential for haemopoiesis initiation during 
embryonic development.  
Genetic targeting studies to ablate mTORC2 function in haemopoiesis revealed a 
more subtle role compared to mTORC1. Studies in Mx1-Rictor cKO (Mx1-cre+ 
Rictorfl/fl) mice indicated that mTORC2 does not play a significant role in HSCs 
and progenitor populations(92). However, Magee et al., elegantly demonstrated 
that after Pten-deletion, which activates the mTOR-signalling pathway, deletion 
of Rictor abrogates leukemogenesis and HSC depletion in adult, but not neonatal 
mice(93), highlighting that the PTEN-mTORC2 signalling axis has a role in 
activating these processes in a temporally-dependent manner. 
1.5.4 mTORC1 and mTORC2 signalling in Erythrocytes 
The mTOR cKO model revealed a block in erythropoiesis at the proE stage, 
highlighting the importance of mTOR signalling in red blood cell (RBC) 
development(84). Interestingly, results from this model are similar to that 
observed in the Tsc1 cKO mouse, which exhibited a reduction in erythrocytes in 
the BM(82), through activation of mTORC1-mediated signalling. These studies 
indicate that a complex regulation of mTOR signalling is required for appropriate 
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RBC development. Analysis of the importance of mTOR function in erythropoiesis 
revealed that loss of FOXO3 in erythroblasts results in an overactivation of the 
mTOR pathway thereby compromising erythroid maturation(94). FOXO3 regulates 
Gata1 expression and represses Exosc8 expression which are both involved in 
erythroid maturation(95). Additionally, ectopic expression of microRNA9 (miR9) 
disrupts erythropoiesis via the suppression of FOXO3-mediated pathways, causing 
an increase in ROS due to the downregulation in ROS scavenging enzymes(96). 
Recent studies show that mTORC1 plays a critical role in RBC commitment, 
growth, proliferation and homeostasis. Knight et al., demonstrated that mTORC1 
activity is regulated by dietary iron, and a loss or overexpression of mTORC1 in 
HSCs leads to microcytic or macrocytic anaemia respectively with a loss of 
proliferation in RBC progenitors(97). Furthermore, mice treated with the ATP 
competitive mTOR inhibitor MLN0128, and subsequently treated with 
phenylhydrazine to induce haemolysis, was shown to be lethal, demonstrating 
the reliance of the mTOR pathway in RBC development(97). Zhang et al., have 
shown that the heme-regulated eIF2 kinase (HRI)-activating transcription factor 
4 (ATF4) pathway, which regulates heme uptake for haemoglobin production and 
stress response genes, suppresses mTORC1 activity in iron deficiency anaemia. 
The HRI-ATF4 pathway promoted RBC progenitor differentiation, and 
pharmacological inhibition of mTORC1 rescued RBC counts and haemoglobin 
content in the blood(98). mTOR also plays a role in microenvironmental 
homeostasis associated with RBC development through regulation of neutral 
essential amino acids (NEAA) uptake into cells during erythropoiesis for 
haemoglobin production. mTORC1/4EBP1 signalling regulates Lat3, a transporter 
of NEAA in RBCs(99). 
1.5.5 mTORC1 and mTORC2 signalling in Myeloid cells 
cKOs of Mtor or Raptor in HSCs lead to a significant accumulation of CD11b+Gr1- 
population(84,100). Mtor cKO mice on a severe combined immunodeficiency 
(SCID) background exhibited reduced monocyte/macrophage populations in in 
vitro and in vivo assays. However, removal of mTOR expression specifically in 
myeloid cells (Mtor-Lyzs-cre), revealed normal levels of monocyte/macrophage 
populations, suggesting that mTOR plays a role during lineage commitment, but 
not during survival and maturation(101). Following mTOR deficiency, a decrease 
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in the expression of macrophage-colony stimulating factor (M-CSF) receptor 
CD115 was noted, which may result in decreased monocyte/macrophage 
populations due to overactive STAT5 and downregulation of IRF8(101). M-CSF 
promotes mTORC1 activation which further promotes CD115 expression, and 
expression of Pu.1 and Irf8 to promote myelopoiesis. In the absence of mTORC1 
activity there is a block in glucose uptake and lipid metabolism thereby 
abrogating myeloid differentiation along with an impaired immune response to 
bacterial infection(102). Constitutive activation of mTORC1 in Tsc KO BM-derived 
macrophages (BMDMs) attenuated AKT signalling through the negative feedback 
loop via mTORC2 leading to a defect in IL4-induced M2 polarisation. These 
BMDMs produce more pro-inflammatory responses compared to controls 
suggesting an important role of mTORC1 in the regulation of inflammation(103). 
Additionally, it has recently been shown that Raptor cKO, but not granulocyte-
specific KO (Raptor-Lyz2-cre) mice lead to a significant increase and 
accumulation of innate myelo-lymphoblastoid effector cells (IMLECs). This 
suggests that IMLEC accumulation driven by Raptor-deficiency occurs earlier in 
development, caused by reduced expression of Myb in CMPs(104). 
A myeloid lineage specific KO model of Rictor (LysM-cre) revealed a significant 
decrease in monocytes, while the neutrophil population was unaffected. BM 
monocytes and peritoneal macrophages displayed decreased proliferation and 
increased susceptibility to pro-apoptotic stimuli.  Furthermore, stimulation of 
TLR4 on Rictor-/- macrophages with lipopolysaccharide (LPS) potentiated a pro-
inflammatory response, with cells skewing towards an M1 phenotype and 
downregulating IL10 expression, suggesting that mTORC2 signalling is a negative 
regulator of TLR signalling in macrophages(105,106). Interestingly, the 
inflammatory response observed in Rictor-/- cells was reversed by the 
inactivation of Raptor, indicating that mTORC1 regulates inflammatory 
responses in macrophages(105).  
1.5.6 mTORC1 and mTORC2 signalling in B cells 
The importance of mTOR signalling during B cell development is evident from a 
study analysing mice in which mTOR expression is reduced. Reduced expression 
was achieved by the neomycin insertion at exon 12 of mTOR thereby creating a 
mTOR-knock-in (KI) model partially disrupting mTOR transcription(107). A 
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reduction in progenitors B cells was observed in these mTOR-KI mice, with a 
block between large preB cells (B220+CD24+CD43+) and small preB cells 
(B220+CD24+CD43-). Within the spleen, an increased number of mature B cells 
(B220+IgDhighCD21+IgM−) and decreased T1 and T2 transitional B cells were 
observed compared to wildtype (WT) mice(107). Deletion of the TSC1 complex in 
B cells (CD19-cre) renders mTOR constitutively active, resulting in a partial block 
in B cell maturation as indicated by an elevation in T1 and T2 transitional B 
cells, and a depletion of MZ B cells(108).  
Assessing mTORC1 signals more directly, Raptor cKO mice exhibit a significant 
decrease in B cell generation, due to an early block in lineage 
commitment(100,109). For this reason, the effect of Raptor ablation on B cells 
was analysed using B cell specific models (Mb1-Cre), which resulted in a 
profound block at the preB cell stage abrogating B cell maturation, proliferation, 
GC reaction and antibody production(109). Additionally, a cKO of Raptor 
specifically in B cells (hCD20-Tam-Cre) resulted in a decrease in GC B cells and 
nascent antibody secreting plasma cells, and the elimination of GCs resulting in 
a decline in serum-antibodies(110). These studies illustrate the importance of 
mTORC1 at multiple stages of B cell maturation, and highlights the critical role 
played by mTOR in mounting an appropriate humoral immune response. 
Rictor KO models revealed a role for mTORC2 during B cell maturation, resulting 
in a decrease in mature B cells(111). Studies demonstrate an increase in early B 
cell populations including the proB, preB and immature B cells in Rictor cKO 
mice, characterised by elevated FOXO1 and RAG1 expression and a subsequent 
reduction in mature splenic B cells(92). However, HSCs isolated from Sin1-/- mice 
reconstituted haemopoietic lineages suggesting a minimal role for mTORC2 in B 
cell development during early stages. However, these mice exhibited increased 
IL7 production and RAG1/2 expression at the proB stage and fewer IgM+ 
immature B cells suggesting a role for mTORC2 after B lineage 
commitment(112). mTORC2 has also been shown to play an important role in B 
cell survival, as Rictor-null mice display increased caspase-3 and PARP 
expression, together with increased cell death and a decrease in B-cell 
activating factor (BAFF) expression in mature B cells(111). Lee et al., proposed 
that mTORC2 regulates canonical and non-canonical nuclear factor kappa B 
(NFκB) signalling pathways responsible for mature B cell maintenance and 
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survival(111). Interestingly, Rictor-null mice possess increased CIP2A binding to 
protein serine/threonine phosphatase A (PP2A) leading to increased c-
myelocytomatosis viral oncogene (C-MYC) phosphorylation and expression, and 
decreased E2F1 expression, which leads to apoptosis(113).  
1.5.7 mTORC1 and mTORC2 signalling in T cells 
T cells develop in the thymus, undergoing rigorous positive and negative 
selection processes at the CD4+CD8+ double positive (DP) stage of development, 
to generate a pool of T cells that recognise foreign peptides in the context of 
self-major histocompatibility complex 1 (MHC-I) (CD8+-cytotoxic T cells) or MHC-
II (CD4+-helper T cells).  Analysis of mTORC1 signalling inhibition during T cell 
development showed that rapamycin treatment and Raptor-deletion in cKO mice 
resulted in reduced thymic cellularity and a decrease in the proportion of DP 
cells, coupled with a concomitant increase in CD4-CD8- double negative (DN) 
cells(114). Within the DN population, rapamycin blocked T cell development at 
the DN3 stage, likely prior to the proliferative burst associated with -selection, 
while development was arrested at the DN1-DN2 transition in Raptor-null mice 
both in vitro and in vivo. This block was associated with a reduction in 
proliferation due to an instability of cyclinD/cyclin-dependent kinase 6 (CDK6) 
complexes. Similar results were noted with an Mtor cKO mouse model, while 
Rictor cKO mice exhibited a block in proliferation at the DN3 stage of 
development (115,116), suggesting that mTORC1 plays a critical role, which is 
distinct from mTORC2, during the early stages of T cell development. 
The thymic microenvironment plays a critical role in enabling the appropriate 
development of nascent T cells, particularly thymic epithelial cells (TECs). 
Selective Rictor-/- in TECs results in a reduction in thymic mass and cellularity of 
TECs, and decreased generation of specific T cell lineages: T-cell receptor  
(TCR), TCR, invariant NK-T(117) and regulatory T cells thereby revealing an 
important role of mTORC2 in thymopoiesis and T cell lineage generation(118).  
In the periphery, reduced mTOR expression/activity decreased T cell numbers, T 
cell activation and proliferation(107). Furthermore, TSC1 ablation drove naïve T 
cells from quiescence to a poor immune response, altering the cell size and 
cycling(119). mTORC1 activation, through TSC2 deletion, led to increased, 
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terminally-differentiated effector CD8+ T cell formation not capable of 
conforming to a memory T cell phenotype. However, mice deficient in mTORC1 
activity, through deletion of RHEB, led to loss of effector CD8+ T cell formation 
with no change in memory T cell expression, suggesting a role of mTORC1 in the 
differentiation of specific T cell subsets(120). Indeed, mTORC1 is involved in Th1 
and Th17 differentiation from naïve CD4+ T cells, as deletion of RHEB blocks Th1 
and Th17 differentiation, but not Th2 differentiation in vivo and in vitro(121). 
Moreover, mTORC1-mediated signalling plays a critical role in CD4+ T cell 
proliferation, by enhancing PPAR activity, which in turn activates fatty acid 
metabolism, thus enabling the metabolic reprogramming required to activate 
CD4+ T cells(122). 
Th cells require mTORC2 for T cell differentiation as ablation of mTORC2 in T 
cells led to impaired Th1 and Th2 differentiation, which could be reversed by 
activating AKT and PKC respectively(123). However, mTORC2 is mainly 
considered to regulate Th2 differentiation, as Rictor KO in CD4+ T cells 
specifically led to the generation of Th1 and Th17 cells but not Th2 cells(124). 
mTORC2 controls CD8+ T cell differentiation in a FOXO1-dependent manner as 
ablation of mTORC2 led to an increase in memory precursor effector cells 
(MPEC) and not in the short lived effector cells (SLEC) driven due to Eomes and 
Tcf-1 upregulation caused by FOXO1(120,125). Recently, Velde and Murray 
demonstrated that mTORC2 plays an important role in microenvironment sensing 
in CD4+ T cells. In a normal setting, CD4+ T cells require essential and non-
essential amino acids (AAs) to undergo cell division. Limiting arginine and 
leucine resulted in cell cycle disruption, which could be bypassed in the absence 
of Rictor. This resulted in cells initiating cell cycle regardless of limiting AA, 
thus bypassing micro-environmental sensing(126). 
1.5.8 mTOR signalling in leukaemogenesis 
The PI3K/AKT/mTOR pathway plays a major role in the haematopoiesis as 
constitutive activation of the mTOR pathway led to impairment of HSC function. 
Additionally, deletion of mTORC1 leads to pancytopenia and is vital for HSC 
regeneration. The AKT/mTOR axis has shown to play a role in leukaemogenesis 
as in a mouse model of leukaemia evoked by Pten-loss, mTORC1 deletion 
resulted in a significant increase in survival(91). mTOR signalling is not only 
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involved in leukaemia, but lymphoma too. For instance, mantle cell lymphoma 
(MCL) has activated BCR signalling with increased activation of Src family kinases 
(SFKs) including Lyn. Consequently, treatment of MCL murine models with 
dasatinib (SFK inhibitor) leads to reduction in tumour size(127). Recent research 
shows that this pathway is upregulated in CLL patients from distinct cohorts and 
this can also be seen in CLL murine models. Inhibition of this pathway with 
AZD8055 (dual mTORC1/2 inhibitor) led to a greater level of apoptosis when 
compared to rapamycin in primary CLL patient samples(128) .  
Rapamycin, along with its analogues, ‘rapalogs’ have shown promise in targeting 
CLL. Rapamycin has shown to induce cell cycle arrest by modulating the 
mTOR/S6K pathway and abrogating cyclin E, cyclin D3 and cyclin A expression. 
Additionally, survivin a protein upregulated in CLL along with other cancers, is 
associated with disease survival. Survivin has also become a therapeutic target 
for many cancers. Rapamycin has shown the potent inhibition of this protein 
suggesting a potent role in CLL abrogation(129). Moreover, due to the known 
role of the microenvironment in CLL maintenance, rapamycin could play a 
potent role in abrogating microenvironmental signals. Rapamycin was first 
identified as an immunosuppressant of T cell mediated signals including IL2 and 
IL4 signalling(130). These signalling pathways are upregulated in CLL and have 
shown to mediate CLL survival highlighting the importance of rapalogs in CLL 
maintenance. Indeed, Decker et al. have demonstrated a block in proliferating 
CLL cells with rapamycin treatment. Rapamycin treatment led to a decrease in 
cyclin D3 and a decrease in CDK2 via the suppression of cyclinE and cyclinA 
leading to cell cycle arrest. Although rapamycin did not induce apoptosis, 
impairment of cell cycle regulating proteins blocked proliferation of CLL 
cells(131). 
FOXO1 is the main isotype observed in CLL patients responsible for cell cycle 
arrest. AKT activation phosphorylates FOXO1 to inactivate it thus halting its 
translocation into the nucleus. However, AZD8055 (but not rapamycin) 
treatment led to an increased translocation of FOXO1 into the nucleus thus 
inducing apoptosis in cells. Cosimo et al., have recently shown that 
microenvironment signals enable constitutive activation of PI3K/AKT/mTOR 
signalling in chronic lymphocytic leukaemia cells, which inactivates FOXO1. This 
may assist in disease progression. Moreover, dual mTOR complex inhibitors 
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AZD8055/2014 enable a reduction in disease progression and an activation of 
FOXO transcriptional program which was enhanced by combination with 
ibrutinib(128). 
1.6 Chronic Lymphocytic Leukaemia 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the 
Western world, which exhibits a monoclonal expansion of B cells. CLL-B cells are 
characterised by CD19+CD23+CD5+IgM+IgDlo surface expression, a phenotype of 
mature B cells(132). It is known to mainly affect the elderly, displaying a median 
age of 70 years and is 1.5 times as prevalent in males as in females, with about 
3,200 patients diagnosed with CLL in the UK in 2011(133). Current diagnosis of 
the disease is based upon the morphology of lymphocytes, >5X109 circulating B 
cells for more than 3 months, and a characteristic immunophenotype(134). This 
scoring system is the CLL scoring system based on the immunophenotypic 
characteristics. Immunophenotype of CLL patients are mostly positive for CD5, 
with dim expression for CD20, along with dim or no expression of surface Ig, 
CD79b, CD22, MFC7. CD38 has shown to be overexpressed in some cases along 
with increased 70 kDa zeta associated protein (ZAP-70) which are correlated 
with patients having a poorer prognosis with unmutated IgVH gene. For instance 
patients are scored depending in the immunophenotype the present, if the 
scoring reaches or exceeds 3, they present true CLL (135). Typically, the Rai and 
Binet staging system is used for assessing the prognosis of the disease. Rai 
staging is mostly used in the USA and the system is divided into 5 stages where 
lymphadenopathy, lymphocytosis and anaemia are taken into account. Binet 
staging system is mostly followed in the UK and Europe and is divided into three 
stages, A-C, which is dependent upon the levels of anaemia and white blood cell 
count (136). Regardless of the staging system, patients with a more advanced 
disease have a median survival of 1-2 yr as opposed to patients with a more 
benign disease with a median survival of more than 10 yr(137,138). Despite 
extensive research on CLL in the past decade, it remains incurable with standard 
therapy, demonstrating the need to develop novel strategies for CLL therapeutic 
research. 
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1.6.1 Mutational status and prognosis 
The differential clinical behaviour of the disease has been associated with the 
somatic mutational status of the IgVH regions of the BCR. It has been shown that 
patients with CLL cells carrying unmutated IgVH regions display a poorer 
prognosis with a diminished survival time (median survival time of ~8 yrs) as 
compared to those patients with somatic IgVH mutations with a median survival 
time of ~24 yrs (139). Patients with poorer prognosis have also been shown to 
express upregulated levels of CD38 (140) and ZAP-70 and activate key signal 
transduction pathways more readily in response to BCR signalling(141).  
While chromosomal abnormalities are not required for the development of CLL, 
80 percent of patients with CLL have chromosomal deletions/gene mutations at 
diagnosis. With the progression of the disease, the cells can acquire increasing 
deletions showing a poorer prognosis of the disease. The most common 
chromosomal deletion, occurring in about 55% of cases, is the 13q band deletion 
which displays a benign phenotype. This region (13q14) encodes for the miR16-1 
and miR15a which have shown to play a role in leukemogenesis and the miRs 
regulate BCL proteins. However, patients with deletions in the 11q chromosomal 
band (in 10% patients with early stage and 25% with advanced disease stage) 
have a more aggressive phenotype with rapid progression and reduced survival. 
The 11q23 region harbours the ATM gene, which encodes a DNA damage 
response kinase, the lack of which leads to a progression of the disease. Another 
chromosomal deletion (found in about 5-7% patients) is deletion in the 17p band 
which deletes the TP53 tumour suppressor gene and displays the most aggressive 
form of the disease(142). Of note, in patients carrying a 17p deletion, the 
accompanying allele has a mutated copy of TP53 in 60% of cases, therefore 
rendering the CLL cells with no functional p53. This makes p53 mutated CLL cells 
highly chemorefractory. 
1.6.2 Role of microenvironment 
Although, CLL was initially classified as a disease of accumulation of B-
lymphocytes(143), since the identification of CLL as a dynamic(144), and not a 
static disease, cross-talk between the microenvironment and malignant B cells 
have shown to further cause clonal expansion of the disease. CLL cells have been 
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shown to migrate to lymphoid organs and proliferate in centres through signals 
further enhanced by the microenvironment. CD4+CD40L+ T cells have shown to 
interact with CD40 receptors on malignant cells in the proliferation centres to 
increase survival by increasing expression of anti-apoptotic proteins BCLXL and 
MCL-1. CD40+ stimulated CLL cells were resistant to drug induced apoptosis(145) 
suggesting that the microenvironment interactions enhances disease progression. 
Furthermore, activated BCR signalling in CLL is responsible for upregulating MCL-
1 via PI3K/AKT signalling(146).  
T cells are known to play a critical role in CLL progression. CLL is associated with 
an increase in CD8+ and CD4+ T cells along with their exhaustion linked with an 
increase in programmed death 1 (PD-1) expression(147). CLL cells have an 
increased expression of PDL1/PD1 with increased CD40 stimulation(148) PD/ 
suggesting a potential role of PD-1/PDL1 in CLL therapy. Indeed, PDL1 inhibitors 
are in clinical trials for other Hodgkin and non-Hodgkin lymphomas(149,150) 
showing promising results which could also prove to be effective in CLL. 
Additionally levels of CCL3 and CCL4 have also shown to be upregulated in 
CLL(151), behaving as chemoattractants for monocyte derived nurse-like cells 
(NLCs), enhancing CLL survival and homing in secondary lymphoid organs.  In 
CLL, these chemokines may help to enhance microenvironment to induce anti-
apoptotic signals thereby further protecting the disease. CCL3 has also been 
associated with a poor prognosis of CLL. 
BM stromal cells (BMSCs) have also shown to protect CLL cells due to an increase 
in anti-apoptotic signals (152) with increasing CLL cell affinity towards BMSCs. 
Increased migration towards stromal cell-derived factor 1 (SDF-1)/ CXCL12 
(released by BMSCs) is due to the increased expression of CXCR4 (153). In normal 
B cells, CXCR5 is responsible for the homing of B cells into the GCs of secondary 
lymphoid organs via the affinity of CXCL13 released by NLCs in these organs. In 
leukaemic B cells, there is an increase in CXCR5 expression, leading to increased 
homing towards CXCL13 leading to changes in actin polymerisation and 
chemotaxis(154). NLC released BAFF and a proliferation-inducing ligand (APRIL) 
have also shown to bind to their receptors on malignant B cells and protect the 
disease in a NFκB dependent manner(155). 
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Calissano et al., have shown heterogeneity within a CLL disease where there 
exist two subpopulations with varying phenotypes. One population comprises a 
CD5dimCXCR4hi resting-cell like population whereas the second subtype has a 
CD5hiCXCR4dim phenotype with a proliferative characteristic with increased Ki67 
suggesting increased cell cycling and an increase in anti-apoptotic genes(156). 
This is termed the Calissano model which highlights the spectrum of CLL cells 
within the same disease. Interestingly, ibrutinib and idelalisib have been shown 
to target the CXCR4-SDF-1 axis and potentially disrupt the ‘resting CLL cells’ 
leading to an increase of these cells from the lymphoid organs into the 
peripheral circulation (lymphocytosis) post ibrutinib treatment(157,158). These 
findings suggest a targeting of a CLL subset with current drugs in clinics. 
1.6.3 Current therapy 
Current therapy has evolved drastically over the past few years and has become 
increasingly heterogeneous depening on the aggressiveness of the disease and 
the fitness level of the patients. How ‘fit’ a patient is depends on other diseases 
and co-morbidities such as cardiac issues, etc. Some clinical trials use the Co-
morbidity illness Rating scale (CIRS) to assesses fitness objectively. According to 
current guidelines, all CLL patients are tested for both TP53 mutations and 
deletions as recent research has shown that attenuated TP53 affects 
therapy(159). This brings in into question the use of the scoring system 
altogether in an age of molecular testing. Currently, the use of the scoring 
system is reassuring with the novelty of molecular testing, in the future, perhaps 
the scoring system will be redundant. 
First line therapy differs between ptients depending on patient fitness and TP53 
mutations. How ‘fit’ they are which alludes to other diseases and co-morbidities 
such as cardiac issues, etc. In the pivotal CLL8 study, Hallek et al., 
demonstrated that the addition of Rituximab (R) (anti-CD20 antibody that 
specifically targets B cells) to the backbone of chemoimmunotherapy comprising 
cyclophosphamide (C) which is an alkylating agent interfering with DNA 
synthesis, and fludarabine (F) which is a purine analogue interfering with DNA 
synthesis improved the progression-free survival (PFS) and overall survival (OS) 
of fit CLL patients without TP53 alterations (134,160). Therefore, FCR is 
approved for first line therapy for fit CLL patients without TP53 alterations and 
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is approved by the National Institute for Health and Care Excellence (NICE). 
Indeed, the mechanism of action of FC drugs require p53 activity, therefore 
patients with 17p deletions or TP53 mutations require different treatments(161). 
Less fit patients, two major clinical trials CLL11 by the German CLL study Group 
and COMPLEMENT-1 led to the introduction of chlorambucil in combination with 
Obinutuzumab or Ofatumumab for less fit CLL patientsa and are NICE approved. 
CLL11 demonstrated superiority of chlorabucil-obinutuzumab over chloambucil-R 
or chlorambucil alone (162). COMPLEMENT-1 study demonstrated superiority of 
chlorambucil-ofatumumab over chlorambucil alone(163). Moreover, ibrutinib is 
licensed for front-line use in CLL patients without TP53 abberations as patient 
showed increased OS with ibrutibin over chlorambucil alone in the RESONATE-2 
trial but has not received approval from NICE as of now(164). 
Recent therapeutic strategies for CLL patients with TP53 abberations have 
focused on inhibiting signalling and survival pathways which are important in CLL 
initiation and development. Indeed, BCR signalling plays a central role in the 
survival of CLL, and in the prognostic outcome of patients, therefore making this 
signalling pathway an attractive therapeutic target(165). Furthermore, recent 
findings demonstrating that autonomous BCR signalling is evident independent of 
cell-antigen interactions makes this pathway an important therapeutic 
target(166). Two major drugs, ibrutinib and idelalisib, which have been 
introduced in clinics are inhibitors of the downstream kinases, Bruton’s tyrosine 
kinase (BTK) and PI3Kδ respectively of the BCR signalling pathway.  
PI3Kδ expression is limited to leukocytes where it plays a role in B cell 
development(167) and in T-regulatory (T-reg) cell function(168). The 
constitutive activation of the BCR in CLL makes PI3Kδ an ideal therapeutic 
target. Indeed, Hoellenriegel et al., have demonstrated an aberration in CLL 
migration and homing (via CXCL12 and CXCL13 impairment) with idelalisib 
treatment(169). Although idelalisib had been approved in by NICE for its efficacy 
and safety profile for patients with TP53 abberations, major side effects of this 
drug included fatal or severe diarrhoea, colitis and hepatoxicity(170). Similar 
side effects were observed in PI3K-deficient mouse model developed by 
Okkenhaug et al., where the mice developed inflammatory bowel disease 
together with impaired B and T cell function(171). These results highlight the 
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need to identify novel therapeutic targets for CLL. This drug was reviewed and 
has been set as first line therapy with rituximab for CLL apatients with TP53 
abberations which are not for for alternative therapy(172). Although BTK was 
not found to be constitutively active, BTK protein levels were upregulated with 
increased BCR activity suggesting increased downstream PI3K/mTOR activity in 
mediating survival signals in CLL(173). Ibrutinib, an irreversible inhibitor of BTK, 
has shown promise in murine models of CLL, as ibrutinib treatment of Eµ-TCL1 
mice (CLL mouse model) leads to a significant increase in survival via a delay in 
disease development by promoting apoptosis(174). Ibrutinib is now increasingly 
being prescribed as to patients with poor prognosis and is NICE approved for 
patients with TP53 abberations after the RESONATE-17 clinical trial(175). 
Nonetheless, side effects such as atrial fibrillation and haemorrhage can lead to 
discontinuation of treatment in some patients with resistant mutations due to 
clonal evolution(176) indicating the need for novel agents/therapeutic targets. 
Recently, ABT-199 (venetoclax), a BH3 mimetic has also entered clinical trials 
and shown promise in patients with 17p deletions(177).  
Currently, ibrutinib synergy with venetoclax, a BH3 mimetic is being tested for 
alternative therapy for CLL in the CLARITY clinical trial(178). Recently, ARQ-531, 
a reversible and less potent target of BTK is was assessed for its efficiency in 
targeting CLL. Despite partial inhibition of BTK, ARQ-531 targeted SFK kinases 
and ERK signalling thereby targeting multiple pathways involved in CLL. Indeed, 
ARQ-531 treatment of Eµ-TCL1 mice resulted in increased survival compared to 
ibrutinib treated mice suggesting global inhibition of signalling pathways leads to 
more robust results(179). 
The BCL family, including anti-apoptotic proteins BCL-2, MCL-1, and the 
counterbalancing pro-apoptotic proteins (eg. BID, BAX), contain BH3 domains in 
their structure. BH3 mimetics such as venetoclax that inhibit the function of 
BCL-2, has recently been approved as second line therapy for relapsed patients 
treated with ibrutinib(180). BCR inhibitors and BH3 mimetics improve outcome 
in patients with a more aggressive disease and improve disease conditions in 
poor prognostic patients, particularly in patients with 17p deletions(181). 
However, resistance mutations are already evident in patients treated with 
venetoclax due recurrent Gly101Val mutations(182), suggesting the need for 
additional therapeutic targets or combination therapies.   
 33 
 
Haematopoietic stem cell transplantation (HSCT) is another CLL therapy 
procedure. However, it can only be considered for the younger/fitter patients 
with an aggressive form of the disease as the older populations with the disease 
cannot undergo such harsh treatments. It is known to decrease treatment-
related mortality but has known to have relapses(183).  However, more 
emphasis has been put on the reduced intensity conditioning (RIC) HSCT which 
can also be given to the elderly population(184).  RIC-HSCT has led to a 
decreased relapse mortality rate by 16-23% and seems to be a powerful 
therapeutic regime(183). According to NICE recommendations, transplants are 
only recommenbed to pateints who have failed chemoimmunotherapy and 
therapy using BCR inhibitors.  
Chimeric antigen receptor-T (CAR-T) cells have recently shown promising results 
in treating various Hodgkin and non-Hodgkin lymphomas. CAR-T cell therapy 
involves the re-engineering of self T cells to recognise specific tumour 
associated antigens including targets such as CD19, CD20(185). Recently, a small 
cohort of patients (18 patients) with relapsed CLL who had been treated with 
ibrutinib, were treated with CD19 CAR-T cells. Results were very promising 
which showed high CAR-T CD4:CD8 ratio with complete responses in patients. 
However, this treatment was only introduced to the clinic in 2016 and thus is in 
an early phase and needs to be monitored for a longer duration(186). 
1.7 Mouse models commonly used in haemopoiesis 
1.7.1 Cre-loxP KO system 
Naturally present in bacteriophage P1, the cre-loxP system is extracted from this 
virus and is now widely used in murine studies and in other mammals for genome 
editing/omitting. Cre (causes recombination) recombinase (cre) re-combines two 
loxP (locus of crossover in P1) sites in the genome, the gene is then considered 
to be ‘floxed’, leading to genome editing depending on loxP orientation.  
Embryonic stem (ES) cells are conventionally used to incorporate cre gene. P1 
encodes Cre, which is a 38 kDa enzyme and it recognises DNA-base pair (bp) 
repeats and recombines them by covalent-linking of protein between the two 
DNA-repeat sites. The expression of cre is usually controlled by a specific 
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promoter, thereby ensuring a controlled expression. It also allows cre expression 
in specific tissues, depending on the promoter of choice. Cre can be expressed in 
the coding sequence of the promoter thereby silencing the gene itself, or it 
could be present at the flanking end. Cre construct is cloned into ES cells via 
conventional methods and is subsequently microinjected into the pronucleus of 
mouse embryos, which can then be injected into mouse oviduct(187).  
LoxP are 34-bp long DNA of which there is an 8 bp long core with 13-bp long 
palindromic DNA repeats at either side. These sites are inserted around a gene 
of choice, usually target gene of excision. The sites of insertion of these genes 
are important: loxP sites should not be inserted at important coding regions, 
thereby ensuring proper functioning of the gene in the absence of cre(187). 
There can be various functions of this system. One of the most straightforward 
uses is gene deletion. Here the gene of interest will be floxed and cre-expression 
will be regulated by a promoter of choice. This can be done both in vivo and in 
vitro. Mice harbouring either loxP sites or cre are bred together to obtain either 
WT mice, mice containing only loxP or cre sites or both, which is the desired 
model(187). Subtle modifications have also been made within the genome by the 
insertion of point mutations utilising the cre-loxP system. This is done by the 
addition of a vector which harbours the mutation along with the flanked loxP 
site around the target gene. Therefore, when cre expression is induced, 
insertion occurs of the point mutation and loxP sites remain. Gene/exon 
replacement is also possible using this model whereby a replacement vector is 
added to one loxP site, where both loxP sites are flanked around the gene/exon 
to be replaced. Cre expression excises the original gene/exon leaving the loxP 
sites together with the replaced vector. Similarly, chromosomal translocations, 
insertions, inversions and conditional deletion of genes have successfully been 
demonstrated using the cre/loxP system(188). There are a variety of cre-loxP 
systems which have been used to assess the role of mTORC1 (via exision of 
Raptor) and mTORC2 (via exision of Rictor) in haemopoiesis. The most commonly 
systems used for haemopoietic cells and B cells are summarised in Table 1.1 
below: 
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Promoter Stage fl/fl Reference 
ROSA26-
Cre 
All cells except brain 
cells 
Raptor/Rictor (111,114) 
MX1-Cre 
All cells except skeletal 
muscle 
Raptor/Rictor (93,104) 
VAV-Cre 
All haemopoietic, 
embryonic, germ cells 
Raptor/Rictor (93,97) 
CD2-Cre 
Common Lymphoid 
progenitors (CLPs) 
Raptor/Rictor (189) 
MB1-Cre Pre-proB cell stage Raptor (109) 
CD19-Cre Mature B cells mTOR, TSC1 (190) 
CD20-Cre 
Mature B cells, more 
specific than CD19 
Raptor (110) 
Aicda-Cre GC B cell development Raptor (191) 
Table 1.1 Summary of various promoters used in the cre-loxP system to excise mTORC1 
(Raptor) or mTORC2 (Rictor) in haemopoietic cells and in B lymphocytes. 
 
In this thesis, three different promoters have been used which control 
expression of cre at different stages of development thereby excising mTORC1 
(Raptor) or mTORC2 (Rictor) at different stages. These are explained and 
summarised in Table 1.2 below:  
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Promoter Cre expression 
Vav 
In all haemopoietic cells. Also expressed in 
embryonic stem cells and germ cells (192).  
Mx1 
Expressed ubiquitously in all tissues. Minimal 
expression in the skeletal muscle. 
CD19 Only expressed in mature B cells. 
Table 1.2 Summary of promoters used to control cre expression. Table also describes all 
the organs/cells the cre transgenes will be active. 
 
1.7.1.1 Vav-cre model 
Vav1 gene has previously shown to be expressed in all haemopoietic organs 
whereas Vav2 and Vav3 have a broader gene expression pattern(193). Besides 
haemopoietic organs, its expression is restricted to developing teeth, ES cells, 
testicular germ cells(192). The ubiquitous expression of Vav1 in haemopoietic 
lineages occurs regardless of their developmental stage. Nevertheless, Vav 
expression is not fundamental for haemopoietic development as Vav-null mice 
still had functional B and T cells but had an aberration in proliferative capacity 
suggesting a redundant role of Vav in haemopoiesis(194). Additionally, Vav has 
shown to play a role in cytoskeletal organisation and proliferation, and has 
shown to activate the Rac/Jun signalling pathway(195). Vav expression also had 
sporadic reductions at later haematopoietic lineages suggesting a potent 
expression at developmental stages(192). 
Vav mediated cre expression has shown to be a very effective method of 
mutagenesis using the cre-loxP system with a complete KO of floxed gene(196). 
However, there have been off-target homologous recombination in endothelial 
cells observed in some laboratories whilst not in others (197). Additionally, there 
have been rare off-target excisions in BM cells lacking haemopoietic markers 
suggesting excisions in stromal cells with Vav-mediated cre expression(198). 
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Nonetheless, the high efficiency of this model is well recognised, and it is widely 
used. 
1.7.1.2 Mx1-cre model 
MX1 is expressed in most organs (besides skeletal muscle), including all 
haemopoietic organs(199), and is widely expressed from very early stages of 
development. It is involved in innate immunity, activated post viral infections, 
with expression of MX1 being effective against influenza virus(200). It is 
activated by STAT-1 activation of TLR3 receptors(201). TLR3 activation has been 
associated with response to virus infiltration within the body. In research, 
polyinosinic-polycytidylic acid (poly(I:C)) mimics the double stranded RNA 
structure of some viruses, and activates the TLR3 thereby activating Mx1 
expression(202). 
Mx1 is widely used in the cre-loxP system to induce a cKO (via poly(I:C) 
inoculation) thereby controlling time of KO induction which is a beneficial tool in 
research. Although this model has been shown to induce almost a complete KO 
in lymphocytes after a few days with complete KO in other haemopoietic 
lineages, there remain some limitations in using this model. One very important 
limitation is the spontaneous recombination caused in the Mx1-cre model prior 
to the inoculation of poly(I:C). This spontaneous recombination has previously 
been demonstrated to occur due to the constitutive activation of internal 
tandem duplications of FLT3 (FLT3-ITD) in acute myeloid leukaemia (AML) in 
mice. This increased the observed recombination prior to poly(I:C) inoculation 
from 2-3% to 30-50%(203). Therefore, it is very important to have appropriate 
controls when using this model to determine affects of spontaneous 
recombination. Another limitation is the phenotype of HSPCs, which is perturbed 
for a short time following poly(I:C) inoculation in mice. Following poly(I:C) 
inoculation, there is a transient change in the expression of HSPCs where there 
is an increase in Sca1+ populations for a short duration (D8), which could disrupt 
the ‘normal’ HSPC phenotype in short-term studies(204). It is important to 
consider this if the timepoint of the experiment comprising this model is very 
short, as it might alter the results. 
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1.7.1.3 CD19-cre model 
CD19 is a surface expressed at the proB cells stage and usually referred to as a 
marker for mature B cells which is responsible intrinsic signalling mediated via 
BCR signalling. CD19 is responsible for the Ig-mediated activation of B cells and 
downstream activation of PI3K and AKT signalling which modulate proliferation 
and expansion of B cells(205). 
CD19-mediated cre excision has also been used in the cre-loxP system. In mice, 
this system has shown to have a good excision in the spleen (90-95% excision), 
however a lower deletion efficiency in the BM: 75-80%(206). The Mb1-cre 
(expressed at the pre-proB cell stage) is the pan-B cell specific KO model for the 
cre-loxP system with a higher deletion efficiency(41). 
1.7.2 Limitations of the cre/loxP system 
Although the cre/loxP system is used widely in research, there remain some 
limitations to this system which should be considered whilst designing the 
experiments depending on the nature experiment. 
The cre/loxP system has shown to have off-target cre-mediated excisions in 
mammals making the model ‘leaky’. There exist pseudo-loxP sites in human and  
murine genome leading to various off target excisions(207). Therefore, it is 
important to determine the level of non-specific excisions ensuring that the off-
target excisions (if any) do not hinder or significantly alter the results. 
Additionally, off-target excisions could occur in cre induced expression in germ-
line due to the presence of many lineages in embryogenesis(208). 
Cre toxicity is another limitation of the system. Increased cre expression has 
been associated with tissue/cell specific cre mediated toxicity. Research has 
shown that increased cre expression is associated with decreased proliferation 
and chromosomal aberrations in certain cell types(209). Additionally Li et al., 
have shown complete tumour regression due to cre expression suggesting cell 
toxicity due to expression of cre(210). Conversely, it has been shown that cre 
excision of target floxed genes may not be completely efficient. This is usually 
due to cre-loxP models with induced expression of cre. As such, the method of 
cre induction could affect cre expression and therefore the deletion-efficiency. 
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For instance, tamoxifen induced inefficient cre-expression could depend on the 
frequency and volume of the inoculation of tamoxifen(211).  
1.7.3 NSG/NRG mouse models 
Several lymphoid mouse models have been generated for transplantation of 
cancer cells or human haemopoietic cells into mice in in vivo studies, with 
efficient models being NOD-SCID-IL2Rγ-/- (NSG) and NOD-Rag-/--IL2Rγ-/- (NRG) 
mouse models. 
In 1983, the severe combined immunodeficiency (SCID) mouse model was 
defined wherein the autosomal recessive mutation of the Prkcd gene led to 
impaired rearrangement of the BCR and the TCR resulting in impaired B and T 
cell signalling. This is because the Prkdc gene encodes a DNA-dependent protein 
kinase catalytic subunit which is vital for VDJ recombination in developing B and 
T cells. In fact, there was almost a complete loss of B and T cells with impaired 
lymph node (LN) development(212). Although the SCID model is efficient at 
engrafting xenografts, the generation of a mouse model where the ‘eat me not’ 
signal was constitutively active, led to the efficient binding of signal regulatory 
protein alpha (SIRPα), ubiquitously expressed, with the human CD47L leading to 
the inhibition of phagocytosis by macrophages(213). These mouse models were 
termed non-obese-diabetic (NOD) mice. Backcrossing this strain with SCID mice 
led to a more effective and efficient xenograft model than SCID mice 
alone(214). Although these mice lacked functional B and T cells, NK cells were 
still present in the mouse models. The depletion of NK cells proved to enhance 
human CD34+ HSC engraftment in NOD-SCID mice without compromising the 
ability of HSC cells to differentiate into haemopoietic lineages(215). 
Consequently, deletion of interleukin 2 receptor common chain gamma (IL2Rγ-/-) 
led to impaired IL2, IL4, IL7, IL9 and IL15 signalling,(216) which are vital for T 
and NK cell development leading to a drastic decrease in NK cells. This model 
was incorporated into the NOD-SCID model as the NOD-SCID-IL2Rγ-/- model (NSG) 
model and has shown to be more effective at xenotransplant engraftment 
compared to NOD-SCID model alone(217). 
Another model that has been shown to have a similar engraftment efficiency as 
NSG mice is the NOD-Rag-/--IL2Rγ-/- (NRG) mouse. This model is similar to that of 
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the NSG mouse model. Nevertheless, NRG mice have a deficiency of Rag1 or 
Rag2 genes as opposed to the Prkcd gene in NSG mice. Recombination-activating 
genes (Rag), as the name suggests are responsible for the initiation of Ig 
recombination in B and T cells. Rag1/2-null mice also have 
abberations/deletions in IL2Rγ chain(218) leading to a similar phenotype leading 
to concomitant decline in B and T cells altogether. Human HSC engraftment in 
NSG and NRG mice are equivalent(218). 
1.8 Mouse models in CLL 
1.8.1 TCL1 mouse model 
T-cell leukaemia 1 (TCL1) was first identified in T-prolymphocytic leukaemia (T-
PLL) as it was overexpressed in almost all cases. TCL1 has shown to affect B and 
T cell differentiation and Tcl1-KO mice have slight effects on B and T cell 
differentiation. It plays a more potent role in modulating embryonic 
development, stem cell differentiation and hair follicle generation(219). It has 
been shown to interact with AKT1/2 downstream of the PI3K signalling pathway 
and modulate cell proliferation and survival via interactions with DNA 
methyltransferases (DNMTs), NFκB inhibitor α (NFκBα) and receptor tyrosine 
kinase-like orphan receptor-1 (ROR1)(219). 
Tcl1-overexpression (OE) studies showed roles of TCL1 in development and a 
slight role in leukocytes. Tcl1-KI led to the development of T and B cell 
leukaemia in mice depending on the promoter of choice. Lck promoter led to the 
development of T-PLL in mice(220) whereas Tcl1-tg OE under the VH-promoter 
IgH-Eµ-enhancer led to the generation of a CLL mouse model(221) (Eµ-TCL1 CLL 
mouse model) which is the most commonly used CLL-mouse model in research. 
It has been shown that this mouse model represents a poor prognostic model of 
CLL. Disease development is associated with increased surface expression of 
CD23+IgM+CD19+ together with increased levels of ZAP-70. There was also an 
increase in unmutated IgVH status with increased BCR signalling. Nevertheless, 
aggressive disease development has shown to take considerable time as disease 
proliferation becomes visible in the peritoneal cavity at 2 months with visible 
disease homing ~4 and ~6 months in the spleen and BM respectively. Monoclonal 
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expansion was evident at ~8 months and was detectable in the blood after 13-18 
months alluding to an aggressive disease(222). 
Leukemic survival is caused by the interactions in the microenvironment which 
involves BCR signalling along with other co-interactions between cytokines and 
CD40L-CD40 signalling(223). The more aggressive CLL phenotype (unmutated 
IgVH) is associated with sustained BCR signalling which leads to the survival and 
proliferation of B cells. Recently Hayakawa et al., showed that early B1 B cells 
taken from an Eµ-T cell leukaemia 1 (Eµ-TCL1; CLL mouse model), develop into 
CLL with an upregulation in C-MYC, suggesting that the BCR repertoire within B1 
B cells is essential for the generation of CLL(224). Other B cell subpopulations 
were not able to develop into disease alluding to B1 B cells as the cell of origin 
in CLL in this mouse model. 
1.8.2 PKCαKR model in vivo 
Protein kinase C (PKC) proteins are serine/threonine kinases which are involved 
in functions including proliferation, apoptosis, cell differentiation(75). There 
exist Ca2+-dependent isoforms (α,β,γ), Ca2+-independent isoforms (δ,ε,η,θ), and 
atypical isoforms (ζ,λ)(225). These kinases modulate B cell functions via well-
known signalling pathways such as the PI3K/AKT, NFκB signalling 
pathways(226,227). PKCs have also shown to play a role in CLL as activation of 
PKCs in CLL cells leads to protection of the disease from apoptosis due to the 
induction of differentiation(228). Moreover, it has been shown that the retroviral 
transduction of a kinase-dead PKCα isoform (PKCαKR), and not the PKCδ or PKCζ 
isoform, lead to the subversion of B cells into CD19+CD23+CD5+IgMlo CLL-like cells 
which are refractory to apoptosis(229). This suggests that PKCαKR isoform has 
this specific characteristic responsible for regulating vital processes involved in 
CLL. These retrovirally transduced PKCαKR HSPCs led to the generation of a 
poor-prognostic CLL mouse model. This model exhibited an upregulation of ZAP-
70, together with an increase in ERK-MAPK-mTOR signalling and PKCβII 
expression, resembling a more aggressive disease phenotype(230). 
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1.8.3 PKCαKR model in vitro: OP9 co-culture 
Nakagawa et al., have previously shown that the retroviral transduction of HSPCs 
with PKCαKR leads to the generation of a poor prognostic disease in vivo. 
However, this disease can also be maintained by the co-culture on the OP9 cell 
line. OP9 cell line is derived from stromal cells from the calvaria of op/op mice 
which lack M-CSF. This cell line is capable of supporting mainly B lineage cells 
with the generation of myeloid and NK cells lineages early in the co-culture, 
together with the addition of the respective growth factors(231,232). This cell 
line was used in co-culture with the PKCαKR retrovirally HSPCs to promote a B 
cell lineage for the generation of a B-CLL-like disease. Cytokines IL7 and Flt3 
have previously been demonstrated to play a vital role in B cell lineage 
commitment(33). Therefore, these cytokines were supplemented to the co-
culture to generate a poor prognostic disease. 
1.9 Aims of project 
Although the mTOR/AKT signalling pathway has shown to be upregulated in CLL, 
the exact mechanism of this signalling pathway was not known. Additionally, the 
individual roles of the mTOR complexes have not been fully determined in 
normal and malignant CLL-like B cells. Therefore, the aim of my PhD was to: 
i) delineate the individual roles of mTORC1 and mTORC2 in normal 
haemopoiesis utilising specific KO mouse models for Raptor (mTORC1) 
and Rictor (mTORC2) in vivo. 
ii) determine the individual roles of mTORC1 and mTORC2 in 
leukaemogenesis in vitro and in vivo via the KO mouse models. 
iii)  utilise mTOR inhibitors in the presence and absence of current drugs 
in clinic to assess synergy in reducing CLL in vivo. 
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2 Materials and Methods 
Names of companies/suppliers and their address details from where all the 
reagents were purchased are listed in Table 2.1. 
2.1 Mouse models 
B6.SJL mice were used as a background for generating the desired KO mouse 
models using the cre-loxP system. For transplants of the CLL-like disease, NSG 
and NRG mice were used as host for the disease.  
2.1.1 Cre-loxP System 
Mice expressing the cre/loxP system with Raptor (Raptorfl/fl) or Rictor 
(Rictorfl/fl) were obtained from Prof. Michael N. Hall (University of Basel, 
Switzerland)(233) and maintained at the Beatson Research Unit (BRU; Glasgow, 
UK). Prof. Tessa L. Holyoake (University of Glasgow, UK) generously provided 
transgenic mice expressing Mx1-cre and Vav-cre. The CD19-cre transgenic mice 
were a gift from Dr. Dinis Calado (Francis Crick Institute, London, UK). The Mx1 
and Vav-cre mice were maintained at the Beatson Research Unit (BRU) while the 
CD19-cre mice were housed at the Veterinary Research Facility (VRF). We 
crossed Mx1-cre+/-, Vav-cre+/- or CD19-cre+/- transgenic mice with Rictorfl/fl or 
Raptorfl/fl on a background of B6.SJL mice to obtain the desired KO models. The 
cre-loxP system excises the floxed gene of interest under the expression of cre 
by homologous recombination. Cre-recombinase expression can be controlled 
under a promotor to induce a genetic deletion or KO at a specific developmental 
stage or lineage (Figure 2.1). The Mx1 promoter is activated upon TLR3 
activation(234), by inoculating, for example, the cre+-Raptorfl/fl mice with 3,4, 
or 5 doses of 10 mg/kg TLR3 agonist poly(I:C) (GE Healthcare, WI, USA) to induce 
Raptor cKO in the mouse. Vav expression is activated at an early HSC stage, 
therefore the Vav-cre model will induce the KO in HSCs at an early stage thus 
inducing a KO in all haemopoietic lineages(235). Lastly, CD19 is expressed at the 
proB cell stage of B lineage development. Thus, CD19-cre+/-Raptorfl/fl (CD19-
cre+/- Raptor KO) mice lack Raptor only in B cells(206). Excessive cre expression 
has been demonstrated to be leaky by causing widespread recombination 
depending on tissue specificity(208). Furthermore, there exist pseudo-loxP sites 
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in the mouse genome, and when cre is highly expressed, it could cause toxicity 
due to off-target deletions(208). Therefore, we focused on mice carrying 
heterozygous (cre+/-) and not homozygous (cre+/+) mice for phenotyping and 
experimental models. 
For Vav-cre Raptor mice, time matings were carried out where Vav-cre 
Raptorwt/fl were mated with Vav-cre Raptorwt/fl mice and if/when the female 
mouse was pregnant, the mouse was sacrificed at E13, E15, or E18. The mouse 
was dissected to obtain the FL from the litter. 
2.1.2 Organ Processing 
2.1.2.1 BM processing 
The BM was obtained by either flushing or crushing the bones of the mouse. For 
BM obtained by flushing, BM was cut on either ends of the femur with a scissors 
and was then flushed using a 1 ml syringe and a needle with phosphate buffer 
saline (PBS). This was repeated 4-5 times to ensure maximum yield. The 
supernatant was then filtered through a 45 µM sieve. For BM obtained by 
crushing: ilium, femur, fibula, tibia, humerus and ulna from both limbs were 
removed from mice and crushed in 2% FBS in PBS using a pestle and mortar. The 
cells were filtered through a 45 µM sieve to obtain a single cell suspension. This 
was centrifuged for 10 min at 300g. 
2.1.2.2 Spleen, LN Thymus, blood, FL processing 
The spleen, LN, thymus and blood was removed from the transgenic mice. The 
spleen, thymus, LN and FL were crushed to obtain a single cell suspension and 
all the cells obtained were filtered through a 70 μm nylon mesh 
(CellMicroSieves™, Thermo Fisher Scientific, Renfrew, UK). All the cell 
suspensions (excluding blood and FL) were counted in thymus and LN using a 
haemocytometer chamber (Hawksley, Lancing, UK) and Trypan Blue (Merck 
Millipore, Livingston, UK) exclusion method. 
2.1.2.3 Lymphocyte enrichment in BM and Spleen 
 The cells collected from the BM and spleen were enriched for haemopoietic 
cells (excluding red blood cells and dead cells) by density centrifugation via a 
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gradient solution, Lympholyte-Mammal (Cedarlane, Ontario, Canada). Cells were 
pelleted for 5 min in 3 ml PBS at 325g. Then cell pellets were re-suspended in 3 
ml PBS and 1 ml Lympholyte at room temperature (RT) was carefully added using 
the underlay method and centrifuged for 20 min at 625g at RT. The leukocytes 
collect at the interface and this layer was carefully isolated using Pasteur 
pipette. These cells were washed in 10 ml PBS and centrifuged at 500g for 10 
min at RT. The cells were washed once more in 5 ml PBS for 5 min at 325g at RT 
and counted using a haemocytometer. 
2.1.3 Transplants 
2.1.3.1 Primary Transplants 
BM was taken from either Mx1-cre Raptor mice (without poly(I:C) inoculation), 
CD19-cre Raptor mice or B6.SJL WT mice, and was processed by crushing the 
bones (Section 2.1.2.1), and was RV transduced with either PKCαKR vectors as 
described below (Section 2.1.6). BM cells were co-cultured with OP9-GFP 
stromal cells supplemented with IL7 and Flt-3 till day 7-9 (D7-9) and then 
counted. 5x105 cells/100µl cells were transplanted into NSG mice via tail vein 
injections to establish a CLL-like disease in vivo. Disease progression was 
monitored by sampling the blood of the mice weekly (20 l/week) and the 
bloods were analysed for GFP+ CLL-like cells, as described in section 2.3.2, by 
flow cytometry. Once the health was compromised, these NSG mice were 
sacrificed and the organs analysed for CLL-like cells. 
2.1.3.2 Secondary Transplants 
As NSG mice injected with PKCαKR CLL-like cells, retrovirally transduced from 
B6.SJL WT mice, were sacrificed, the spleens were processed in a sterile hood, 
and 3x105 splenic cells were further transplanted into NSG or NRG mice for 
secondary transplants.     
2.1.3.3 Drug Treatments in vivo 
After confirmation of CLL-like disease (≥0.4% GFP+CD19+ cells for primary 
transplants and ≥10% GFP+CD19+ cells for primary transplants in the blood), NSG 
or NRG mice (CLL-like disease generated from BM of B6.SJL WT mice) were 
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treated for 2 wk (primary transplants) and 3 wk (secondary transplants) with 
individual inhibitors, or combination or vehicle control and then sacrificed. BM, 
spleen, LN and blood were collected for analysis (as described in section 2.1.2). 
AZD2014 (a gift from AstraZeneca, Macclesfield, UK) was formulated at 3 mg/mL 
in 20% Captisol (Ligand Pharmaceuticals, Inc., La Jolla, CA) and administered 
daily at 15 mg/kg via oral gavage (OG). Ibrutinib (LC Laboratories, MA, USA) was 
prepared at a concentration of 2.4 mg/ml in 0.5% methyl cellulose (Sigma-
Aldrich, Irvine, UK) and administered at a dose of 12 mg/kg. For vehicle 
controls, captisol and methylcellulose alone or in combination were 
administered. Rapamycin (rapa) was delivered once daily by intraperitoneal (ip) 
injection at a dose of 4 mg/kg dissolved in Tween-80 5.2% / PEG-400 5.2% (v/v). 
2.1.4 OP9-GFP cell line 
OP9 was derived from the new born calvaria of C57BL/6XC3H F2-op/op mice 
which lack the production of M-CSF due to a genetic mutation in the M-CSF 
gene(231). OP9 cell line supports the differentiation of HSCs into B cells when 
culture is supplemented with IL7 and β-mercaptoethanol (βME)(236). OP9 cell 
line was retrovirally-transduced with GFP and grown in culture in complete 
media: alpha-MEM (Gibco, Thermo Fisher Scientific) media supplemented with 
10 mM HEPES, 1 mM sodium pyruvate, 10 µg/ml gentamycin, 50 µM βME, 100 
µg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine, 20% foetal bovine 
serum (FBS). The cells were kept in culture at 37ºC in a humidified incubator 
with 5% (v/v) CO2 and passaged every 2 – 3 days.  
2.1.5 Retroviral packaging lines 
The cell line derived from mouse embryonic fibroblast cells, NIH-3T3 cells were 
transfected with gag, pol and env genes to produce GP+E.86 cells(237). These 
cells were retrovirally-transduced to express MIEV (empty vector control; 
GP+E.86-MIEV), or PKCαKR (GP+E.86-PKCKR)(238). These were cultured at 37ºC 
in a humidified incubator with 5% (v/v) CO2 in complete DMEM media containing 
10 mM HEPES, 1 mM sodium pyruvate, 10 µg/ml gentamycin, 50 µM βME, 100 
µg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine, 10% FBS.   
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2.1.6 Retroviral transduction 
2.1.6.1 Mitomycin C preparation and treatment 
Mitomycin C (2mg/ampule) (Sigma-Aldrich, Irvine) was prepared to a stock 
concentration of 200 µg/ml (20x) in serum free DMEM and was stored in 4ºC for 
up to 6 wk in the dark. 
GP+E.86-MIEV and GP+E.86-PKCαKR packaging lines were cultured in T75 flasks 
in DMEM complete media and when cells reached 70% confluence, they were 
treated with 10 µg/ml mitomycin C in DMEM complete media for 3 hr. 
Thereafter, mitomycin C was removed and 10 ml PBS was added to each flask. 
This was repeated 3-4 times until no residual media was visible and was replaced 
by complete DMEM media for recovery overnight in culture at 37ºC in a 
humidified incubator with 5% (v/v) CO2.  
Three hours prior to retroviral transduction, mitomycin C treated GP+E.86-MIEV 
and GP+E.86-PKCαKR cells were trypsinised and plated in individual 6 well plates 
at 70-80% confluence. This enabled the GP+E.86 cells to adhere to the plates.  
2.1.6.2 CD117 enrichment using magnetic assorted cell sorting (MACS) 
BM was obtained by crushing as mentioned in section 2.1.2.1 and was enriched 
for lymphocytes as described in section 2.1.2.3. Post lymphocyte enrichment 
from BM, cell pellets were re-suspended in 80 µl MACS buffer (2% FBS, 2 mM 
EDTA in PBS) and 20 µl CD117 MicroBeads (MACS Miltenyi Biotec, Surrey, UK) 
were added and incubated for 15 min at 4°C in the dark. Post incubation, 2 ml 
MACS buffer was added to each sample and was centrifuged for 10 min at 500g. 
MS columns (MACS Miltenyi Biotec) were used for CD117 enrichment as described 
in the manufacturer’s protocol. Briefly, the plunger was removed, and the 
columns were placed on a MS column-holding magnet. The columns were first 
activated using 500 µl MACS buffer. Subsequently, each sample was re-
suspended in 500 µl MACS buffer and pipetted onto the top of the MS columns. 
Once all the flow-through was collected, 500 µl MACS buffer was added onto 
each column to wash the column. This was repeated 3 times. Subsequently, the 
MS column was removed from the magnet and placed onto a 15 ml falcon tube. 1 
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ml MACS buffer was added onto the column and the plunger was immediately 
inserted into the column to elute CD117+ cells within the column. The plunger 
was then removed and an additional 500 µl buffer was added and then plunged. 
The CD117+-purified cells were then centrifuged at 500g for 10 min. 
2.1.6.3 Retroviral transduction 
HSC-enriched cell pellets of individual samples were re-suspended in 4 ml 
complete DMEM media containing IL7 and Flt3 (10 ng/ml of each; Peprotech, 
London, UK) and hexadimethrine bromide (Polybrene) (4 µg/ml) (Sigma-Aldrich).  
The supernatants of GP+E.86-MIEV and GP+E.86-PKCαKR cells, when adhered to 
6 well plates, were removed by pipetting and 2 ml of each sample of HSCs was 
added onto individual MIEV and PKCαKR wells. These were then cultured 
overnight at 37ºC in a humidified incubator with 5% (v/v) CO2 (Figure 2.2). 
2.1.6.4 Post transduction and growth of MIEV and PKCαKR transfected cells 
The retrovirally transduced HSC-enriched cells were removed from the plates 
and centrifuged at 400g for 10 min. The pellets were then re-suspended in 
complete alpha-MEM media supplemented with IL7 and Flt3 (10ng/ml of each) 
and plated onto OP9-GFP cells at 20% confluence. The day the BM samples were 
co-cultured with OP9-GFP stromal cells is D1 of culture. These cells were re-
plated with fresh OP9-GFP cells every 3-4 days, and Flt3 was removed after D7 
of culture. 
2.1.7 In vitro KO induction 
The Mx1-cre-Raptor/Rictorfl/fl models were used to induce KO in vitro to assess 
disease maintenance. RV-transduced BM cells were cultured in vitro until D10 for 
Raptorfl/fl or D20 for Rictorfl/fl. Wells containing between 0.5-1x106 cells were 
treated with 50 units (U)/well interferon β (IFNβ) (Pbl Assay Science, NJ, USA) 
for 2 or 3 days, or 200 U/well IFNβ for 24 hr, and harvested 4 days post 
treatment. 
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2.2 K562 cell lines 
K562, a chronic myeloid leukaemia (CML) cell line which is derived from a CML 
patient in blast crisis by pleural effusion(239). This cell line was used to induce 
erythroid differentiation. Differentiation was induced by hemin(240) treatment 
or by galactose supplementation(241) in media. 
2.2.1 Hemin treatment induced erythroid differentiation 
2x105 K562 cells were cultured in either K562 media comprising RPMI-1640 
media, no glutamine, supplemented with 10% FBS, 50 U/ml penicillin, 50 μg/ml 
streptomycin and 2 mM L-Glutamine, in a 6 well plate. The cells were treated 
with 50 μM Hemin (or 20 mM NaOH as control) to the culture. Erythroid 
differentiation was confirmed by pellet colour (red). 
2.2.2 Galactose supplemented erythroid differentiation 
2x105 K562 cells were cultured till D7 in either K562 media, or with  K562 media 
supplemented with galactose (Gal-media) comprising RPMI-1640, no glucose, 
supplemented with 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, 2 mM L-
Glutamine and 11 mM galactose (Figure 2.3A). 
2.2.3 Drug treatment 
2x105 K562 cells were cultured with either K562 media or Gal-media to induce 
erythroid differentiation. Each was also treated with either DMSO, 10 nM 
rapamycin (LC Laboratories) or 100 nM AZD8055 (Stratech Scientific Ltd., 
Suffolk, UK). The cells were cultured till D7 and analysed by either qPCR or by 
flow cytometry (Figure 2.3B, C). 
2.3 Flow cytometry 
Data was acquired using the fluorescent assorted cell sorting (FACS) Canto II 
using the BD FACS DIVA software and analysed using the FlowJo software 
(Oregon, USA). 
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2.3.1 Assessing K562 differentiation 
5x105 K562 cells were stained with 3 µl GlycophorinA (GlyA) (BD Biosciences, 
Clone: GAR2) and 10 µl CD71 (Miltenyi Biotec, Clone: AC102) and incubated on 
ice in the dark for 25-30 minutes. The cells were then washed twice with 1 ml 
PBS at 300g for 5 min and analysed. 
2.3.2 CLL and lineage phenotyping 
Single cell suspensions obtained by in vivo or in vitro experiments (sections 
2.1.2, 2.1.7) were stained with cocktails of antibodies containing cell surface 
markers for either CLL disease comprising CD23, CD5, CD19, CD45, CD11b 
surface markers, lineage detection with CD19, CD4, CD8, CD11b, NK1.1, Gr1 as 
surface markers, early B and myeloid markers (CD45, B220, CD19, Lineage (Table 
2.3), sca-1, CD117, CD16/32, CD34) (Figure 2.4), or late B cell markers (CD19, 
CD23, CD1d, IgD, IgM, CD21, AA4.1) (Figure 2.5) (Table 2.2). 5x105 cells obtained 
from cell suspensions were initially stained with FcRII/III (CD16/32) antibody 
(except for the early B and myeloid staining cocktail) to block any non-specific 
staining for 2 min. Proceeding this, a cocktail of antibodies was added to the 
cells and incubated on ice, in dark for 25-30 min. The cells were washed once 
with 2 ml PBS, resuspended in 100µl and analysed using the flow cytometer 
(Canto II, BD Biosciences, Berkshire). For the early B and myeloid staining, cells 
were then stained with V450 streptavidin (SA, BD Biosciences) for 20 min in the 
dark on ice to bind the lineage biotin antibody mix. Cells were washed in 2 ml 
PBS, resuspended in 100µl and analysed.  
2.3.3 Fixation and permeabilization  
After cell culture/treatment or single cell suspensions obtained from tissues, 
0.5-1x106 cells were harvested and washed twice in PBS by centrifugation at 
325g for 5 min. Then 1 ml 80% ethanol was added dropwise to each sample while 
vortexing to minimise cell stress. Of note, 80% ethanol was added in order to 
make the final concentration of ethanol 70% with the residual supernatant in 
each sample after centrifugation. The cells were then stored in -20ºC overnight 
or for up to 2-3 wk.  
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2.3.4 Assessing intracellular markers 
After fixing and permeabilization (section 2.3.3), each sample was stained with 
the recommended amount/Test (listed in Table 2.4) of either isotype control or 
phospho-AKT, phospho-4EBP1, phospho-S6 or Ki67 and stained for 30 min on ice 
in the dark. The samples were then washed with 2 ml PBS and centrifuged for 5 
min at 325g. Cells were then analysed using flow cytometry. 
2.3.5 Assessment of Apoptosis 
5x105 cells were counted and were washed with 1x Hank’s Balanced Salt Solution 
(HBSS) (Thermo Fisher Scientific) at 300g for 5 min at RT. 100 µl HBSS containing 
2.5 µl AnnexinV and 2.5 µl 7AAD (BD Biosciences) was added into each ample and 
was incubated for 10 min at RT in the dark (Table 2.5). The samples were then 
analysed using the flow cytometer (Figure 2.6). 
2.3.6 Assessment of Cell Cycle 
After fixing and permeabilization (section 2.3.3), cells were pelleted by 
centrifugation at 350g for 5 min and were washed twice in PBS by centrifugation 
at 350g for 5 min to remove any excess ethanol. 350-500µl propidium iodide 
(PI)/RNAase Staining Buffer (BD Biosciences) was added to each sample and was 
incubated at RT in the dark for 15 min. The samples were then analysed using 
the flow cytometer (Figure 2.7). 
2.3.7 Assessment of proliferation 
A 5 mM stock concentration was prepared by adding 20 µl DMSO (component B) 
to one vial of CellTrace™ Violet reagent (Component A) and mixing (Invitrogen, 
Paisley, UK). Then, 1 µL 5 mM CellTrace™ Violet stock solution in DMSO was 
added to each mL of 1x106 cell suspension in PBS/2% FBS for a final working 
concentration of 5 µM. The cells were incubated for 20 min at 37°C, protected 
from light. Five times the original staining volume of culture medium (containing 
at least 1% protein) was added to the cells and incubated for 5 min at 37°C in 
the dark, to remove any free dye remaining in the solution. The cells were 
pelleted by centrifugation and were re-suspended in pre-warmed complete 
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medium and kept in culture for at least 20 min before analysis (d0 timepoint) to 
allow the CellTrace™ Violet reagent to undergo acetate hydrolysis. 
300 µL of each sample was then transferred into FACS tubes and analysed with 
flow cytometry, where 10,000 events were collected on the machine for 3 
consecutive days (every 24 hr) to assess proliferation levels (Figure 2.8).  
2.4 Colony Forming Cell (CFC) Assay 
MethoCult™ (Stem Cell, Cambridge, UK) was thawed and frozen at -20ºC in 4 ml 
aliquots. When needed, MethoCult was thawed at RT. Single cell suspensions of 
1x105 HSC-enriched BM cells (Section 2.1.2.1) /100µl IMDM containing 20% FBS 
were added per ml of MethoCult into the falcon tube containing 4 ml of 
MethoCult aliquot. Tubes were then vortexed for 3-4 sec to homogenise the 
mixture. To set up colony formation units (CFUs), a 5 ml syringe attached to a 
16-gauge blunt-end needle was used. Most of the MethoCult was taken up in the 
syringe, and the plunger was gently depressed completely (to remove air 
bubbles). This was repeated 3 times in 5 min intervals. More than 3.3 ml of 
MethoCult media (from a total of 4ml) was taken up in the syringe and 1.1 ml 
was gently expelled into a 35mm dish in a spiral motion. This was repeated 
twice to make three technical replicates. These dishes were rotated to evenly 
spread the solution across the total surface area. 3-6 dishes were kept in a 
150mm petri dish along with 2 dishes (without a lid) filled with 3-5 ml sterile 
deionised water (dH2O). The lid of the 150mm petri dish was added on top to 
maintain humidity and was incubated at 37°C, 5% CO2 and ≥95% humidity till D7-
10. Colonies were counted after D7 (Figure 2.9). Colonies included: CFU-GEMM 
(colony formation unit-granulocyte-erythroid-megakaryocyte-macrophage), CFU-
GM (colony forming unit-granulocyte macrophage), CFU-G (colony forming unit-
granulocyte), CFU-M (colony forming unit-macrophage), CFU-E (colony forming 
unit-erythroid), BFU-E (burst forming unit-erythroid). 
2.5 Migration Assay 
2.5.1 Cell Starvation 
Between 2-5x105 cells/100 µl was prepared where each sample was counted and 
cultured for 2 hr at 37ºC in a 48 well plate in 250 µl in starvation media (DMEM 
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containing 0.5% bovine serum albumin (BSA), 10 mM HEPES, 1 mM sodium 
pyruvate, 10 µg/ml gentamycin, 50 µM βME, 100 µg/ml streptomycin, 100 U/ml 
penicillin, 2 mM L-glutamine).  
2.5.2 SDF-1 mediated Migration Set-up 
During the starvation step, 150 ng/ml SDF-1 (Peprotech) was added to the 
starvation media to make up the migration media. Transwell® permeable support 
chambers (Corning Inc, ME, USA) were set up such that the bottom of each well 
contained 600 µl of migration media and 100 µl of the cells from the starvation 
step was carefully pipetted onto the chamber in duplicate. For the negative and 
positive controls, starvation media was used instead of the migration media 
where starved cells were either pipetted onto the chamber or directly into the 
bottom respectively. Cells were cultured at 37ºC for 4 hr.  
To assess migration after 4 hr, the chambers were removed from all wells, and 
150 µl media was pipetted from every well into 3 FACS tubes. The cells were 
then acquired in the flow cytometer on low speed for exactly 30 sec. The live 
cells counted were then assessed using FlowJo software. 
2.6 RNA extraction 
Haemopoietic enriched cells removed from BM of Vav-cre Rictorfl/fl mice were 
retrovirally transduced with either MIEV or PKCαKR (section 2.1.6). These cells 
were co-cultured with OP9-GFP cells till D21 and were harvested for messenger 
RNA (mRNA) extraction.  RNA was extracted from cells using the RNA mini kit 
columns (Qiagen, Manchester, UK) using the manufacturer’s protocol and RNA 
(PolyA selection) was eluted in RNA-ase free H20. 
2.7 cDNA Synthesis: 
2.7.1 cDNA synthesis - RT-PCR 
Up to 1 μg RNA was used per 20 μl reverse transcription reaction using the First 
Strand cDNA Synthesis Kit for real time-polymerase chain reaction (RT-PCR) 
(Roche, West Sussex, UK). Each sample was diluted in 1x Tris-EDTA (TE) buffer. 
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2 μl cDNA was used per 10 μl PCR reaction containing 2x PowerUp™ SYBR® Green 
Master Mix (Thermo Fisher Scientific) and 300 nM of forward and reverse primer 
for each gene (listed in Table 2.6). All reactions were performed in technical 
triplicates and at least three biological replicates using the 7900HT Fast Real-
Time PCR system (Applied Biosystems, Warrington, UK) programmed to complete 
40 cycles as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 
95°C for 15 sec, and 60°C for 1 min. After normalization to the endogenous 
control gene, levels of gene mRNA expression in each sample were determined 
by the ΔΔCT method of relative quantification(242). TATA-Box binding protein 
(TBP) was used as the reference gene unless otherwise stated. 
2.7.2 One-step cDNA synthesis: 
2.7.2.1 Sample, master mix and primer mix preparation: 
Retrovirally transduced cells (MIEV or PKCKR) were stained with anti-CD45 
antibody (Table 2.2) on ice for 30 min in the dark. Samples were then washed 
once with 2 ml PBS for 5 min at 300g and resuspended in 500µl PBS. From each 
sample, 300 cells GFP+CD45+ cells were sorted into the PCR tubes containing the 
master mix. 
For the master mix, a 2x reaction mix of 5 µl was added to each PCR tube per 
sample containing: Cells direct 2x reaction (2.8 µl), 0.2x Primer mix (1.4 µl), 
RNAase out (0.056 µl), Superscript III RT/Platinum Taq Mix (0.112 µl), TE Buffer 
(0.672 µl) (part of SuperScript™ III Platinum™ One-Step qRT-PCR Kit, Invitrogen). 
For the primer mix, all primers of interest were selected (Table 2.6) and each 
forward and reverse primer were added to a master mix with a final 
concentration of 0.125µM for each primer in a total volume of 200µl (made up 
with TE buffer). 
2.7.2.2 FACS and PCR:  
After sorting, the tubes were vortexed and centrifuged at 500g for 30 sec. The 
samples were then run on a PCR with the following conditions: 50ºC for 15 min, 
95ºC for 2 min followed by 20 cycles of 95ºC for 15 sec and 65ºC for 4 min. After 
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these cycles, the samples were brought to a hold at 4ºC. After the completion of 
the PCR, the samples were diluted 10x with TE buffer (45 µl). 
Quantitative PCR was performed to assess gene expression of genes included in 
the primer mix (Table 2.6). 
2.8 DNA extraction and Gel electrophoresis 
DNA was extracted for samples using the Qiagen DNA blood/tissue extraction kit 
and following the manufacturer’s protocol (Qiagen). The DNA was quantified 
using a spectrophotometer (Nanodrop ND1000 Spectrophotometer; Labtech 
International Ltd, East Sussex, UK).  
240 ng/ 25 µl of DNA was amplified in a PCR reaction with a hot start of 95ºC for 
2 min followed by 35 cycles of: 30 sec denaturation at 95°C, 30 sec annealing at 
59°C, 1 min extension at 72°C; and a final extension at 72°C for 5 min. The 
primers used are listed in Table 2.6. Products were separated by 1% agarose gel 
electrophoresis in 1x Tris-acetate-EDTA (TAE) buffer and visualised by the 
addition of SYBR Safe DNA (Invitrogen) in the agarose gel (1:10,000). Gel 
electrophoresis was performed at 100 volts (V) for 45 min and the gel was 
imaged using the Odyssey® Fc Imaging system (LI-COR Biosciences, Germany). 
2.9 Western blotting 
Single cell suspensions from organs were counted and 1x107 cells were pelleted 
and were re-suspended in 100 µl lysis buffer (20 mM Tris pH 7.4, 2mM EDTA, 1% 
Triton, 1mM DTT) containing protease inhibitor cocktail (Roche) (Table 2.7) and 
phosphatase inhibitor cocktail (Roche) on ice for 30 min. Lysates were then spun 
at 21900g for 10 min at 4⁰C and supernatant was collected. Quantification of 
protein concentration in the lysates was calculated using the Bradford 
assay(243). BSA standards with concentrations of 0, 2.5, 5, 7.5, 10, 15, 20 µg/ml 
were prepared in 1 ml Bradford dye in 1.5 ml eppendorfs. Following this, 1 µl of 
each unknown sample was added to 1 ml Bradford dye in 1.5 ml eppendorfs. 
These were then vortexed and then 100 µl from each standard and unknown 
sample was loaded on a flat bottomed 96 well plate in duplicate. Absorbance 
was read at 562 nM on a Spectramax M5 plate reader (MDS Analytical 
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Technologies, Berkshire, UK) and analysed with SoftMax Pro 5.2 software (MDS 
Analytical Technologies). 
Equal amounts of protein (typically 10 µg/10 µl) were incubated with 4x NuPage 
LDS Sample buffer and 10x DTT used as a reducing agent at 70°C for 10 min. 
Proteins were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) in a 4-12% NuPAGE Novex BisTris precast gel 
(Invitrogen) (unless otherwise stated), using 1x solution of 20x 50 mM 3-(N-
morpholino) propane sulfonic acid (MOPS) SDS Running Buffer (50 mM 
TrisBase,3.5 mM SDS and 1.0 mM EDTA (pH 7.7)) supplemented with NuPAGE 
antioxidant (Invitrogen). Samples were run alongside HyperPAGE pre-stained 
protein marker (Bioline, TN, USA) at 80 V for 45 min and then at 180 V for 1 hr. 
Gels were then transferred onto Immun-Blot polyvinyliden difluoride (PVDF) 
membranes (Bio-Rad Laboratories, Hertfordshire, UK) using a 1x solution of 20x 
NuPAGE transfer buffer (25 mM Bicine, 25 mM Bis-Tris, 1.0 mM EDTA, 50 µM 
Chlorobutanol (pH 7.2)) supplemented with 20% (v/v) methanol (Merck 
Millipore). Briefly, the PVDF membrane was soaked in 100% methanol for 1 min, 
rinsed in distilled water (dH20) and equilibrated in transfer buffer prior to 
assembly of gel/membrane sandwiches using 1.0 mm gel blotting paper 
(Whatman plc, Kent, UK) and sponges in an XCell IITM Blot Module (Invitrogen, 
Paisley). Transfer was performed at 30 V for 1 hr. 
Blots were washed with 1x Tris-buffer saline (TBS) (20 mM Tris HCl pH 7.4, 150 
mM NaCl), blocked in TBS containing 5% milk for 1 hr at RT, and incubated with 
primary antibody overnight at 4ºC (Table 2.8). Thereafter, the blots were 
washed 2 times with TBS and 2 times with TBST (TBS+ 0.01% Tween 20) for 5-10 
mins each and incubated with horseradish-peroxidase (HRP)-labelled secondary 
antibodies for 1 hr at RT. After 2 washes with TBST and 2 washed with TBS for 5-
10 mins each, the blots were developed with Immobilon Forte Western HRP 
substrate (Merck Millipore) for 1 min and imaged with the Odyssey® Fc Imaging 
system (LI-COR Biosciences). Western blot antibodies were purchased from Cell 
Signalling Technology (Herts, UK) unless otherwise stated. 
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2.10 Immunohistochemistry 
Immunohistochemistry (IHC) was performed by the Beatson Institute of Cancer 
Research. Organs were removed from the mouse and drop-fixed in 5ml 10% 
neutral buffered formalin (NBF) (Cellpath, Newtown, UK) prior to tissue 
infiltration, a process whereby the tissue is suspended in a series of graded 
ethanol baths (70-100% ethanol) to displace water in the tissue. Proceeding this, 
the tissue is paraffin-embedded onto a paraffin wax block. Once the wax has 
solidified and set (takes 1 hr), the block is then sectioned into 5 µM sections and 
placed onto clean glass slides and left for 20 min in a 65°C oven to just melt the 
paraffin into the glass slide. Slides are left overnight at RT to cool. To assess the 
expression levels of various proteins (Table 2.9), sectioned slides are immersed 
in 100% xylene for 5 min to remove paraffin and subsequently placed in 100% 
ethanol baths twice, 70% ethanol, and dH2O bath for 1 min each to rehydrate the 
tissue.  
2.10.1 Antigen retrieval: 
Slides were kept in washing containers with 1x Citrate retrieval buffer (Thermo 
Fisher Scientific) and were kept in a water bath at 98˚C for 30 min. Containers 
were then removed from the water bath and allowed to cool at RT. Slides were 
washed in dH2O for 5 min. 
Endogenous peroxidase quenching and blocking: slides were treated with 3% H2O2 
solution for 10 min (Agilent Dako) followed by a 5 min wash with TBST. Sections 
were blocked with 5% normal goat serum in TBST for 30 min at RT. 
2.10.2 Antibody staining:  
pAKTS473, p4EBP1T37/T46, pS6S235/S236 or Ki67 antibody was added to the sections in 
5% NGS O/N at 4˚C and left overnight (Primary Antibody diluent, Agilent Dako) 
(Table 2.9). The sections were then washed twice in TBST for 5 min. Biotinylated 
anti-rabbit secondary antibody (Table 2.9) was added to the sections for 30 min 
at RT (Vector Labs, Peterborough, UK). Sections were then washed twice in TBST 
for 5 min. 
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NB: Haematoxylin and eosin (H&E) staining was performed by the IHC 
department at the Beatson (Colin Nixon). This was done via standard 
procedures. 
2.10.3 Amplification and Visualisation:  
Sections were then incubated with pre-mixed avidin/biotin complex (ABC) (HRP 
tagged) (Vector ABC Kit, Vector Labs) for 30 min at RT followed by 2 washes in 
TBST for 5 min. For visualisation, sections were treated with 3,3’-
Diaminobenzidine tetrahydrochloride (DAB), which forms a brown precipitate on 
oxidation by HRP, for 10 min followed by a wash in dH2O for 1 min. 
2.10.4 Counterstaining and dehydration: 
The slides were counterstained by staining with haematoxylin Z for 7 min for 
nucleus visualisation, followed by dH2O wash for 1 min. The slides were then 
dehydrated by placing the slides in 70% ethanol for 1 min twice and then in 100% 
ethanol for 5 min. The slide was then treated with one drop of distyrene, 
polystyrene, xylene (DPX) solution to mount and preserve the staining and left to 
dry for 5 min. The slides were visualised under an inverted microscope at x4 
magnification (Olympus Life Sciences, Japan). 
2.11 Statistics 
Statistical analyses were carried out between the data sets by using GraphPad 
Prism 6 Software (San Diego, California, USA). The analysis carried out was, 
either paired or unpaired, student t-test or one-way ANOVA. Data is represented 
as mean±standard error of mean (SEM) or as mean±standard deviation (SD) 
where p≥0.05, as stated in the figure legends. 
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2.12 Tables and Figures 
Supplier Supplier Address 
Applied Biosystems 
Part of Thermo Fisher Sceintific 
Lingley House, 120 Birchwood 
Boulevard, Warrington, WA3 
7QH, UK 
Agilent Dako 
5301 Stevens Creek Blvd, Santa Clara, 
CA 95051, United States 
AstraZeneca Charter Way, Macclesfield, SK10 2NA 
BD Biosciences 
1030 Eskdale Road, Winnersh Triangle 
Wokingham, Berkshire, RG41 5TS 
Bioline, Meridian life sciences, Inc. 
Meridian Life Science, Inc., 5171 
Wilfong Rd., Memphis, TN 38134 
Bio-Rad Laboratories Ltd. 
Bio-Rad Laboratories Ltd. 
The Junction, Station Road, Watford, 
Hertfordshire, WD17 1ET 
eBioScience 
Part of Thermo Fisher Scientific 
3 Fountain Dr, Inchinnan, Renfrew 
PA4 9RF, UK 
Clarivate Analytics 
1500 Spring Garden, Philadelphia, PA 
19130, United States 
Cedarlane 
4410 Paletta Court, Burlington, 
Ontario 
L7L 5R2, Canada 
Cellpath 
Mochdre Enterprise Park, Mochdre, 
Newtown SY16 4LE 
Cell Signaling Technology 
c/o New England Biolabs 
75-77 Knowl Piece, Wilbury Way, 
Hitchin, 
Herts SG4 0TY, UK 
Corning Incorporated 
2 Alfred Road, Kennebunk, ME 04043 
USA 
GE Healthcare 
3000 N Grandview Blvd 
Waukesha, WI 53188 
United States 
Greiner Bio-One Ltd. 
Unit 5, Stroudwater Business Park, 
Gloucestershire, 
GL103SX, UK 
Hawksley 25 Marlborough Rd, Lancing BN15 8TN 
Illumina Inc. 
5200 Illumina Way, San Diego, CA 
92122, United States 
Invitrogen, Paisley, UK Ltd. 
Part of Thermo Fisher Scientific 
3 Fountain Dr, Inchinnan, Renfrew 
PA4 9RF, UK 
LC Laboratories 
165 New Boston Street, Woburn, MA 
01801, USA 
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LI-COR Biosciences 
Siemensstraße 25, 61352 Bad Homburg 
vor der Höhe, Germany 
Merck Millipore Fleming Rd, Livingston EH54 7BN, UK 
Miltenyi Biotech 
Almac House, Church Lane, Bisley, 
Surrey, GU24 9DR, UK 
Olympus Life Sciences 
Shinjuku Monolith, 2-3-1 Nishi-
Shinjuku, Shinjuku-ku, Tokyo 163-
0914, Japan 
Pbl Assay Science 
131 Ethel Road West #6, Piscataway 
Township, NJ 08854, USA 
PeproTech EC Ltd 
PeproTech House, 29 Margravine 
Road, 
London, W6 8LL, UK 
Polyomics, University of Glasgow 
Switchback Road, Bearsden, Glasgow, 
G61 1BD, UK 
Qiagen 
Skelton House, Lloyd St N, Manchester 
M15 6SH, UK 
R&D Systems 
 
R&D Systems Europe Ltd., 19 Barton 
Lane, Abingdon Science Park, 
Abingdon, OX14 3NB, UK 
Sigma-Aldrich Co Ltd 
Second Ave, Heatherhouse Industrial 
Estate, Irvine, KA12 8NB 
Stem Cell Technologies 
Building 7100, Cambridge Research 
Park, Beach Drive, Waterbeach, 
Cambridge CB25 9TL 
Stratech Scientific Ltd. 
Cambridge House, St Thomas' Pl, Ely 
CB7 4EX 
Thermo Fisher Scientific 
3 Fountain Dr, Inchinnan, Renfrew 
PA4 9RF 
Vector Labs Bakewell Rd, Peterborough PE2 6XS 
Table 2.1: List of companies and their addresses from where reagents and materials were 
purchased.  
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Table 2.2: Antibodies used for flow cytometry. Master mixes (MM) made for phenotypic 
identification. 
CLL disease MM: CD23, CD5, CD19, CD45, CD11b; Lineage MM: CD19, CD4, CD8a, CD11b, 
NK1.1, Gr1, Ter119; Early B and myeloid MM: CD45, B220, CD19, Lineage 
Table 2.3), sca-1, CD117, CD16/32, CD34; Late B cell MM: CD19, CD23, CD1d, IgD, IgM, CD21, 
AA4.1.   
Name Reactive 
Species 
Clone Format Manufacturer Dilution 
CD19 Mouse 1D3 APC-Cy7 BDBiosciences 1:200 
CD11b Mouse M1/7O Pacific Blue BDBiosciences 1:200 
CD45 Mouse 30-F11 PerCP BDBiosciences 1:200 
CD5 Mouse 53-7.3 APC BDBiosciences 1:200 
CD23 Mouse B3B4 PeCy7 BioLegend 1:200 
Gr1 Mouse RB6-8C5 PerCP-
Cy5.5 
eBiosciences 1:200 
CD4 Mouse RM4-5 PE BDBiosciences 1:200 
CD8a Mouse 53-6.7 APC BDBiosciences 1:200 
NK1.1 Mouse PK136 PECy7 BDBiosciences 1:200 
Ter119 Mouse TER-119 FITC BioLegend 1:200 
CD34 Mouse RAM34 FITC BDBiosciences 1:200 
B220 Mouse RA36B2 PE BDBiosciences 1:400 
CD117 Mouse 2B8 APC BDBiosciences 1:200 
Sca-1 Mouse D7 Pe-Cy7 BDBiosciences 1:200 
CD16/32 Mouse 2.4G2 BV510 BDBiosciences 1:200 
Streptavidin   V450 BDBiosciences 1:200 
IgD Mouse 11-26c.2a BV510 BioLegend 1:200 
CD1d Mouse 1B1 PerCP-
Cy5.5 
BioLegend 1:200 
AA4.1 Mouse AA4.1 PE BDBiosciences 1:200 
IgM Mouse II/41 APC BDBiosciences 1:200 
CD21 Mouse 7E9 Pacific Blue BioLegend 1:200 
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Table 2.3: Biotinylated antibodies used to delineate early B and myeloid developmental 
stages and lineages for flow cytometry. 
  
Name Reactive 
Species 
Clone Format Manufacturer Dilution 
CD4 Mouse GK1.5 Biotin BDBiosciences 1:200 
CD8a Mouse 53-6.7 Biotin BDBiosciences 1:200 
CD3e Mouse 145-2C11 Biotin BDBiosciences 1:200 
NK1.1 Mouse PK136 Biotin BDBiosciences 1:200 
TCR Mouse H57-597 Biotin BDBiosciences 1:200 
Ter119 Mouse Ter119 Biotin BDBiosciences 1:200 
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Name Reactive 
Species 
Clone Format Dilution 
anti-4EBP1 
(pT36/pT45) 
Mouse M31-16 PE 15µl/Test 
anti-S6 
(pS235/pS236) 
Mouse N7-548 V450 3µl/Test 
anti-AKT 
(pS473) 
Mouse, 
Human 
M89-61 Alexa 
Fluor® 647 
3µl/Test 
anti-Ki67 Mouse, 
Human 
B56 PE-Cy™7 3µl/Test 
κ Isotype 
Control 
Mouse MOPC-
21 
V450 3µl/Test 
IgG1 κ Isotype 
Control 
Mouse MOPC-
21 
Alexa 
Fluor® 647 
3µl/Test 
Table 2.4: List of antibodies used for phospho-flow cytometry. All antibodies were 
purchased from BD Biosciences, unless stated otherwise. 
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Table 2.5: Antibodies used for viability assays on the flow cytometer. 
  
Name Format Manufacturer Dilution 
AnnexinV APC BDBiosciences 2.5µl/Test 
7-AAD  BDBiosciences 2.5µl/Test 
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Gene Forward Reverse Complement Species 
Actb ctcctcctga gcgcaagtac gccatgccaat gttgtctct Mouse 
Bcl2 a tgactgagta cctgaaccg tcaaacagaggtcgcatgct Mouse 
Bid gccagattctg aaagtcagg gctagctgtc tcaccagtgt Mouse 
Ccnd1 gtg ccacagatgt gaagttc gt cacacttgat gactctgg Mouse 
Ccnd2 caagatcacc cacactgatg gtt atgctgctct tgacgga Mouse 
Ccnd3 atg cggaagatgc tggcata gaagct gcaattgcgc cttt Mouse 
Cdkn1a cggtggaactttgacttcgt agagtgcaagacagcgacaa Mouse 
Cdkn1b gata cgagtggcag gaggtg tctga cgagtcaggc atttg Mouse 
Cebpa aaga acagcaacga gtaccg ttctgtt gcgtctccac gtt Mouse 
Ebf1 tac agaaggtcat tcctcgg atcccatacagggcttc aac Mouse 
Gata1 atgatt gtcagcaaac gggc aggcattgcataccgga tct Mouse 
Gata2 gacgacaacc accaccttat ggt cagtggcctg ttaacat Mouse 
Gusb ta agacgctgat cacccaca cagataacatccacgtacg g Mouse 
Hba-a1 aacttcaag ctcctgagcca tgctca agaggcaaggaat Mouse 
Klf1 ctaagagg caggcggcacat ctgagcgagcgaacctcc Mouse 
Klf2 ccaagagc tcgcacctaaag gtggcactgaaa gggtctgt Mouse 
Pax5 acagga catggaggag tgaa tgacaccttg atgggcaagt Mouse 
Prkcb catcgacaga gaggttctca g gatcagggat cagtttcag Mouse 
Pu.1 cagcgatgga gaaagccata ctctgtgaagtggttctcag Mouse 
Rptor atggtagcaggcacactcttcatg gctaaacattcagtccctaatc Mouse 
Rptor-Del  ctcagagaactgcagtgctgaagg Mouse 
Rictor ttattaact gtgtgtgggttg cgtcttagt gttgctgtctag Mouse 
Rictor-Del  cagattcaagca tgtcctaagc Mouse 
Tbp gtacccttcaccaatgact c cagccaagattcacg gtaga Mouse 
HBB gcaaggtga acgtgg atgaa agcact ttcttg ccatgagc Human 
GATA1 tattcc tctccc aagcttcg catctt gtgata gaggcc gca Human 
GATA2 gacgacaacc accaccttat ggt cagtggcctg ttaacat Human 
RNF20 ggtgtc tcttca acggag gaa tagtgaggc atcatc agtggc Human 
Table 2.6: List of primers used for PCR reactions.  
The full sequence for each gene was obtained from PubMed website. Each primer was designed to 
have close to 10 C=G and 10 A=T bonds. The length between the forward and reverse primer is 
between 150-300 base pairs (bp). Rptor-Del and Rictor-Del are reverse primers designed to 
complement the gene of interest (Raptor and Rictor respectively) between the two loxP sites. 
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Inhibitor 
Aprotinin 
Bestatin 
Calpain Inhibitor I 
Calpain Inhibitor II 
Chymostatin 
E-64 
Leupeptin 
α2-Macroglobulin 
Pefabloc SC 
Pepstatin 
PMSF 
TLCK-HCl 
Trypsin Inhibitor (chicken, egg white) 
Trypsin Inhibitor (soybean) 
Table 2.7: List of protease inhibitors in the cOmplete mini, EDTA-free protease inhibitor 
cocktail from Roche. 
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Name Reactive 
Species 
Clone Dilution Secondary 
Ab 
RAPTOR Human, 
Mouse, Rat 
24C12 1:1000 Rabbit 
RICTOR Human, 
Mouse 
D16H9 1:1000 Rabbit 
pAKTS473 
 
All 23C8D2 1:1000 Rabbit 
AKT (pan) Human, 
Mouse, Rat 
C67E7 1:1000 Rabbit 
pS6S235/S236   Human, 
Mouse, Rat 
D57.2.2E 1:1000 Rabbit 
S6 Human, 
Mouse, Rat 
54D2 1:1000 Mouse 
p4EBP1T37/T46 Human, 
Mouse, Rat 
 1:1000 Rabbit 
4EBP1 Human, 
Mouse, Rat 
53H11 1:1000 Rabbit 
GAPDH Human, 
Mouse, Rat 
D16H11 1:1000 Rabbit 
β-ACTIN Human, 
Mouse, Rat 
 1:1000 Rabbit 
Anti-mouse IgG, HRP-
linked Antibody 
  1:10000  
Anti-rabbit IgG, HRP-
linked Antibody 
  1:10000  
Table 2.8: List of antibodies used for western blotting. 
List of antibodies and their dilutions in 5% BSA in TBST (except for S6 ribosomal protein, which 
was in 5% milk in TBST). All antibodies were purchased from Cell signalling (Herts, UK). 
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Name Reactive 
Species 
Clone Dilution Manufacturer Isotype 
pS6S235/S236 Mouse D57.2.2E 1:800 Cell signalling Rabbit IgG 
Ki67 Mouse RM-9106-S 1:100 Thermo Fisher Rabbit IgG 
pAKTS473 Mouse 9DE 1:25 Cell signalling Rabbit IgG 
p4EBP1T37/T46 Mouse 236B4 1:500 Cell signalling Rabbit IgG 
Biotinylated 
goat anti-
rabbit 
Mouse   Vector Labs Rabbit IgG 
Table 2.9: List and details of antibodies used for IHC.  
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Figure 2.1: Cre-loxP system and excision of Rictor/Raptor under promoters including Vav, 
Mx-1 and CD19.  
Upon the expression of the promotors, cre is expressed and it excises the floxed gene flanked by 
loxP sites thereby generating a KO of the gene of interest (in this case gene of interest being 
Raptor and Rictor). 
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Figure 2.2 In vitro system for the retroviral transduction of BM removed from KO mouse 
models.  
BM is enriched for CD117 by MACS, and co-cultured overnight with GFP tagged GP+E.86 
MIEV/PKCαKR supplemented with IL7, Flt3, and polybrene in complete DMEM media to retrovirally 
transduce the enriched BM cells. Post transduction, cells are co-cultured on OP9-GFP+ stromal 
cells supplemented with IL7 and Flt3 cytokines to promote B cell lineage generation. 
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Figure 2.3 K562 cell line and its differentiation into an erythrocyte-like lineage. 
A. Flow cytometry representative plot of K562 demonstrating the increase in CD71+GlyA+ surface 
expression with the substitution of glucose with galactose in media. Live cells were gated by 
looking at forward scatter and side scatter area (FSC-A and SSC-A). Doublet cells were excluded 
by FSC-A and forward scatter height (FSC-H).  Representative flow cytometry plots showing the 
change in size and granularity through FSC-A and SSC-A plots of K562 cells (B) or K562 cells 
cultured with galactose (C) and treated with 10 nM rapamycin or 100 nM AZD8055.
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Figure 2.4 Representative flow cytometry graphs and gating strategy. 
Flow cytometry graphs demonstrating gating strategy for various haematopoietic lineages (A), early 
B cells (B), early myeloid populations (C). Various organs obtained from Mx1-cre Raptorfl/fl mice 
stained for lineage, and early B and myeloid surface markers. Live cells were gated by looking at 
FSC-A and SSC-A. Doublet cells were excluded by FSC-A and FSC-H. Mature B cells (CD11b-
CD19+), CD4 T cells (CD19-CD8a-CD4+), CD8 T cells (CD19-CD4-CD8a+), NK cells (CD19-CD4-
NK1.1+), mature myeloid cells (CD19-CD11b+Gr1+), pre-proB cells (lin-CD19-B220+), proB cells (lin-
CD19+B220+), LSK (lin-CD19-B220-Sca-1+CD117+), scaloCD117hi (lin-CD19-B220-sca-1loCD117hi), 
CMP (lin-CD45+ScaloCD117hiCD34+CD16/32-), GMP (lin-CD45+ScaloCD117hiCD34+CD16/32+), 
MEP (lin-CD45+ScaloCD117hiCD34+CD16/32+). 
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Figure 2.5 Representative flow cytometry plots showing the gating strategy for late B cell 
subsets.  
Spleens obtained from Mx1-cre Raptorfl/fl mice stained for late B cell surface markers. Live cells 
were gated by looking at FSC-A and SSC-A. T1 cells (CD19+CD23-IgM+CD21-), T2 
(CD19+CD23+CD21-CD1dloIgD+IgM+AA4.1+), T3 (CD19+CD23+CD21-CD1dloIgD+IgM-AA4.1+), MZP 
(CD19+CD23+CD21+CD1d+), MZ (CD19+CD23-IgM+CD21+), Fol1 (CD19+CD23+CD21-
CD1dloIgD+IgM-AA4.1-), Fol2 (CD19+CD23+CD21-CD1dloIgD+IgM+AA4.1-). Abbreviations: T1-3 – 
Transitional cells, fol – follicular cells, MZP – marginal zone progenitors. 
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Figure 2.6 Representative flow cytometry plot showing AnnexinV and 7AAD staining. 
 AnnV-7AAD- are viable cells, AnnV+7AAD- are apoptosing cells, AnnV+7AAD+ are dead cells. BM cells 
obtained from CD19-cre Raptorfl/fl mice. 
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Figure 2.7: Flow cytometry representative plot showing the different phases of cell 
cycle by propidium iodide (PI) staining.  
Retrovirally transduced PKCαKR cells, which were derived from BM of Vav-cre Rictorfl/fl 
mice. PI assay was set up at D22 in vitro. Live cells were gated by looking at FSC-A and 
SSC-A. Doublet cells were excluded by FSC-A and FSC-H. GFP- cells were excluded and 
then PI was observed in the graph above. Sub G0 phase contains apoptotic cells, cells in 
G0 phase are quiescent cells, cells in G1 phase are in preparation for doubling the 
chromosomal levels for mitosis, cells in S phase indicate DNA synthesis, G2 phase is where 
mitosis preparation occurs, and M phase is where mitosis occurs. RCN - Relative cell 
number. 
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Figure 2.8 Representative plot showing cell trace violet (CTV) fluorescence over 3 days 
thereby measuring the proliferation of a population.  
Retrovirally transduced PKCαKR cells, which were derived from BM of Mx1-cre Raptorfl/fl mice. 
Cells were treated with 200 U/well interferonβ (IFNβ) for 24 hr in vitro. This proliferation assay was 
set up 3 days after treatment. Live cells were gated by looking at FSC-A and SSC-A. Doublet cells 
were excluded by FSC-A and FSC-H. GFP- cells were excluded and then CTV fluorescence was 
observed in the graph. Red, blue and yellow peaks represent CTV fluorescence at D1, 2, and 3 
respectively. RCN - Relative cell number. 
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Figure 2.9 Different colonies formed by Vav-cre Rictorfl/fl BM (CD117 enriched cells) using 
the m3434 and m3334 MethoCult media.  
CFU-GM (colony forming unit-granulocyte macrophage), CFU-G (colony forming unit-granulocyte), 
CFU-M (colony forming unit-macrophage), CFU-E (colony forming unit-erythroid), BFU-E (burst 
forming unit-erythroid). Pictures are taken using an inverted microscope (Olympus Life Sciences, 
Japan) at x4 magnification. 
x4 
x4 x4 
x4 x4 
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Chapter 3 
 
The Role of mTOR in Erythropoiesis and 
Myelopoiesis 
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3 Role of mTOR in erythropoiesis and 
myelopoiesis 
3.1 Aims and objectives 
The mTOR pathway has previously been shown to play a role in RBC 
development(97). The aims of this chapter are to determine the role of mTORC1 
and mTORC2 in RBC development and the role of mTORC1 in myelopoiesis using 
mouse models:  
i) The Vav-cre Raptor/Rictorfl/fl mouse model, which excises either 
Raptor or Rictor (inactivating mTORC1 or mTORC2 respectively) at the 
HSC stage under the Vav promoter.  
ii) The Mx1-cre Raptorfl/fl mouse model which excises Raptor (thus 
rendering mTORC1 inactive) in all tissues in a time controlled manner 
by the inoculation of poly(I:C) (Section 1.7.1.2).  
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3.2 Results 
3.2.1 Mice lacking mTORC1 within the haemopoietic lineage do 
not survive after birth and Raptor-null adult mice display 
splenomegaly 
To assess the role of mTORC1 at the HSC stage we used the Vav-cre model. To 
obtain the desired Raptor KO model, Vav-cre+/-Raptorwt/fl were mated with Vav-
cre-/-Raptorfl/fl to obtain the possible mendelian phenotypic filial generations: 
Vav-cre-/-Raptorfl/fl (Vav-Raptor control), Vav-cre+/-Raptorwt/fl, Vav-cre-/-
Raptorwt/fl, or the desired KO model Vav-cre+/-Raptorfl/fl (Vav-Raptor KO). From 
previous literature, it is preferable to use heterozygous cre expression for the 
KO models, as homozygous expression of cre has shown to be ‘leaky’, leading to 
non-specific deletions due to the presence of pseudo-loxP sites present in the 
mouse genome(208). Therefore, cre+/-Raptorfl/fl was the desired KO model.  
Analysis of Vav-cre matings demonstrated a lack of Vav-Raptor KO mice 
specifically at weaning age (4 wk) (Table 3.1). We thus performed time- 
matings, obtaining foetus’ at E13, E15 and E18, to determine whether the Vav-
Raptor KO mice were present at these embryonic stages. Indeed, between E13-
18, we obtained the desired model/phenotype of interest in the expected 
mendelian ratios (Table 3.1). This suggests that mice with Raptor KO at the HSC 
do not survive much longer after birth and undergo perinatal lethality. Post birth 
genotyping then revealed that Vav-Raptor KO mice do not survive more than 2 
days (D2) after birth. Genotyping Vav-Raptor KO FL confirmed the KO as these 
FLs had a significant downregulation in Raptor expression (Figure 3.1A). 
Additionally, the Raptor-null foetus’ had a much increased pallor (Figure 3.1B) 
alluding to a fundamental role of mTORC1 in RBC development.  
To assess the role of mTORC1 at a later developmental stage, the Mx1-cre 
Raptorfl/fl model was used where Mx1-cre-/-Raptorfl/fl mice were mated with 
Mx1-cre+/-Raptorfl/fl to obtain the desired KO model Mx1-cre+/-Raptorfl/fl (Mx1-
Raptor cKO), along with the control Mx1-cre-/-Raptorfl/fl (Mx1-Raptor control). 
Compared to Vav-Raptor KO mice, both possible genotypes Mx1-Raptor control 
and cKO models (without poly(I:C) inoculation) were obtained in the filial 
generations (Table 3.2) and induction of mTORC1 cKO, by poly(I:C) inoculations, 
in adult mice did not result in lethality (data not shown). The Mx1 promoter is 
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only expressed under the activation of TLR3. Therefore, poly(I:C), an RNA 
mimetic which activates TLR3 was used to induce the cKO(202,244). Upon 
successful cKO, which was confirmed by a significant downregulation of Raptor 
gene expression in BM and spleen of Mx1-Raptor cKO compared to Mx1-Raptor 
control (Figure 3.1C), Mx1-Raptor cKO mice exhibited splenomegaly and a 
significant increase in spleen weight and spleen cellularity compared to Mx1-
Raptor controls (Figure 3.1D-F). 
3.2.2 Raptor-null mice have a disruption in RBC, myeloid, and B 
cell lineages in vivo 
Analysis of haemopoietic lineages isolated from primary lymphoid organs in 
these mouse models, by flow cytometry, revealed a significant decrease in the 
percentage of Ter119+ erythroid populations in Vav-Raptor KO FL at E15 
compared to Vav-Raptor controls (Figure 3.2A-D, Figure 3.3A). Additionally, 
there was a trend in decrease in the percentage of Ter119+ erythroid populations 
in the BM (Figure 3.2E-F), together with a significant increase in percentage of 
Ter119+ population in the spleen in Mx1-Raptor cKO mice compared to Mx1-
Raptor controls (Figure 3.3B). A significant increase in percentage of Ter119+ 
expression in the spleen in Mx1-Raptor cKO mice suggests either a compensatory 
mechanism of the organism to overcome the loss in erythrocytes, or a functional 
role of the spleen in erythrocyte metabolism. Given the ability for mice to 
survive in the absence of white blood cell populations, and supported by 
previous literature(97) we concluded that the absence of Vav-Raptor KO mice 
was due to the critical role of mTORC1 in erythropoiesis. 
 
Further assessing the mTORC1 KO models, both the mTORC1 KO models showed 
a significant increase in percentage of CD11b+ Gr1- immature myeloid population 
along with a decrease in percentage of CD11b+Gr1+ mature myeloid populations 
compared to controls (Figure 3.2, Figure 3.3C-E). This suggests that mTORC1 is 
not important for myeloid lineage commitment but is essential for myeloid 
maturation. Looking at the role of mTORC1 in B cell lineage generations, our 
results demonstrate that both the Vav-Raptor KO FL and Mx1-Raptor cKO mice 
exhibit a significant decrease in the percentage of CD19+ B cell populations in 
E15 and E17 FL of Vav-Raptor KO and in the BM, spleen and a trend in decrease 
in the blood of Mx1-Raptor cKO mice compared to their respective controls 
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(Figure 3.2, Figure 3.3F-H). These data suggest a vital role of mTORC1 in B cell 
lineage commitment at early and late stages of development. 
3.2.3 Mice lacking Raptor at the HSC stage have a disruption in 
early B cell population and a block in RBC development at 
the MEP stage in vivo 
To gain a deeper understanding of the stage at which Raptor-deficiency blocks 
lineage commitment/development we carried out flow cytometry analysis of the 
haemopoietic progenitor populations. Supporting the lack of CD19+ B cells, a 
significant reduction in the percentage of proB cells was noted across E13-18 of 
Vav-Raptor KO FL (Figure 3.4, Figure 3.5A) and Mx1-Raptor cKO BM, along with a 
significant reduction in percentage of pre-proB cells in Mx1-Raptor cKO BM 
(Figure 3.5D), and trends in reduction in percentage of pre-proB cells across E13-
18 of Vav-Raptor KO FL compared with their respective controls (Figure 3.5B). 
This was coupled with a trend in increase in percentage of LSK population at 
E13, along with a significant elevation at E15, while no significant difference 
was noted at E18 in Vav-Raptor KO FL. There was a significant elevation in the 
percentage of LSK in BM of Mx1-Raptor cKO adult mice compared to cre- 
controls (Figure 3.4, Figure 3.5C&D), suggesting a block in B cell development 
prior to lineage commitment with Raptor deficiency, at an early stage in 
gestation and in adult mice.  
Analysis of the proportion of myeloid progenitors revealed a significant elevation 
in the percentage of Sca-1loCD117hi population in Vav-Raptor KO FL at E13 and 
E15 (Figure 3.7A), a population consisting of CMP population, which gives rise to 
GMP and MEP populations (Figure 3.6). There were no changes in the 
percentages of CMP and GMP populations at E13, E15 or E18 of Vav-Raptor KO FL 
(Figure 3.7B, C). However, there was a trend towards an increase in percentage 
of GMP populations at E13, and E15 suggesting a skew towards myeloid lineages 
in Raptor-deficient mice at the HSC stage, which alludes to the observed 
accumulation of CD11b+ immature myeloid population. Comparatively, the Mx1-
Raptor cKO BM exhibit a decrease in the percentage (but not cellularity) of Sca-
1loCD117hi population, with no significant changes in the CMPs, but with a 
significant decrease in the percentage (but not cellularity) of GMPs compared to 
controls (Figure 3.6, Figure 3.8A&B), which confirms the decrease in percentage 
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of CD11b+Gr1+ mature myeloid population in BM of Mx1-Raptor cKO mice as GMPs 
give rise to myeloid lineages. The difference in progenitor populations between 
the FL and BM with Raptor-deficiency illustrates the varied functioning of the 
two organs and highlights that mTORC1 plays similar but not identical roles in 
lineage maintenance at different stages of development and ontogeny. Assessing 
the MEP population, there was an elevation in the percentage of MEPs at E13 
and E15, with no observed change at E18 (Figure 3.7D) indicating a 
developmental block for erythropoiesis at the MEP stage in the absence of 
Raptor expression in vivo at the early HSC stage. The lack of change in early 
progenitors at E18 may be due to the shift of haemopoiesis towards the BM after 
E16.5 to prepare for birth (245). Adult mice with Raptor-deficiency exhibit a 
significant decrease in the percentage (not cellularity) of MEP population in the 
BM, which confirms the block in erythropoiesis at an earlier developmental stage 
in the BM. There is a significant decrease in the cellularity and trends in 
reduction in the percentage of MEP population in the spleen (Figure 3.8C&D), 
which suggests that there is a depletion of erythrocytes in the spleen. 
Therefore, the significant increase of erythrocytes in the spleen could allude to 
an acceleration in erythrophagocytosis, which occurs in the spleen(246). 
Interestingly, there is a significant increase in percentage and cellularity of MEP 
population with Rictor-deficiency at the HSC stage at 2 wk (Vav-Rictor KO mice) 
with similar trends at 8 wk compared to cre- controls (Vav-Rictor control mice, 
Figure 3.8E&F). These are opposing trends to what is observed with Raptor-
deficiency, suggesting a regulatory mechanism of erythropoiesis between 
mTORC1 and mTORC2 where mTORC1 is fundamental for the development of 
erythrocytes whereas mTORC2 suppresses erythrocyte generation. 
In support of our phenotypic analysis showing a block in B cell and RBC 
development, expression analysis of key genes at the HSC stage responsible for 
enabling differential lineage commitment revealed a significant downregulation 
in the B cell specific transcription factors Ebf1 and Pax5, while expression levels 
of the myeloid regulator Cebpα was unaltered. Assessing expression levels of 
vital TFs involved in erythroid lineage commitment, Pu.1 and Gata1 expression 
levels were significantly downregulated in the FL of Vav-Raptor KO mice with 
trends in an increase in Gata2 levels alluding to aberrations in Gata-factor 
switching. Additionally, there was a significant downregulation in the expression 
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of β-Globin, e-Klf/Klf1 and Klf2, TFs which play a role in embryonic and adult 
erythropoiesis and development (Figure 3.7E-G). Collectively, these results 
indicate an aberration B and RBC lineage commitment with Raptor deficiency in 
Vav-Raptor KO FLs. 
3.2.4 Exploiting K562 CML cell line as an in vitro model for 
erythropoiesis 
In order to further analyse the role of mTORC1 in RBC development in vitro, we 
made use of the BCR-Abl+ human CML cell line K562, an erythroleukaemia line 
that differentiates towards a RBC lineage when exposed to stressful 
environments(247–249). To induce differentiation, cells were treated with either 
50 μM hemin(240) or 11 mM glucose was replaced with 11 mM galactose in 
complete media(241) and cultured till D5-7 in vitro. Hemin treatment showed 
the differentiation towards a RBC-like lineage as seen by the colour change in 
cells with hemin treatment (Figure 3.9A). As hemin is strongly auto-fluorescent, 
moving forward, we supplemented glucose for galactose in the media (Gal-
media) to induce stress and thus RBC differentiation (as described in section 
2.2.2). Indeed, we observed a significant increase in the percentage of 
CD71+GlyA+ cells (erythroid markers), an elevation in CD71 expression and a 
reduction in granularity (cell scatter – SSC-A) (Figure 3.9B-D, Figure 3.10A-C) in 
K562 cells cultured in Gal-media, coupled with a significant increase in gene 
expression of β-GLOBIN, and GATA2, which are involved in erythropoiesis (Figure 
3.10D). Interestingly, we see a change in the activity of the mTOR pathway with 
erythroid differentiation in vitro as was indicated by an increase in expression of 
pAKTS473, coupled with a decrease in RAPTOR and p4EBP1T37/T46 expression in 
K562 cell cultured in Gal-media, suggesting an increase in mTORC2 and a 
decrease in mTORC1 activity (Figure 3.11A-D). 
3.2.5 K562 cell line differentiation into RBCs is blocked with 
mTOR inhibition in vitro 
To assess the role of mTORC1 in RBC differentiation, K562 cell line was treated 
with a partial mTORC1 inhibitor, rapamycin and the dual mTOR complex 
inhibitor AZD8055, and cultured in either complete media or Gal-media to 
induce RBC differentiation. Treatment of K562 cells with rapamycin or AZD8055 
blocked erythroid differentiation in vitro, as indicated by a significant decrease 
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in the percentage of CD71+GlyA+ erythroid cells, and a reduction in gene 
expression of erythroid markers β-GLOBIN, GATA1 and GATA2, (Figure 3.10A-D), 
indicating mTORC1 inhibition blocks RBC differentiation in vitro. Interestingly, 
there was a trend in increase in pAKTS473 and p4EBP1T37/T46 levels with rapamycin 
treatment in K562 cells cultured in both complete or in Gal-media suggesting 
there was no change or an increase in activity of the downstream targets of 
mTORC1 including mTORC2 with rapamycin treatment (Figure 3.11A-D). 
Consistent with previous literature(250), as rapamycin is an allosteric inhibitor 
of mTORC1 and a partial inhibitor, these data suggest that even though 
rapamycin affects erythroid differentiation, the effects are not as potent. 
However, pAKTS473 is not a direct target of rapamycin and although rapamycin 
inhibits 4EBP1 function, this function is restored in prolonged treatments 
depending on the cell type(251). 
Nevertheless, there was a significant decrease in pAKTS473 and p4EBP1T37/T46 
expression with AZD8055 in K562 cells cultured in complete media, alluding to 
the potent role of mTOR in leukaemia. There was also a significant decrease in 
pAKTS473 with an unexpected increase in p4EBP1T37/T46 with AZD8055 in erythroid-
like cells (Figure 3.11A-D). 
 
3.2.6 mTORC1 and mTORC2 regulate RBC maintenance ex vivo. 
To assess erythroid colony formation capacity of HPCs in the absence of mTORC1 
activity, HPCs were isolated from BM of Mx1-Raptor control or Mx1-Raptor cKO 
mice and CFC assays were performed. We establish that Mx1-Raptor cKO mice 
lack CFC capacity, as indicated by the lack of colony formation of CFU-E, BFU-E 
or CFU-GEMM colonies in the absence of Raptor expression, compared to cre- 
controls (Figure 3.12A&B). Interestingly, myeloid progenitor CFC assays 
performed in Vav-cre-Rictorfl/fl (Vav-Rictor control) and Vav-cre+Rictorfl/fl (Vav-
Rictor KO) HPCs to assess the role of mTORC2 in early myeloid/erythroid colony 
formation demonstrated a significant increase in CFU-E colonies, along with a 
trend in increase in GEMM colonies in Vav-Rictor KO HSPCs compared to controls 
(Figure 3.12C&D) suggesting a suppressive role of mTORC2 in erythropoiesis.  
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3.3 Discussion 
The data presented in this chapter supports previously published data 
demonstrating a significant decrease in B cells with mTORC1 deficiency, 
together with an increase in CD11b+ and decrease in CD11b+Gr1+ myeloid 
cells(91). Additionally, it has been reported that mTORC1 plays a role in 
erythropoiesis. Previous literature has identified mTORC1 a critical role in 
erythropoiesis whereby mTORC1 is regulated by dietary iron and Raptor ablation 
at the HSC stage leads to perinatal lethality(97). In turn, mTOR also regulates 
cellular iron homeostasis by its downstream target Tristetraprolin(252). 
Furthermore, Raptor-/- and overexpression leads to microcytic and macrocytic 
anaemia respectively(97). However, there remain discrepancies in the field as 
there are studies demonstrating the redundant role of mTORC1 in anaemia(253), 
while others indicate that mTORC1 inhibition improves anaemia in a sickle cell 
disease model(254). Thus, we proposed to elucidate the mechanism by which 
this is regulated. This was done by assessing two different KO models of mTORC1 
using the cre-loxP system to identify the exact role of mTORC1 in haemopoiesis 
with a focus on erythropoiesis. The cre-loxP system was used to KO mTORC1 at 
the HSC stage, by excising Raptor under the Vav promoter, and across all tissues 
in adult mice using a conditional KO (cKO) system which excises Raptor under 
the Mx1 promoter, which is expressed upon TLR3 activation. The Mx1-cre Raptor 
model was time controlled and cKO was induced upon the inoculation of 
poly(I:C) to activate TLR3. This enabled us to compare the role of mTORC1 at 
different stages of haemopoietic development. 
While assessing the role of Raptor at the HSC stage, we demonstrated that 
Raptor-deficiency leads to perinatal lethality. Raptor-deficient embryos have an 
increased pallor, which is seen already at E13, suggesting that Raptor-deficient 
embryos are severely anaemic. In murine physiology, each foetus within the 
uterine horn has a dual supply of maternal blood – from the uterine branch of 
the ovarian artery and the uterine artery, which form a network of irrigation 
fields within each foetus. Additionally, the female bearing the litter undergoes 
vascular remodelling depending on the litter-size, as a larger litter size has 
shown to result in greater vascular remodelling to accommodate each foetus. 
Foetus’ in the periphery of the horn have been shown to receive a greater blood 
supply as compared to those located in the middle of the horn. However, the 
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foetus’ in the middle have shown to have a better survival capability, an 
example of evolutionary preservation of the litter in case of complications in the 
pregnancy(255). Genetic abnormalities within each foetus cause changes in the 
blood supply to accommodate for those changes to preserve the litter as best as 
possible. This could be one reason why Vav-Raptor KO (Raptor-deficient) mice 
are born but die soon after as they cannot survive after the circulation switch 
from maternal to new-born circulation, which takes place at birth. Additionally, 
circulation within the embryo is fully established after E10 in normal murine 
embryos, which is coupled together with vascular remodelling and vessel 
branching(256). However, our data shows that mTORC1 activity is involved in 
this circulation at an early stage due to the observed pallor in murine embryos 
as early as E13. 
The pallor was likely due to a significant decrease in Ter119+ erythrocytes with 
Raptor-deficiency at the early HSC stage. To assess whether erythropoiesis was 
blocked at an earlier developmental stage, we looked at surface markers for 
erythroid progenitors. There was a significant increase in the ScaloCD117hi 
population with Raptor-deficiency, which gives rise to CMPs which further divide 
into GMP and MEPs. Indeed, we observed a significant increase in the MEP 
population suggesting a block at the MEP stage (the erythroid progenitor 
population) at E13 and E15 Vav-Raptor KO FL. It is seen that there is a reduction 
in the progenitor populations in all E18 Vav-Raptor FL, and there is no significant 
difference between the controls and the Vav-Raptor KO FL at E18. It is 
important to note here that haemopoiesis, broadly put, occurs in two waves, 
primitive and definitive. Primitive haemopoiesis mainly involves the formation of 
primitive erythrocytes from HSC residing in the yolk sac to induce oxygenation. 
The definitive wave comprises of the formation of other haemopoietic 
progenitors when haemopoiesis moves to the AGM region followed by the FL. In 
mice, the transition of haemopoiesis from the FL to the BM occurs before birth 
at E16.5(245). This confirms the steady decline in progenitor populations in all 
E18 FLs thereby diminishing any significant differences observed in FLs at E13 
and E15, due to a shift in haemopoiesis from the FL to the BM. 
The block in erythropoiesis was further confirmed by the significant 
downregulation in the gene expression of Gata1, β-Globin, Klf1 and Klf2 genes, 
which are vital for erythrocyte development, with Raptor-deficiency at the HSC 
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stage. Gata2 is a transcription factor highly expressed in haematopoietic cells. 
Additionally, literature has shown that both transcription factors Gata1 and 
Gata2 in ‘Gata-factor switching’, which involves the decrease in Gata2 and 
increase in Gata1 expression with erythroid differentiation, occupy the same 
binding domains(10). Gata1 plays a vital role in erythroid differentiation, 
sustaining its own expression and suppressing Gata2 expression. Gata1 
expression is vital for erythropoiesis as it inhibits Pu.1 expression(257) thereby 
repressing myeloid and lymphoid lineage generation and inhibiting Cebpα 
expression, a TF vital for myeloid differentiation. Klf1 TF is vital for 
erythropoiesis as it regulates MEP lineage fate during erythrocyte development, 
is responsible for the globin switching from γ- to β-Globin for the maturation of 
erythrocytes(258) from the yolk sac to the FL(23). Whilst KLF1 plays a major role 
in erythropoiesis, Klf2 has shown to be involved in γ-Globin activation (involved 
in primitive erythropoiesis)(259) and also plays a role in endothelial growth, 
vascular remodeling(260) and inflammation responses(25), which are vital for 
embryonic development. Interestingly, there was no significant difference in 
Gata2 expression alluding to Gata-factor switching, suggesting it is not Gata2 
but Gata1, which is affected by mTORC1.  
To determine whether this block is apparent only at an early stage, we analysed 
the Mx1-cre Raptor model, where poly(I:C) was inoculated into adult mice to 
induce cKO. Mx1-Raptor cKO BM exhibit a decrease in percentages of 
ScaloCD117hi and MEP populations with a significant decrease in the splenic MEP 
cellularity with Raptor-deficiency. There could be several reasons for the 
difference in ScaloCD117hi and MEP population between the FL and BM. It is 
possible that haemopoiesis, and lineage potential of progenitors differs in foetal 
vs. adult mice. Indeed, HSCs residing in the FL differ from HSCs in the BM such 
that FL HSCs have a higher proliferative and metabolic capacity (increased 
oxidative phosphorylation) than BM-derived HSCs(261) which could affect 
ScaloCD117hi and MEP primitive populations. Nevertheless, there is a trend in 
decrease in Ter119+ erythroid population in the BM of adult mice with Raptor-
deficiency. However, looking at the spleen, there is a significant increase in 
Ter119+ population. Similar trends are seen literature where there is a decrease 
in the BM and an increase in the spleen in Ter119+ expression in Raptor-deficient 
Mx1-cKO mice(262), which could suggest a possible compensatory mechanism 
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wherein the organism drives for erythropoiesis due to a lack in erythrocytes. 
Kalaitzidis et al., also observe splenomegaly with Raptor-deficiency in adult 
mice and refer to the spleen as a site for extramedullary haemopoiesis due to an 
increase in splenic LSK cells(262). Therefore, the spleen could be a secondary 
site for haemopoiesis driving erythropoiesis. Additionally, as the spleen is known 
to be a main site for erythrophagocytosis, and it is possible that the function of 
erythrocytes is compromised and are accumulating in the spleen for 
phagocytosis(246). We observe splenomegaly and an increase in red pulp. As the 
red pulp is one of the major sites of erythrocyte destruction, it is a possibility 
that an accumulation of erythrocytes in the spleen indicates erythrocyte 
depletion.  
To assess other haemopoietic lineages affected by Raptor deletion, surface 
markers for various lineages were assessed at the HSC stage and in adult mice 
lacking mTORC1. We observed a significant reduction of mature myeloid 
population CD11b+Gr1+ and an increase in immature myeloid (CD11b+) population 
in the FL and BM suggesting a block in myelopoiesis with Raptor KO at both the 
HSC stage and in adult mice. Guo et al., have shown a similar reduction in 
CD11b+Gr1+ myeloid population, together with a decrease in CMP population 
with conditional mTOR deletion in the BM(263), which suggests that mTORC1, 
and not mTORC2, is vital for myeloid maturation. Literature has also shown that 
Mx1-cKO of Raptor leads to a decline in CD11b+Gr1+ myeloid population with the 
accumulation of CD11b+Gr1mid/lo immature myeloid population(262). However, 
whether this population is an immature myeloid population is debatable as a 
similar increase in CD11b+Gr1- population with Mx1-Raptor cKO is classified as 
being a novel innate myelo-lymphoblastoid effector cell (IMLEC) population. This 
novel leukocyte population has similar phenotypic characteristic to myeloid cells 
and are produced by CMP progenitors which cause self-destructive innate 
immunity by producing excess IMLECs(104). 
A significant decrease in mature B cell lineages was observed with Raptor-
deficiency in the FL and BM at the HSC stage and in adult mice, together with a 
decrease in proB cell lineages. Furthermore, there was a significant reduction in 
pre-proB cells in Raptor-deficient BM along with trends in decrease in pre-proB 
cells in Vav-Raptor KO FL. The increase in LSK population, which give rise to pre-
proB cells, in both BM and E15 FL (with trends increase in E13 FL) suggest a block 
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at the LSK stage in B cell development with Raptor-deficiency at the HSC stage 
and in adult mice. A similar trend has been observed, where mTOR cKO in the 
BM leads to an increase in LSK cells and a decrease in B cells. The increased LSK 
population was in S phase suggesting increased cell cycling thereby leading to 
HSC exhaustion with mTOR deficiency(263). Indeed, there was a decrease in 
mature B cells with an increase in LSK population in the spleen of Mx1-Raptor 
cKO mice which exhibit cell cycling and metabolic changes(262). Iwata et al., 
demonstrate a block in B cell development at the preB cell stage with cKO of 
Raptor in B cells in adult mice (Mb1-Raptor cKO), which is not rescued by the 
introduction of an anti-apoptotic BclXL transgene, suggesting that this block 
caused due to the lack of mTORC1 is independent of BCLXL(109). Our data 
suggest a block in B cell development at an earlier LSK stage, as the Mb1-Raptor 
cKO model was specific to B cells and could have led to differing stages of B cell 
development block, with similar results.  
 
Analysing the key master TFs that regulated lineage commitment, we show a 
significant downregulation in Pu.1. High levels Pu.1 expression inhibit Gata1 
expression and is correlated with a myeloid population along with the expression 
of Cebpα. Cebpα KO causes an expansion in erythropoiesis(264) and its 
expression has shown to be a determining factor responsible for myeloid lineage 
generation by inhibiting erythropoiesis(15). As Cebpα levels were not altered in 
Vav-Raptor KO FL, it suggests that either Raptor does not regulate erythropoiesis 
via Cebpa, or that the significant downregulation of Pu.1 prior to Cebpα 
expression is sufficient to abrogate myeloid lineage generation. Moreover, lower 
expression levels of Pu.1 give rise to lymphoid populations and a decrease in 
Pu.1 expression by Gata1 is associated with a drive towards an erythroid 
lineage(14). The fact that Pu.1 is a vital TF in regulating haemopoiesis, and our 
data show a reduction in Pu.1 and Gata1, supports the aberrations in RBC and B 
cell lineage fates. Indeed, we observe a downregulation in Ebf1 and Pax5, TFs 
responsible for the development of B cells. PU.1 expression enhances the 
expression levels of E2A, which is a TF involved in the earliest stages of B cell 
development. Lack of E2A leads to a block in B cell development at the pre-proB 
and proB stages(32). E2A drives the expression of EBF1, which together with 
E2A, regulate the RAG and PAX5 genes responsible for V(D)J recombination to 
form the pre-BCR complex on preB cells(265). 
 92 
 
To assess the role of mTORC1 in erythropoiesis in vitro, we exploited the fact 
that the K562 cell line differentiates into an erythrocyte-like lineage when 
exposed to stress(247–249,266). Various methods exist to induce this 
differentiation, some of which include lactic acid treatment(267), nicotinic acid 
and by cisplatin analogues. We used two different methods to induce 
differentiation, hemin treatment(268) and galactose substitution for glucose in 
complete media(241). Hemin is an iron-porphyrin, protoporphyrin IX, and has a 
ferric ion with a chloride ligand. Upon treatment of K562 cells with hemin till D5 
in culture, the cell pellet turned red indicative of RBC differentiation. However, 
as hemin is auto fluorescent, analysis of surface markers by flow cytometry was 
not possible. Therefore, erythrocyte differentiation was induced by replacing 
glucose in complete media with galactose (Gal-media) to initiate differentiation. 
Indeed, we observed an increase in CD71+GlyA+ erythroid-like population and a 
decrease in cell granularity with galactose substitution along with an increase in 
GATA2, and β-GLOBIN gene expression levels. We used established mTOR 
complex inhibitors to assess the role of mTORC1 in erythrocyte differentiation. 
We used rapamycin, which is an allosteric(269) and partial inhibitor of 
mTORC1(270), and AZD8055, which is a competitive and dual mTOR complex 
inhibitor(271). Treatment of K562 cells with either rapamycin, or AZD8055, led 
to a significant decrease in the gene expression levels and surface markers of 
erythroid-like cells suggesting a block in erythropoiesis with mTORC1 in vitro. 
The significant decrease in GATA1, GATA2, and β-GLOBIN expression levels with 
mTOR inhibitors is consistent with the results observed in Raptor-deficient FL 
thereby confirming the role of mTORC1 in erythrocyte development. As 
erythrocytes are less granular compared to K562 cells, it was reassuring that we 
observed a decrease in cell granularity between K562 cells cultured in complete 
media and Gal-media. As mTORC1 plays an important role in maintaining cell 
size(272), we also observed a decrease in cell granularity in K562 cells with both 
mTOR inhibitors regardless of erythroid differentiation confirming mTORC1 plays 
a role in cell size, regardless of the cell type. 
 
K562 cells cultured in Gal-media to induce erythropoiesis have an increased 
mTORC2 functionality coupled with a decrease in mTORC1 activity, as there is 
an increase in pAKTS473 protein expression along with a decrease in RAPTOR and 
p4EBP1T37/T46 protein expression. This suggests increased mTORC2 activity during 
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RBC differentiation. As not much is known about the role of mTORC2 in 
erythropoiesis, this is an interesting finding, which suggests that both mTORC1 
and mTORC2 modulate erythrocyte development. FOXO3 has shown to be vital 
for erythrocyte maturation, and metabolic regulation as a lack of Foxo3 leads to 
increased ROS mediated by an increase in expression of Cdkn1a and a shortened 
life span of animals(273). As AKT lies upstream of FOXO3, mTOR/AKT/FOXO3 
cross-talk has shown to be vital for erythrocyte maturation(274). This directly 
implicates a role of mTORC2 in erythrocyte maturation. 
We would have expected to see a decrease in expression in downstream targets 
of mTORC1 targets with rapamycin treatment in K562 cells. However, rapamycin 
treatment did not have any significant change on RAPTOR, p4EBP1T37/T46 levels 
with a trend in increase in pAKTS473 expression, suggesting that rapamycin 
treatment leads to a strong induction of the mTORC2 complex. Carayol et al., 
see similar results of rapamycin treatment on K562 cells with no changes and 
trends in increase in pAKTS473 and p4EBP1T37/T46 expression(250). This could be 
because rapamycin is a partial inhibitor of mTORC1, and the data suggest a 
continuous activation of the mTOR pathway regardless of the inhibitor. Indeed, 
rapamycin inhibits mTORC1 via 4EBP1 and S6K inhibition. However, prolonged 
treatment with rapamycin increased 4EBP1 phosphorylation which is insensitive 
to rapamycin, whereas S6K inhibition remains constant(251) making p4EBP1T37/T46 
an unfavourable target to assess rapamycin function.  Therefore, as we observe 
phenotypic (CD71+GlyA+ expression) and genotypic (GATA1, GATA2, βGLOBIN) 
changes suggesting a block in erythropoiesis with rapamycin treatment, S6K or 
pS6S235/S236 expression levels could be assessed to determine the effects of 
rapamycin on downstream mTORC1 targets. However, there was an expected 
decrease in pAKTS473 levels with the dual mTOR complex inhibitor, AZD8055 in 
both K562 cells and erythrocyte-like cells alluding to the antileukemic potential 
of the drug in K562 cells and the role of mTOR in erythropoiesis. Interestingly, 
there was a significant increase in p4EBP1T37/T46 expression with rapamycin and 
AZD8055 treatment in cells differentiated into an erythrocyte-like lineage. 
4EBP1, when dephosphorylated binds to eIF-4E cap-protein which is a part of the 
eIF-4F complex. This binding inhibits the interaction of eIF-4E with eIF-4G (part 
of the complex), thereby inhibiting protein translation (275). The activation of 
the mTOR pathway has shown to directly influence and increase 4EBP1 
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phosphorylation(276). However, protein phosphatases (PP) including PP1, 
PP2A(277), and PPM1G(278) have been shown to be responsible for the 
dephosphorylation of 4EBP1 thereby inhibiting translation thereby regulation 
translation. As we see an unexpected increase in 4EBP1 phosphorylation at 
T37/T46 with rapamycin and AZD8055 mTOR inhibitors in erythrocyte-like cells, 
an evaluation of the functional levels of these PPs (PP1, PP2a and PPM1G) would 
give us more information about the reasons for increase in 4EBP1 
phosphorylation. Previous literature has demonstrated that PP1 and PP2a are 
important for erythroid colony formation(279). Additionally, PP2A is known to be 
important for the maintained survival of mature erythrocytes(280). There is a 
possibility of abrogated PP levels with a block in erythrocyte-like cells with 
mTOR inhibitors which lead to an increase in 4EBP1T37/T46 phosphorylation. 
Lastly, we wanted to assess the colony formation capacity of Raptor-deficient 
cells. Thus, we harvested Mx1-cre Raptorfl/fl BM to assess erythroid colony 
formation capacity. As expected, Raptor-deficient BM lacked colony formation 
capacity altogether demonstrating a lack in formation of CFU-E, CFU-GEMM or 
BFU-E colonies. This also confirms the perinatal lethality in Vav-Raptor KO mice 
due to their inability to generate haemopoietic lineages to survive. Interestingly, 
when we assessed Rictor-deficient BM and their capacity of myeloid colony 
formation, we observed that HPCs from the BM of Vav-Rictor KO mice formed 
significantly higher CFU-E erythroid colonies than their controls together with a 
trend in increase in CFU-GEMM colonies. Furthermore, there was a significant 
increase in the percentage and cellularity of the MEP population in Vav-Rictor 
KO BM compared to controls, suggesting a skew in erythrocyte generation in the 
absence of Rictor. This suggests a possible regulatory system for erythroid 
regulation wherein mTORC1 drives erythroid formation, whereas mTORC2 limits 
erythropoiesis suggesting mTORC1 and mTORC2 play opposing roles in regulating 
erythropoiesis. Interestingly, a conditional mTor KO results in diminished CFU-E 
and BFU-E colonies, with a block in erythropoiesis at the proerythroblast stage 
compared to controls(263) suggesting that mTORC1 is vital for the generation of 
erythrocytes whereas mTORC2 might be involved in the regulation of 
erythrocytes. As a future direction, it would be interesting to culture erythroid 
cells or an erythroid cell line: Bristol Erythroid Line Adult (BEL-A)(281) to 
directly test the role of mTORC1 and mTORC2 in erythropoiesis by performing 
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shRNA or CRISPR knock down (KD) of mTORC1 and mTORC1 in vitro. From our 
data, we would expect to see an enhanced erythrocyte generation with mTORC2 
KD with a concomitant decline in RBC generation with mTORC1 KD.  
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3.4 Tables and Diagrams 
Breeding Ratios Vav cre
-
Raptorwt/fl 
Vav-cre
-
Raptorfl/fl 
Vav-cre
+ 
Raptorwt/fl 
Vav-cre
+ 
Raptorfl/fl 
Chi Test  
Value (x
2
) 
p 
value 
At weaning 
(n=26) 
Expected 
mendelian 
ratios 
6.5 6.5 6.5 6.5 
14.92 ** 
  Actual 
Genotypes 13 9 4 0 
Embryonic 
Day 13 
(n=49) 
Expected 
mendelian 
ratios 
12.25 12.25 12.25 12.25 
2.92 0.50 
(ns) 
  Actual 
Genotypes 12 8 15 14 
 
Table 3.1: Vav-cre+Raptorfl/fl mice do not survive to weaning (4 wk old), exhibiting perinatal 
lethality.  
Timed-mated mice were generated where Vav-cre+/-Raptorwt/fl mice mated with Vav-cre+/-Raptorfl/fl to 
obtain filial generations with Vav-cre-/-Raptorwt/fl, Vav-cre-/-Raptorfl/fl, Vav-cre+/-Raptorwt/fl, or Vav-cre+/-
Raptorfl/fl genotypes according to Mendel’s law. Table shows expected mendelian ratios and the 
actual genotyped ratios of the mice at weaning and E13, together with chi test values and whether 
they are statistically different. (p, **≤0.001). 
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Table 3.2: Mx1-cre Raptorfl/fl mice genotypes at weaning (4 wk).  
Mx1-cre+/-Raptorfl/fl  mice were mated with Mx1-cre-/-Raptorfl/fl mice and the obtained genotypes of 
the filial generations were recorded. Table shows the expected medelian ratios and the actual 
genotyping of the filial generations upon matings, together with chi test values and whether they 
are statistically different. (p, *≤0.05). 
  
Breeding Ratios Mx1-cre
-
Raptor
+/+ 
Mx1-cre
+ 
Raptor
+/+ 
Chi Test  
Value (x
2
) 
p 
value 
At weaning 
(n=76) 
Expected 
mendelian 
ratios 
38 38 
0.053 3.84 
(ns) 
  Actual 
Genotypes 37 39 
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Figure 3.1:Vav-Raptor KO mice are perinatally lethal and Raptor-null adult mice exhibit 
splenomegaly in vivo.  
A. Gene expression data showing expression of Raptor with cre expression in Vav-cre+Raptorfl/fl 
(Vav-Raptor KO) compared to Vav-cre-Raptorfl/fl (Vav-Raptor control) E15 FL. B. Picture showing 
the difference in pallor in E13 FL between Vav-cre-Raptorwt/fl and Vav-Raptor KO foetal mice. C. 
Gene expression of Raptor in the BM and spleen in Mx1-cre-Raptorfl/fl (Mx1-Raptor control, blue 
bar) and Mx1-cre+Raptorfl/fl mice (red, Mx1-Raptor cKO). D. Picture showing splenomegaly in Mx1-
Raptor cKO mice compared to Mx1-Raptor control. Graphs showing spleen weight (mg) (E) and 
cellularity (F) of Mx1- Raptor control and Mx1-Raptor cKO mice. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 3.2: Gating strategy of haemopoietic lineages in Vav-cre Raptor and Mx1-cre 
Raptorfl/fl primary lymphoid organs.  
Representative flow cytometry plots demonstrating the proportion of B cells (CD19+CD11b-), 
mature myeloid cells (CD19-CD11b+Gr1+), myeloid cells (CD19-CD11b+), and erythroid (CD19-
CD11b-Ter119+) lineages in Vav-cre-Raptorwt/fl (A), Vav-Raptor control (B), Vav-cre+Raptorwt/fl (C) 
and Vav-Raptor KO (D) E15 FL, and the same of Mx1-Raptor control (E) and Mx1-Raptor cKO (F) 
BM. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. RCN – relative cell 
number. 
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Figure 3.3: Vav/Mx1-cre+Raptorfl/fl mice exhibit a disruption in haemopoiesis in vivo.  
Graph demonstrating the percentage of surface expression of Ter119 in Vav-Raptor KO FL (n=7, 
cre+ ; loxP +/+) compared to Vav-cre-Raptorwt/fl (n=10, cre- ; loxP -/+) and Vav-Raptor control (n=8, 
cre- ; loxP +/+) of E15 FL (A), and in the BM and spleen of Mx1-Raptor cKO (cre+, red bars) 
compared to Mx1-Raptor control mice (cre-, blue bars) (B). Flow cytometry graphs showing surface 
expression of percentage of CD11b+ myeloid population, and CD11b+Gr1+ myeloid lineage (C) in 
Vav-Raptor KO (n=8) compared to Vav-cre-Raptorwt/fl (n=11), Vav-Raptor control (n=8) and Vav-
cre+Raptorwt/fl (n=6, cre+ ; loxP -/+) E15 FL. Flow cytometry data of BM and spleen of Mx1-Raptor 
cKO and Mx1-Raptor control mice showing surface expression of percentage of CD11b+ myeloid 
population (D) and CD11b+Gr1+ myeloid lineage (E). Bar graphs showing expression of percentage 
of CD19+ B cells in Vav-cre-Raptorwt/fl, Vav-Raptor control, Vav-cre+Raptorwt/fl, and Vav-Raptor KO 
FL at E15 (F) and E17 (G), together with expression of percentage of CD19+ B cell population in 
the BM, spleen and blood in Mx1-Raptor cKO compared to Mx1-Raptor controls (H). Data are 
expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 3.4: Gating strategy of progenitor cells and early B haemopoietic lineages in Vav- 
and Mx1-cre Raptor models.  
Representative flow cytometry plots demonstrating the proportion of proB (Lin-B220+CD19+), pre-
proB (Lin-B220+CD19-), Sca-1loCD117hi  (Lin-B220-CD19- Sca-1loCD117hi) and LSK (Lin-B220-
CD19- Sca-1+CD117+) cell populations in Vav-cre-Raptorwt/fl (A), Vav-Raptor control (B), Vav-
cre+Raptorwt/fl (C) and Vav-Raptor KO (D) E15 FL, and the same in BM of Mx1-Raptor control (E) 
and Mx1-Raptor cKO (F) mice. Lin- gating is done by taking into account the unstained control 
(blue peak), where the red peak represents Lin+ cells. Plots are live and size (FSC-A/SSC-A) gated 
prior to the gating shown. RCN – relative cell number. 
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Figure 3.5: Mx1- and Vav-cre+Raptorfl/fl mice exhibit a block in B cell development at the LSK 
stage. 
Surface expression of percentage of proB (CD19+B220+) (A), pre-proB (B220+CD19-) (B) and LSK 
(C),  populations in E13, E15, E18 in Vav-cre-Raptorwt/fl (cre-, loxP -/+), Vav-Raptor control (cre-, 
loxP +/+), Vav-cre+Raptorwt/fl (cre+, loxP -/+) and Vav-Raptor KO (cre+, loxP +/+) FL, and in BM of 
Mx1-Raptor control (blue, cre-) compared to Mx1-Raptor cKO (red, cre+) mice (D). Data are 
expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 3.6: Gating strategy of early myeloid progenitors in Vav- and Mx1-cre Raptor models.  
Representative flow cytometry plots demonstrating the proportion of Sca-1lo CD117hi cells, common 
myeloid progenitors (CMP) (CD45+Lin-ScaloCD117hiCD34+CD16/32-), megakaryocyte-erythrocyte 
progenitors (MEP) (CD45+Lin-ScaloCD117hiCD34-CD16/32-) and granulocyte-macrophage 
progenitors (GMP) (CD45+Lin-ScaloCD117hiCD34+CD16/32+) cell populations in Vav-cre-Raptorwt/fl 
(A), Vav-Raptor control (B), Vav-cre+Raptorwt/fl (C) and Vav-Raptor KO (D) in E15 FL, and in BM of 
Mx1-Raptor control (E) and Mx1-Raptor cKO (F) mice. Plots are live and size (FSC/SSC) gated 
prior to the gating shown. 
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Figure 3.7: Vav-Raptor KO mice exhibit a block in RBC development at MEP stage in vivo. 
Graph showing surface expression of percentage of S1loCD117hi (Sca-1loCD117hi) (A), CMP (B), 
GMP (C), MEP (D) populations in E13, 15, 18 FL in Vav-cre-Raptorwt/fl (light blue, cre-, loxP -/+) and 
Vav-Raptor control (blue, cre-, loxP +/+), Vav-cre+Raptorwt/fl (pink, cre+, loxP -/+) and Vav-Raptor 
KO (red, cre+, loxP +/+). Gene expression of E17 FL demonstrating the fold change (log10) in Pu.1, 
early B cell factor 1 (Ebf1), and Pax5 (E), along with fold changes (log10) in gene expression of 
Cebpα, Gata1, Gata2, βGlobin (F), and Krüppel-like factor (Klf1) and Klf2 (G) at E15 FL in Vav-
Raptor KO (cre+) compared to Vav-Raptor control (cre-) FL. Data are expressed as mean±SEM (p 
*≤0.05, p **≤0.001, p ***≤0.0001). 
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Figure 3.8: Mx1-Raptor cKO mice have aberrations at the MEP stage with opposite trends in 
Vav-Rictor KO mice in vivo. 
Graph showing surface expression of the percentage (A) and cellularity (B) of S1loCD117hi (Sca-
1loCD117hi), CMP, GMP populations in BM of Mx1-Raptor control (cre-) or Mx1-Raptor cKO (cre+) 
mice. Graph showing surface expression of the percentage (C) and cellularity (D) of MEP in BM of 
Mx1-Raptor control or Mx1-Raptor cKO mice. Graph showing surface expression of the percentage 
(E) and cellularity (F) of MEP in BM of Vav-cre-Rictorfl/fl (Vav-Rictor control, cre-) or Vav-
cre+Rictorfl/fl (Vav-Rictor KO, cre+) mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, 
p ***≤0.0001, p ****≤0.00001). 
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Figure 3.9: K562 cells differentiate into an erythrocyte-like lineage with changes in surface 
markers and size, which are changed with mTOR inhibitors.  
A. Picture showing the colour change in the cell pellet confirming RBC-like differentiation upon 
treatment of 5X105 K562 cells with 50 μM hemin treatment till D5 (right) compared with the white 
pellet observed in untreated K562 cells (NDC – no drug control, left). B. Flow cytometry plots 
showing expression of CD71+GlyA+ population in K562 cells cultured in either complete media (-
Galactose) or in Gal-media (+Galactose). Representative flow cytometry plots demonstrating 
changes in FSC-A and SSC-A in K562 cells cultured in complete media (C) or in Gal-media (D) 
with no drug (untreated; left) or treated with rapamycin (middle) or AZD8055 (right). 
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Figure 3.10: mTOR inhibitors abrogate RBC differentiation in a human cell model. 
Percentage of CD71+GlyA+ surface expression (A), mean fluorescent intensity (MFI) ratio of CD71+ 
erythroid cells (B) and MFI of side scatter area (SSC-A) (C) of K562 cells and K562 cells treated 
with mTOR inhibitors cultured in either complete media or in Gal-media. D. Gene expression data 
showing fold changes (log10) of β-GLOBIN, GATA1 and GATA2 in K562 cells cultured in complete 
media and in Gal-media with or without mTOR inhibitors – rapamycin (mTORC1 inhibitor), 
AZD8055 (dual mTOR complex inhibitor). Data are expressed as mean±SEM (p *≤0.05, p 
**≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 3.11: Proving the role of mTORC1 in the differentiation of RBCs in K562 cells at the 
phenotype and molecular level. 
Representative western blot (A) and ratios of protein expression levels of RAPTOR/GAPDH (B), 
pAKTS473/GAPDH (C), and p4EBP1T37/T46/GAPDH (D) in K562 cells either cultured in complete 
media (with glucose) or in Gal-media and treated with AZD8055 (AZD) or rapamycin (rapa). Data 
are expressed as mean±SEM (p *≤0.05, p **≤0.001). 
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Figure 3.12: Demonstrating a functional block in RBC development in Mx1-Raptor cKO mice, 
together with an increase in RBC generation in Vav-Rictor KO mice.  
A. CFCs which optimise for the growth of erythroid cells were carried out on Mx1-Raptor control 
(left) and Mx1-Raptor cKO (right) BM enriched for HPCs. B. Colony counts of different erythroid 
colonies: CFU-E, BFU-E and CFU-GEMM in Mx1-Raptor cKO models and in Mx1-Raptor controls. 
C. CFCs which optimise for the growth of HPCs were carried out on Vav-Rictor control (left) and 
Vav-Rictor KO (right) BM enriched for HPCs. D. Colony counts of different haemopoietic colonies: 
CFU-E, BFU-E and CFU-GEMM in Vav-Rictor KO models and in Vav-Rictor controls. Data are 
expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Chapter 4 
 
Role of mTORC1 and mTORC2 in 
Lymphopoiesis 
  
 111 
 
4 Role of mTORC1 and mTORC2 in lymphopoiesis 
4.1 Aims and Objectives 
The mTOR pathway has previously known to play an important role in 
haemopoiesis(282). Here, we use the cre-loxP system to individually KO Raptor 
(mTORC1) and Rictor (mTORC2) at different stages of development to assess the 
individual roles of the mTOR complexes during haemopoiesis. The complexes 
were removed at the HSC stage (Vav-cre model) resulting in a KO specifically in 
haemopoietic lineage cells, in the whole organ system in adult mice by using the 
cKO system (Mx1-cre model) and specifically in B cells by using the CD19-cre 
model. This enabled us to determine the exact role of mTORC1 and mTORC2 in 
haemopoiesis and allowed us to elucidate the stages at which these complexes 
play a role (if any) in lineage development/commitment.  
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4.2 Results 
4.2.1 Mice with induced Raptor deficiency at an adult stage 
exhibit optimal characteristics of KO when assessed 5 wk 
post 4 poly(I:C) inoculations. 
As the Vav-Raptor KO mouse model is lethal at the perinatal stage (Chapter 3, 
Figure 3.1), two mTORC1 KO models, the Mx1-cre and CD19-cre models were 
used to assess the role of mTORC1 in adult mice and specifically in B cells 
respectively, during normal haemopoiesis. As the cKO system in the Mx1-cre 
model is dependent upon the inoculation of poly(I:C), it was essential to 
optimize the cKO system, assessing the dose of poly(I:C) to be given to the mice, 
and the time taken to induce the cKO. Due to the discrepancies in the dosage of 
poly(I:C), in terms of number and concentration, along with the timeline at 
which these mice were assessed in previous literature(91,263), optimization of 
this model was carried out with variables being the number of doses (3, 4, 5 
inoculations on alternate days) and time of analysis after inoculations (3, 5, 8, 
10 wk) at 10 mg/kg poly(I:C). 
Mx1-cre-Raptorfl/fl (Mx1-Raptor control) and Mx1-cre+Raptorfl/fl (Mx1-Raptor 
cKO) mice, inoculated with 3 doses of 10 mg/kg poly(I:C) every alternate day, 
were assessed at 3, 5, 8 or 10 wk post the last inoculation. There was significant 
splenomegaly in Mx1-Raptor cKO spleens 5 and 8 wk post poly(I:C) inoculation 
with similar trends 3 and 10 wk post inoculation compared to Mx1-Raptor 
controls (Figure 4.1A). Although there was no trend in increase in spleen organ 
cellularity, there was a greater difference between Mx1-Raptor cKO splenic 
organ cellularity 5 wk post poly(I:C) compared to analysis at other weeks (Figure 
4.1B). Moreover, there was no significant difference in BM or LN organ cellularity 
over time, however there was a strong trend in decrease in Mx1-Raptor cKO LN 
organ cellularity 5 wk post poly(I:C), and a significant decrease in thymic 
cellularity in Mx1-Raptor cKO mice 5 wk after 3 poly(I:C) inoculations compared 
to control mice (Figure 4.1C-E). These data suggested that the cKO was more 
pronounced 5 wk post 3 poly(I:C) inoculations compared to earlier or later 
weeks. To test whether increasing the dose frequency would improve the cKO 
model, the frequency of the dose was increased from 3 to 5 doses at 10 mg/kg 
poly(I:C) and the mice were assessed 5 wk post inoculation. Greater 
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splenomegaly was noted in Mx1-Raptor cKO mice with 5 poly(I:C) doses 
compared to those with 3 doses. These cKO mice exhibited a significant increase 
in splenic cellularity and a decrease in thymic cellularity, with no changes in BM 
and LN cellularity compared to 5 wk 5 poly(I:C) control mice (Figure 4.1F&G). 
To assess the Mx1-Raptor cKO model treated with 3 and 5 doses of poly(I:C), B 
cell lineage was assessed at different developmental stages, compared to Mx1-
Raptor controls. There was a trend in increase in percentage of lineage-sca-
1+CD117+ (LSK) population, and a significant increase in LSK cellularity in the BM 
of Mx1-Raptor cKO mice compared to Mx1-Raptor controls with 5 doses 
compared with 3 doses of poly(I:C) (Figure 4.2A,B,E,F). Additionally, with 3 
doses of poly(I:C), there was a significant decrease in the percentage of pre-
proB cells (lin-B220+CD19-) after 3 and 10 wk, with a greater significant reduction 
at 5 wk post inoculation, and a significant decrease in the pre-proB cell 
cellularity in the BM 5 wk post inoculation in Mx1-Raptor cKO mice compared to 
controls (Figure 4.2C,D). A similar trend in percentage and cellularity decrease 
of pre-proB cells was noted in the BM with a trend in increase of the same in the 
spleen 5 wk post 5 poly(I:C) inoculation in Mx1-Raptor cKO mice compared to 
controls (Figure 4.2G,H). These results suggested that there may be a block in B 
cell lineage commitment in the Mx1-Raptor cKO mouse model, which was 
supported by a significant decrease in the percentage of mature B cell (CD11b-
CD19+) lineage in the BM and spleen 3, 5 and 10 wk post 3 poly(I:C) inoculation, 
coupled with a decrease in B cell lineage percentage in the blood at 5 and 8 wk 
post 3 poly(I:C) inoculation. Similar trends were seen in the LN across the weeks 
in Mx1-Raptor cKO mice compared to Mx1-Raptor controls (Figure 4.3A). Mx1-
Raptor cKO mice assessed 5 wk post 5 poly(I:C) doses showed a significant 
decrease in B cell lineage percentage in the BM, spleen and thymus and a 
decreasing trend in the blood compared to Mx1-Raptor controls (Figure 4.3B). 
Lastly, to determine whether late stages of B cell development were also 
affected in Mx1-Raptor cKO mice, and to compare 5 doses of poly(I:C) treatment 
with 3 doses, the presence of the following B cell populations were assessed. 
Mx1-Raptor cKO mice treated with 3 poly(I:C) doses showed a significant 
decrease in percentage of transitional 1 (T1, CD19+CD23-IgMhiCD21int) B cell 
population after 3 wk, together with a decrease in percentage of fol1 
(CD19+CD23+CD21loCD1dintIgDhiIgMloAA4.1-) B cells after 5 wk, and a decrease in 
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percentage of fol2 (CD19+CD23+CD21loCD1dintIgDhiIgMhiAA4.1-) B cells after 3, 5 
and 10 wk in the spleen compared to controls (Figure 4.4A&B). Similarly, 
treatment of mice with 5 poly(I:C) doses showed Mx1-Raptor cKO mice exhibit a 
significant decrease in the percentage of T1, T3 
(CD19+CD23+CD21intCD1dintIgDhiIgMloAA4.1+), MZ (CD19+CD23-IgMhiCD21hi) and fol2 
B cells with a trend of a decrease in T2 
(CD19+CD23+CD21intCD1dintIgDhiIgMhiAA4.1+), fol1 and MZP 
(CD19+CD23+CD21hiCD1dhi) percentages in the spleens compared to controls 
(Figure 4.4C&D).  
These data suggest that analysis of the mice 5 wk post 5 poly(I:C) inoculations 
results in a more potent cKO compared to 3 poly(I:C) doses. However, treatment 
of mice aged >18 wk with 5 poly(I:C) doses resulted in death soon after the last 
poly(I:C) dose (data not shown), therefore 5 poly(I:C) inoculations was 
considered too severe. Thus, for the remainder of the experiments, we treated 
mice with 4 poly(I:C) inoculations and assessed them at 5 wk post the last 
injection. The cKO in mice with 4 poly(I:C) inoculations was as robust as seen in 
cKO mice with 5 poly(I:C) inoculations as indicated by the spleen weight (mg) in 
Mx1-Raptor cKO mice with 3, 4 and 5 poly(I:C) injections assessed after 5 wk 
(Figure 4.6A), and Raptor expression data (see below – Figure 4.7). Before 
proceeding with additional experiments, it was vital to assess whether the 
transgenic cre-loxP system initiates phenotypic changes in mice compared to WT 
mice without the cre-loxP background. Therefore, phenotypic analyses of 
different haemopoietic lineages were compared between Mx1-Raptor control 
and WT mice assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculations. As expected, 
no significant difference was seen between the spleen weight or whole organ 
counts of the BM, spleen and thymus between the two sets of mice. 
Furthermore, there was no significant difference in the percentage and 
cellularity of CD19+ B cells and CD11b+Gr1+ mature myeloid cells in the BM, 
spleen and thymus along with no difference in CD4+CD8+ DP and CD4-CD8- DN T 
cell populations in the thymus (Figure 4.5) suggesting that both the Mx1-Raptor 
control and WT mice are phenotypically similar after treatment with poly(I:C), 
thereby defining Mx1-Raptor control mice as a ‘wildtype’ reference for 
comparison to Mx1-Raptor cKO mice. 
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4.2.2 mTORC1 plays a role in developmental haemopoiesis in 
vivo. 
To assess the role of mTORC1 in normal B lymphopoiesis, Mx1-cre and CD19-cre 
models were used which KO Raptor in adult mice upon poly(I:C) inoculation 
(Mx1-Raptor cKO) and specifically in B cells at the proB cell stage (CD19-Raptor 
KO). As seen in Section 4.2.1, Raptor deficiency in adult mice led to a significant 
increase in splenic weight and cellularity along with similar trend towards an 
increase in the BM, and a significant decrease in thymic cellularity (Figure 
4.6A&B).  To further analyse the spleen in Mx1-Raptor cKO mice with 
splenomegaly, H&E staining was carried out, which demonstrated a disruption of 
splenic architecture with a lack of GC and MZ and an increase in red pulp. Ki67 
staining was increased suggesting increased cell cycling/proliferation (Figure 
4.6C) in Mx1-Raptor cKO mice compared to Mx1-Raptor controls. As the CD19-
cre model excises Raptor solely in B cells, there was no difference in the spleen 
weight between CD19-cre-Raptorfl/fl (CD19-Raptor control) and CD19-cre+/-
Raptorfl/fl (CD19-cre+/-Raptor KO) mice. However, there was a significant 
decrease in the spleen weight along with BM and spleen cellularity in CD19-
cre+/+Raptorfl/fl mice (CD19-cre+/+Raptor KO) compared to both the CD19-Raptor 
control and CD19-cre+/-Raptor KO mice (Figure 4.6D&E).  
To confirm the cKO in Mx1-Raptor cKO mice, levels of Raptor were assessed at 
the protein and genomic levels. Although there was no signal in the BM at the 
protein level, there was a significant decrease in RAPTOR expression in the 
spleen and thymus. Furthermore, there was a trend towards a decrease in 
RICTOR expression in the spleen, and a significant decrease in the thymus of 
Mx1-Raptor cKO mice compared to controls (Figure 4.7A-C). These data were 
supported by a significant decrease in Raptor expression in the BM, spleen and 
liver, coupled with a decreasing trend in Rictor expression in the spleen (Figure 
4.7F&G) of Mx1-Raptor cKO mice compared to control mice. These data confirm 
that Raptor is excised upon treatment with poly(I:C) in adult Mx1-Raptor cKO 
mice. 
The representative Western blot also showed a decrease in t4EBP1 expression in 
the BM, spleen and thymus and a similar trend in reduction of 
p4EBP1T37/T46/isotype MFI ratio in the BM, spleen and thymus of mice with 
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Raptor-deficiency (Figure 4.7A,D). However, no reduction in pAKTS473 or 
pS6S235/S236 was seen in the absence of Raptor expression (Figure 4.7A&E).  
To assess the effect of Raptor-deficiency in adult mice on all major 
haemopoietic lineages, surface markers for B, T, myeloid and NK cells were 
assessed in the BM, spleen, thymus, LN and blood. A significant reduction in 
CD19+CD11b- B cell lineage percentage was observed in the BM (Figure 4.8A&B) 
and spleen, together with a significant decrease in B cell cellularity in the BM 
and thymus. No difference in the B cell splenic cellularity was seen due to the 
significant increase in splenic cells altogether in Mx1-Raptor cKO mice compared 
to controls (Figure 4.6B, Figure 4.9A&B). Furthermore, there was a significant 
decrease in percentage of CD11b+Gr1+ mature myeloid population in the BM 
(Figure 4.8A&B) and blood, while significantly increased in the spleen and LN, 
with similar trends noted in cellularity of CD11b+Gr1+ myeloid population in Mx1-
Raptor cKO mice (Figure 4.8A&B, Figure 4.9C&D). Analysing the CD11b+Gr1- 
immature myeloid population, there was a significant increase in percentage of 
this population in the BM and spleen (data not shown). A significant decrease in 
NK cells percentage was observed in the BM and spleen, with a significant 
decrease in cellularity of NK cells in the thymus (Figure 4.8A&B, Figure 4.9E&F). 
Analysing T lineage cells in the thymus, a significant decrease in the percentage 
and cellularity of CD4+CD8+ DP thymocytes was seen, together with a significant 
increase in percentage of CD4-CD8- DN thymocytes, however the CD4-CD8- 
population cell number remained largely unchanged (Figure 4.8A&B, Figure 
4.9G&H) in Mx1-Raptor cKO mice compared to controls. There was also an 
increase in percentage of CD8+ T cells with no change in CD4+ T cell lineage with 
Mx1-Raptor cKO compared to controls (data not shown). These data suggest a 
significant role of mTORC1 in B cell development and a role in myeloid and T 
cell lineages in vivo.  
The Mx1-cre model excises Raptor in all haemopoietic tissues, enabling analysis 
of Raptor-deficiency in various haemopoietic organs and cell lineages, 
generating results that were consistent with previously published data (282). 
However, by generating Raptor-deficiency specifically in B cells in the CD19-cre 
model, we wanted to assess the extent of this deficiency in B cells and whether 
the KO affected the ratio and composition of other haemopoietic lineages. 
Analysing the CD19-cre+/-Raptor KO mice initially, there was a significant 
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decrease in percentage and cellularity of CD19+ B cell lineages in the BM and LN, 
with a further significant decrease in the percentage of CD19+ B cells in the 
spleen and blood compared to CD19-Raptor controls (Figure 4.8C&D, Figure 
4.10A&B). However, as we solely assessed CD19+ B cells, it is important to note 
that there still exist early B cells, just not B cells with CD19 as a marker. The 
percentage of NK cells in the spleen of CD19-cre+/-Raptor KO mice increased 
significantly with no other changes in other haemopoietic lineages compared to 
controls (Figure 4.8C&D, Figure 4.10C-H). Assessment of CD19-cre+/+Raptor KO 
mice revealed a significant reduction in B cell lineage percentage and cellularity 
in BM, spleen and LN together with reduction in percentage in the blood 
compared to both CD19-cre+/-Raptor KO and control mice as expected (Figure 
4.8C-E, Figure 4.10A&B). There was also a significant increase in the percentage 
of mature myeloid cells in the spleen coupled with an increase in NK cell lineage 
population in the BM and spleen in CD19-cre+/+Raptor KO mice (Figure 4.8C-E, 
Figure 4.10C&E). Moreover, a significant decrease in the cellularity of 
CD11b+Gr1+ myeloid cells and NK cells was observed with no changes in T cell 
lineage in CD19-cre+/+Raptor KO mice compared to CD19-cre+/-Raptor KO mice 
(Figure 4.10D,F-H). These data suggest that CD19-cre+/-Raptor KO mice do 
indeed have a decline in B cell lineage across haemopoietic organs compared to 
controls with a compensatory increase in the percentage of NK cells. However, 
changes in B cell percentage/cellularity is expected in CD19-cre+/+Raptor KO 
mice due to the placement of the cre recombinase gene within the first coding 
exon of CD19 antigen gene thereby blocking the expression of CD19 altogether 
(283). Thus, CD19-cre+/-Raptorfl/fl mice were considered the KO mice, while 
CD19-cre+/+Raptor KO mice were disregarded for further analyses of early and 
late B cell phenotyping due to the lack of CD19 antigen expression. 
In order to further assess the nature of B cell subsets affected by Raptor-
deficiency, late B cell subsets were analysed in the spleen and LN of control, 
Mx1-Raptor cKO and CD19-cre+/-Raptor KO mice. There was a significant 
decrease in the percentage of T2, MZP, MZ and fol2 cells in the spleen along 
with decreasing trends in the percentage of T2, MZ and fol2 cells in the LN of 
Mx1-Raptor cKO mice compared to controls (Figure 4.11A&B, Figure 4.12). 
However, these changes were not mirrored by changes in cellularity of late B 
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cell subsets in the spleen or LN likely due to the increase in splenic organ 
cellularity with Mx1-Raptor cKO. 
Analysis of the splenic late B cell populations in CD19-cre+/-Raptor KO mice 
revealed a similar phenotype to Mx1-Raptor cKO mice, with a significant 
decrease in percentage of T2, MZP, MZ and fol2 late B cell populations in the 
spleen compared to controls (Figure 4.11C&D, Figure 4.13A&C). Additionally, 
there was a significant decrease in percentage of fol1 and fol2 cells in the LN 
together with a decrease in cellularity of T2 population in the spleen and fol2 
population in the LN in CD19-cre+/-Raptor KO mice compared to controls (Figure 
4.13B,G&H).  
The role of mTORC1 on B cell viability was assessed by analysing apoptotic 
markers (Annexin V/7AAD) in BM cells. Induced Raptor-deficiency in adult Mx1-
Raptor cKO mice led to a significant decrease in percentage and cellularity of 
viable B cells (CD19+AnnV-7AAD-) and increased apoptotic cells 
(CD19+AnnV+7AAD+), with a significant decrease in the percentage of early 
apoptotic B cells (CD19+AnnV+7AAD-) in the BM compared to controls (Figure 
4.14A&B, Figure 4.15A&B). While there was an increase in apoptosis in B cells 
with Raptor-deficiency, there were only trends towards an increase in apoptotic 
cells in all haemopoietic cells, with a significant decrease in percentage of early 
apoptotic cells and an increase in 7AAD+ cells in the BM in Mx1-Raptor cKO mice 
(Figure 4.15C&D). As there was an increase in apoptosis in B cells with Raptor-
deficiency in adult mice, the CD19-cre model was assessed to determine 
whether a similar trend was observed. Indeed, there were trends of an increase 
in the percentage of apoptosis, with a decrease in viability in B cells in CD19-
cre+/-Raptor KO BM compared to controls, with no difference in all cells (Figure 
4.14C&D, Figure 4.15E-H). These data suggest that Raptor-deficiency in B cells 
causes death by apoptosis without affecting other haemopoietic lineages. 
4.2.3 mTORC2 plays a role in later stages of development. 
To assess the role of mTORC2 in haemopoiesis, Vav-cre Rictorfl/fl, Mx1-cre 
Rictorfl/fl and CD19-cre Rictorfl/fl KO models were generated and analysed to 
determine whether the role of mTORC2 differed when removed at the HSC stage 
vs. in all haemopoietic lineages of adult mice. Moreover, to specifically assess 
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the role of mTORC2 in B cells, the CD19-cre Rictorfl/fl model was used. As with 
Raptor-KO models, it was vital to first determine the optimal timepoints (for the 
Vav-cre Rictorfl/fl) and frequency of inoculations of poly(I:C) (Mx1-cre Rictorfl/fl) 
for the mouse models.  
To determine the optimal timepoint for phenotypic changes in haemopoietic 
lineages upon Rictor-deficiency at the HSC stage, Vav-cre-Rictorfl/fl (Vav-Rictor 
control) mice and Vav-cre+Rictorfl/fl (Vav-Rictor KO) mice were analysed at E18 
(data not shown), 2, 8, and 24 wk of age. A significant decrease in splenic 
weight was seen at all ages (Figure 4.16B). Additionally, splenic cellularity was 
reduced at 2 and 8 wk of age, along with a decreasing trend in LN cellularity at 
all ages (Figure 4.16C).  
B cell cellularity was significantly reduced in the spleen at 8 wk with similar 
trends in the percentage and cellularity over different ages in the spleen of Vav- 
Rictor KO mice (Figure 4.16D&E). Due to the known role of mTORC2 in T cell 
development (284), surface markers of haemopoietic lineages were analysed to 
assess the effect of Rictor-deficiency at the HSC stage over different age groups. 
A significant decrease in the percentage of CD4+CD8+ DP thymocytes cells was 
seen with a concomitant increase in CD4-CD8- DN T cells in the thymus at 8 and 
24 wk of age in Vav-Rictor KO mice compared to controls. Furthermore, there 
was a significant decrease in cellularity of CD4+CD8+ DP T cells at 8 wk in Vav-
Rictor KO mice compared to controls (Figure 4.17A&B). NK cell lineage 
cellularity significantly decreased in the spleen at 8 wk in Vav-Rictor KO mice 
compared to control due to the significant decrease in splenic cellularity in Vav-
Rictor KO mice (Figure 4.16B, Figure 4.17E&F). No other changes in other 
haemopoietic lineages (including myeloid lineage) were observed in mice over 
weeks (Figure 4.17C&D), which led us to conclude that Vav-Rictor KO mice at 8 
wk time was the optimal timepoint to view phenotypic changes in the Vav-Rictor 
KO model.  
Mx1-cre+Rictorfl/fl (Mx1-Rictor cKO) mice assessed 5 wk post 4 inoculations of 
poly(I:C) had a more pronounced phenotype by the cKO compared to mice 
assessed 3 wk post 4 poly(I:C) inoculations (data not shown). Rictor-deficiency at 
the HSC stage, in adult mice and in B cells specifically led to a significant 
decrease in spleen weight together with a significant or decreasing trend in 
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spleen organ cellularity compared to controls (Figure 4.16A, Figure 4.18A-B). 
Furthermore, there was a significant decrease in thymic and LN cellularity in 
Mx1-Rictor cKO mice with similar trends of the same in Vav-Rictor KO mice 
compared to controls (Figure 4.18B). A significant loss in splenic architecture 
was observed in Vav-Rictor KO mice compared to controls, with an increase in 
Ki67 staining. No visible changes in pS6S235/S236 staining was seen with loss in 
splenic architecture in mice with Rictor-deficiency at the HSC stage. On the 
contrary, Mx1-Rictor cKO mice did not lead to a complete loss in splenic 
architecture and showed an increase in Ki67 and pS6S235/S236 staining within the 
GCs suggesting increased proliferation/cell cycling in these regions of the spleen 
compared to controls. Additionally, unlike in Vav-Rictor KO mice, Mx1-Rictor 
cKO spleens also had an increased MZ area as compared to controls (Figure 
4.18C&D) alluding to accumulation of MZ B cell population. Successful KO of 
Rictor at the HSC stage and in adult mice was confirmed by a significant 
decrease in RICTOR expression in the spleen with a decreasing trend in the 
thymus of Vav-Rictor and Mx1-Rictor KO models coupled with a significant 
decrease in RICTOR expression in the liver in Mx1-Rictor cKO mice compared to 
controls (Figure 4.19A-C,F). Furthermore, Rictor-deficiency was confirmed by a 
reduction in Rictor expression in the BM, spleen and thymus in Vav-Rictor KO 
mice and in the BM, spleen and liver in Mx1-Rictor cKO mice compared to 
controls (Figure 4.19I&K). This was coupled with a significant decrease in 
downstream target pAKTS473 in the BM and spleen with a decreasing trend in the 
thymus of Vav-Rictor KO mice with similar decreasing trends in the BM of Mx1-
Rictor cKO mice compared to controls. As expected, RAPTOR expression was 
unaffected by Rictor-deficiency (Figure 4.19D,E,G,H,J,L). These studies suggest 
a cleaner KO in the Vav-cre Rictorfl/fl model as compared to the Mx1-cre 
Rictorfl/fl model.  
To assess the extent by which Mx1- and CD19-Rictor KO models differ from the 
Vav-Rictor KO model, different haemopoietic lineages were assessed in all three 
models. Mx1-Rictor cKO and Vav-Rictor KO mice exhibited a significant decrease 
in the CD4+CD8+ DP T cell percentage, together with an increase in percentage 
of CD4-CD8- DN T cells in the thymus (Figure 4.20, Figure 4.21D-F). There was no 
change in CD4+ T cells with an increasing trend in CD8+ T cells with Rictor-
deficiency in all three models (data not shown). Moreover, there were no 
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changes in the CD11b+Gr1+, B or NK populations with Rictor-deficiency at the 
HSC stage suggesting a vital role of mTORC2 in T cell development (Figure 
4.20A&B, Figure 4.21A,G,J). In addition to aberrations in T cell lineage, a 
significant decrease in percentage of B cell and an increase in NK cell lineage 
was observed in the LN and spleen respectively with Rictor-deficiency in adult 
mice (Mx1-Rictor cKO) (Figure 4.20C&D, Figure 4.21B,H,K). CD19-cre+/-Rictorfl/fl 
(CD19-Rictor KO) led to a significant decrease in percentage of B cells in the BM, 
spleen and blood with an increase in percentage of CD11b+Gr1+ cells (with no 
changes in cell number – data not shown) in the spleen and blood compared to 
CD19-cre-/-Rictorfl/fl (CD19-Rictor control) (Figure 4.21C,I). Furthermore, there 
was a significant increase in percentage of NK cells in the blood, with no 
changes in T cell lineage in CD19-Rictor KO mice compared to CD19-Rictor 
controls (Figure 4.21F,L). These data suggest that Rictor-deficiency at the HSC 
and in adult mice leads to aberrations in mature B, T cell populations. As 
expected, Rictor-deficiency specifically in B cells leads to significant changes in 
mature B cells, with increased percentages of myeloid and NK cells lineages 
likely due to the decrease in B cells. Interestingly, there was no change in the 
percentage of apoptotic cells in all haemopoietic or in B cells in the BM (Figure 
4.22). However, there was a decreasing trend in live cells with an increasing 
trend in early and late apoptotic haemopoietic cells and B cells in the spleen of 
Vav- and Mx1-Rictor KO mice (Figure 4.23A-H). Moreover, there was a significant 
increase in the percentage of apoptotic B cells, together with trends in decrease 
in percentage of live cells with CD19-Rictor KO (Figure 4.23I,J), suggesting only 
a subtle role of mTORC2 in apoptosis in B cells and other haemopoietic lineages. 
To assess the role of Rictor in B cells, early and late B cells markers were 
assessed in the BM, spleen, and LN. Unlike with Raptor-deficiency, Rictor-
deficiency did not lead to any changes in the percentage or cellularity (data not 
shown) of early B progenitors including LSK, pre-proB and proB cells in the BM of 
Vav- and Mx1-Rictor KO mice compared to their respective controls (Figure 4.24, 
Figure 4.26A&B). However, there was a significant increase in the percentage of 
pre-proB cells in the BM of CD19-Rictor KO mice, together with a significant 
decrease in the percentage of proB cells compared to controls, suggesting a 
block in B cell development at the pre-proB cell stage within the CD19-Rictor KO 
model specifically (Figure 4.26C). To assess late B cell lineage development, we 
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focussed on the percentages, not cellularity, of late B cell populations due to 
the significant decrease in total splenic cellularity thereby decreasing the 
cellularity of most late B cell populations with Rictor-deficiency at the HSC stage 
and in adult mice (Figure 4.18B). There was a significant decrease in the 
percentage of T1 cells in the LN, and a decreasing trend in T3 B cell populations 
in the spleen of Vav-Rictor and Mx1-Rictor KO mice respectively compared to 
controls (Figure 4.25, Figure 4.26D&E), along with a significant decrease in T1 
and T3 percentages in the spleen and T1 B cells in the LN of CD19-Rictor KO 
mice compared to controls (Figure 4.26F). As T1 B cells transition to T2 and 
subsequently fol2 which give rise to MZ cells, looking at mature B cell lineages, 
it was not surprising to observe a significant decrease in MZP and MZ 
percentages in spleens of Vav-Rictor KO mice, which is consistent with H&E 
staining showing a decrease in MZ (Figure 4.26G, Figure 4.16C). Additionally, a 
decrease in the percentage of fol1 B cell population in the LN with a decreasing 
trend in the spleen in Mx1-Rictor cKO mice was observed compared to controls. 
There was also a trend in increase in the MZP and MZ population which was 
consistent with the H&E staining in the spleens of Mx1-Raptor cKO mice (Figure 
4.26H, Figure 4.16D) suggesting an accumulation of MZ B cell population. Lastly, 
a significant decrease in the MZ percentage was observed in the spleen and LN 
of CD19-Rictor KO mice suggesting aberrations in late B cell populations, 
specifically in MZ and fol1 B cells with Rictor-deficiency in vivo (Figure 4.26I). 
These data suggest an important role of mTORC2 in later stages B cell subtypes. 
  
 123 
 
4.3  Discussion 
In order to determine the individual roles of mTORC1 and mTORC2 in normal 
haemopoiesis, the Vav-cre, Mx1-cre and CD19-cre Raptor and Rictor KO mouse 
models were used to assess haemopoiesis at various stages – the HSC stage, adult 
mice and specifically in B cells. However, in order to do so, each model needed 
to be optimised to obtain the robust phenotypic evidence of changes in 
haemopoietic cell development upon KO/cKO of mTORC1/mTORC2.  
4.3.1 Optimisation 
Previous literature comprising the Mx1-cre Raptorfl/fl and Mx1-cre Rictorfl/fl 
models used differing doses and volume of poly(I:C) to induce a cKO in mice. 
Kalaitzidis et al., induced Mx1-Raptor cKO with 3 poly(I:C) inoculations every 
other day at 15 mg/kg(91), whereas Guo et al., carried out 6-8 poly(I:C) 
inoculations at 10 mg/kg(263), with no reference to the timepoint these mice 
were assessed post poly(I:C) inoculation. The Mx1-Rictor cKO has previously 
been induced by 4 poly(I:C) inoculations at 5 mg/kg and assessed at either 1 or 6 
months(92). However, data for 1 month was not shown in the paper suggesting a 
poorer cKO. In other laboratories Rictor cKO has been induced by 7 poly(I:C) 
inoculations every other day at 400 µg with no mention of the age of the mice 
when assessed(115). Due to additional papers suggesting 4 poly(I:C) or fewer 
inoculations(93) reproduced the desired phenotype, a dose of 4 poly(I:C) at 10 
mg/kg was delivered to our mice where the timepoint at which the mice were 
assessed differed between 3 and 5 wk post 4 poly(I:C) inoculation in the Mx1-
Rictor model. Kuhn et al., showed that one dose of poly(I:C) is sufficient to 
induce a 100% KO in the liver suggesting that fewer doses can lead to potent 
KO(234). We determined that the Mx1-cre induced cKO via poly(I:C) inoculation 
was optimal 5 wk post 4 rounds of poly(I:C) at 10 mg/kg in both Mx1-cre 
Raptorfl/fl and Mx1-cre Rictorfl/fl models. Successful excision of Raptor and 
Rictor in these mouse models was confirmed. Additionally, Mx1-Raptor control 
mice were compared with WT mice inoculated with 4 poly(I:C) inoculation and 
assessed 5 wk post to assess any changes between the two models with poly(I:C) 
inoculation. As both the models did not show any significant difference, Mx1-
Raptor control mice were used as reference whilst assessing Mx1-Raptor cKO 
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mice as it suggested that polyI:C inoculation did not produce any drastic effects 
in either WT or Mx1-Raptor control model. 
Discrepancies in the field existed for the timepoint at which the Vav-cre 
Rictorfl/fl mouse model should be assessed to obtain the best phenotype for the 
KO. Indeed, Vav-cre Rictorfl/fl mice have been assessed at 3-4 wk(285) or at 6-8 
wk(116) in previous studies. Therefore, the mice were assessed at 2, 8, and 24 
wk of age to determine the optimal timepoint for the best phenotype from the 
KO. Analysis of the development of B, T, NK and myeloid lineages concluded that 
mice with Rictor deficiency at the HSC stage have an optimal phenotype from 
the KO at 8 wk of age.  
The CD19-cre models for Raptor and Rictor were analysed between 8-10 wk and 
18-24 wk respectively due to the known role of Raptor and Rictor at early and 
later stages of B cell lineage haemopoiesis respectively(282). CD19-
cre+/+Raptorfl/fl mice, having homozygous cre expression, exhibited a severe 
phenotype with a drastic decrease in mature B cells due to the insertion of cre 
recombinase gene into the first exon of CD19 antigen gene thereby causing a 
block in CD19 expression and essentially creating a CD19 KO (283). Moreover, 
Vav-cre model has been shown to be better at the excision of a gene of interest 
than CD19-cre models, where cre excision is 75-80% and 95% accurate in the BM 
and spleen respectively (206). The Mb1-cre model (Mb1 is expressed at the pro-
proB cell stage) is a better B cell specific model with a better deletion efficiency 
than CD19-cre model (208). Additionally, the homozygous expression of cre has 
been well known to be associated with non-specific excisions within the genome 
due to the presence of pseudo-loxP sites within the murine genome leading to 
toxicity(208). Therefore, a heterozygous expression of cre was used for all the 
models to limit non-specific excisions and the CD19-cre+/+Raptorfl/fl model was 
not considered for further B cell lineage analysis. 
4.3.2 Validation of KO Targets 
Testing the gene and protein expression levels of Rictor and Raptor together 
with their downstream targets in deficient mouse models revealed a significant 
downregulation of Raptor in haemopoietic organs in Mx1-Raptor cKO as 
expected. Less expected was the decrease in Rictor expression in the spleen 
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with Raptor-deficiency in Mx1-Raptor cKO mice. Similarly, there was a 
significant decrease in RAPTOR and RICTOR expression in haemopoietic organs in 
Mx1-Raptor cKO mice. It is possible that mTORC1 controls the protein synthesis 
of RICTOR thereby decreasing RICTOR expression altogether. This is supported by 
the finding that Rictor gene expression was not significantly modulated in Mx1-
cre Raptorfl/fl mice. mTORC1 is known to phosphorylate S6K1 which negatively 
regulates mTORC2 activity (65). However, as our data presented did not show a 
reduction in S6 phosphorylation, there could be other possible substrates 
phosphorylating S6. Five phosphorylation sites have been identified for S6, at 
S235, S236, S240, S244 and S247, where there is an orderly progression of 
phosphorylation with S236 as the primary phosphorylation site(286). 
Interestingly, Pende et al., have shown that although S6K2 is primarily 
responsible for S6 phosphorylation, there are still lower levels of detection of 
S235 and S236 phosphorylation, after the KO of S6K1 and S6K2, by MAPKs (287) 
which could be responsible for the phosphorylation of S6. Nevertheless, it is 
possible that the upstream S6K, a primary effector of S6, is being modulated by 
other pathways despite Raptor cKO thereby phosphorylating S6. Previous 
literature suggests that S6K1 is phosphorylated directly by PDK1 at T308 
residue(288), and by insulin stimulated MAPKs (289,290) which could be other 
possible upstream substrates phosphorylating S6K1.  
Analysis of p4EBP1T37/T46 in Raptor-deficiency in adult mice, showed a slight 
decrease in phosphorylation. A reason behind the lack of significant decrease of 
p4EBP1 could be due to the antibody used for western blotting. The signal seen 
on the Western blot was weak, with no signal on various occasions in tissues of 
Raptor-control mice thereby explaining the lack of significance.  
Similarly, Rictor-deficiency at the HSC stage (Vav-Rictor KO) and in adult mice 
(Mx1-Rictor cKO) showed a significant decrease in Rictor expression at the mRNA 
and protein levels. It was interesting to observe a significant decrease in Raptor 
expression at the mRNA level in the BM and thymus of Vav-Rictor KO mice. 
However, there was no difference in RAPTOR expression at the protein level in 
these mice suggesting mTORC2 does not regulate mTORC1 at the early HSC stage 
(Vav-Rictor KO model). Moreover, Mx1-Rictor cKO mice did not show any 
changes in RAPTOR expression at the protein/mRNA levels. These studies 
indicate that mTORC1 regulation of mTORC2/RICTOR expression is more potent 
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compared to mTORC2 vs. mTORC1 dysregulation. Assessing a downstream 
substrate of mTORC2, Vav-Rictor KO mice displayed a significant decrease in the 
downstream AKTS473 phosphorylation as compared to Mx1-Rictor cKO mice, which 
displayed similar, yet non-significant trends in the BM, spleen, and thymus. As 
mentioned, Vav-cre model is regarded as system with a very high efficiency in 
deletion of the target(208). The Mx1-cre model on the other hand has shown to 
have other immunogenic side effects(204) and may not represent a complete 
KO(234). Previous literature has shown that an inducible model of Rictor-
deficiency in adult mice (Rosa-cre ER) results in a significant reduction of AKTS473 
phosphorylation with increased AKTT308 phosphorylation and increased FoxO1 
activity(111). This suggests there is an increase in PDK1 activity(291) potentially 
activating the mTORC1 complex, evident by no change in RAPTOR expression 
with Rictor deficiency in both Rosa-cre and Mx1-cre models. Nevertheless, the 
difference observed between the phosphorylation of AKTS473 in Mx1-cre vs. Rosa-
cre could be model specific. Rosa26 is a promoter which is ubiquitously 
expressed in all tissues and is expressed at an early stage in ES cells, but its 
function is not yet known(292). On the other hand, Mx1 promoter is expressed in 
the nucleus of most tissues including spleen, liver, uterus, kidneys, BM, 
peripheral blood mononuclear cells (PBMCs)(293) in mice, and in most tissues 
with lower expression in smooth muscle in humans(199). However, its ubiquitous 
expression in mice has not been confirmed. This difference in the nature of the 
promoter expression and function together with the mechanism of cre induction 
(via tamoxifen vs. poly(I:C)) could account for the potent KO in Rosa-cre vs. 
Mx1-cre transgenic mice. 
4.3.3 Splenic Architecture in KO models 
Mx1-Raptor cKO in mice resulted in an increase in splenic weight and cellularity 
and a decrease in BM cellularity, which has been demonstrated previously, 
together with a disruption in splenic structure with Raptor cKO 5-7 months post 
poly(I:C) inoculation(91). The reasons for the aberrations in the spleen are 
unclear. mTORC1 has shown to play a role in cytoskeletal reorganisation, as 
rapamycin has shown to inhibit IGF1 activated cytoskeletal structure and cell 
motility in a RhoA dependent manner in tumour cell lines(294). Therefore, it is a 
possibility that there is an aberration in the F-actin filaments with mTORC1 
deficiency thereby demolishing the structure of the spleen as our data 
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demonstrate a loss of GC and MZ in the spleen altogether with Raptor cKO. 
However, literature has also shown that mTORC2 controls actin cytoskeleton in a 
rapamycin independent manner(295) and is mediated by PKCα(296), thereby 
suggesting contradictory roles of mTOR complexes in actin organisation. 
Recently, Rictor has shown to positively regulate BCR signalling as Rictor-
deficiency in B cells results in overactivation of ezrin, a protein responsible for 
connecting actin filaments, leading to the formation of a rigid fence of actin 
thereby restricting lateral BCR movement on the membrane(297). Indeed, we do 
see a disruption of splenic morphology and architecture in Vav-Rictor KO mice 
suggesting that both mTOR complexes play a role in splenic architecture. 
However, whether this is dependent on actin organisation is unclear. 
Additionally, the increase in spleen weight with a loss of Raptor has been 
associated with a compensatory mechanism of the body to increase the 
population of other cells such as erythrocytic, dendritic (not tested) or 
macrophages leading to extramedullary haemopoiesis due to the decrease in 
other lymphoid haemopoietic lineages(91).  
Interestingly, we show an increase in Ki67 staining in the red pulp of the spleen 
in Mx1-Raptor cKO mice. Ki67 is a marker for proliferating cells with expression 
present in all stages of cell cycling - G1, G2, S phases(298). Therefore, observing 
an increase in Ki67 expression with Raptor cKO suggests a disruption in cell 
cycling. Dowling et al., have published an essential role of 4EBPs in regulating 
cell proliferation and cycling in an mTORC1 dependent manner confirming the 
observed increase in Ki67 expression in mice with Raptor-deficiency(299). In 
Vav-Rictor KO mice there was no change in proliferation and cycling. 
Nevertheless, Mx1-Rictor cKO mice (and not Vav-Rictor KO) showed increased 
accumulation of Ki67 expression in the GCs of the spleen. This suggests a block 
in proliferation and cell cycling in adult mice alluding to a specific role of Rictor 
in later stages of development as opposed to at the HSC stage. Wang et al., 
demonstrated a decrease in proliferation in adult murine endothelial cells with a 
decrease in vascular endothelial growth factor (VEGF) with Rictor 
deficiency(300). Similarly, Rictor-deficiency in B cells affected proliferation with 
the significant decrease in MZ B cells(111). 
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4.3.4 mTORC1/2 signalling in apoptosis 
As discussed in section 3.3, the increase in spleen weight due to Raptor-
deficiency correlates with an increase in the red pulp as seen from the H&E 
staining, which could suggest an increase in erythrophagocytosis in the spleen 
(301). Mx1-Raptor cKO in adult mice led to increased apoptotic death of B cells 
with similar trends in mice with deletion of Raptor in B cells. As Raptor-
deficiency did not demonstrate other significant changes (but trends in increase 
in apoptotic cellularity due to the likely effect of mTORC1 on apoptosis in B 
cells) in other haemopoietic lineages, it is a possibility that B cells are 
particularly sensitive to apoptosis in the absence of Raptor. Guo et al., observe 
an increase in apoptosis in myeloid, erythroid and B cell lineages in the BM 
coupled with a decrease in the anti-apoptotic protein, MCL-1, with mTOR-
deficiency(263). These data could allude to the role of both mTORC1 and 
mTORC2 in apoptosis as they did not assess the individual roles of mTOR 
complexes. Additionally, induced deletion of Raptor in adult mice led to an 
increase in apoptosis of differentiated, but not leukaemic stem cells (LSCs), in a 
mouse model of AML(100). However, these data focusses on a murine model of 
AML and not healthy haemopoietic lineages. Our data show that B cells are 
particularly sensitised to apoptosis with Raptor-deficiency in the BM. The BM 
does not have many T cell subsets but has an increased population of myeloid 
cells. It would be interesting to assess other haemopoietic organs such as the 
spleen or thymus and assess myeloid, and other lymphoid lineages to determine 
the exact role of mTORC1 in apoptosis within different haemopoietic lineages.   
Our data suggest a subtle role of mTORC2 in apoptosis as there exist slight 
trends illustrating an increase in early and late apoptotic cells in the spleens of 
Vav-Rictor KO and Mx1-Rictor cKO mice and a significant increase in apoptotic B 
cells in CD19-Rictor KO mice. In agreement with this, published data 
demonstrates an important role of Rictor in apoptosis. It has previously been 
shown that Vav-Rictor KO mice exhibit an increase in the pro-apoptotic target 
Bim with a decrease in the anti-apoptotic BclXL in mature B cells by impairing 
the canonical and non-canonical NFκB pathway, thereby demonstrating a 
balance of apoptosis in mature B cells by mTORC2(111). Furthermore, Brunet et 
al., demonstrated an important role of AKT in phosphorylating and inhibiting the 
forkhead TF FKHRL1 (FOXO3), thereby inhibiting apoptosis suggesting a role of 
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mTORC2 in balancing apoptosis(70). RICTOR (and not RAPTOR) knock down (KD) 
in MCF-7 cells (human breast cancer cell line) revealed that mTORC2 regulates 
apoptosis in B cells and epithelial cells in a C-MYC dependent manner whereby 
RICTOR KD upregulates C-MYC expression and subsequent downregulation of 
E2F1(113). In contrast, conditional Rictor deletion in CD8+ effector T cells did 
not affect the rate of apoptosis suggesting a redundant role of mTORC2 in 
regulating T cell mediated apoptosis(125). This suggests a role of mTORC2 in 
apoptosis in B cells and in other haemopoietic lineages excluding T cells. Clearly 
there exist discrepancies between our data and in previous literature as our data 
does not allude to significant apoptosis in B cells with Rictor-deficiency. Perhaps 
the trends observed in our data could allude to other lineages not affected by 
mTORC2 which skew the percentages.  
4.3.5 Impact of mTORC1/2 deletion on haemopoietic lineage 
development 
4.3.5.1 B cells 
To assess the individual roles of mTORC1 and mTORC2 in normal haemopoiesis, 
haemopoietic lineages were assessed in mice with Raptor and Rictor-deficiency. 
In agreement with previously published literature (91), Mx1-Raptor cKO mice 
lacked mature B cells in haemopoietic organs, while Rictor-deficient mice only 
revealed major phenotypic changes later in development. To determine the 
exact role of mTORC1 and mTORC2 in B cells, populations of early B cells in the 
BM and late B cells in the spleen and LN were assessed. There was a significant 
elevation of LSK cells in the BM of Vav-Raptor KO and Mx1-Raptor cKO mice 
(chapter 3) suggesting a block in B cell development and B cell lineage 
commitment with Raptor-deficiency. Iwata et al., have shown a block in B cell 
development at the preB cell stage along with a lack in peripheral B cells 
independent of BCLXL in mice with Raptor-deficiency in B cells specifically (Mb1-
cre cKO). B cell populations with Raptor-deficiency had decreased glycolysis and 
oxidative phosphorylation indicating an aberration in metabolism(109). This 
group used a different KO model, which rendered only B cells deficient of 
mTORC1 via the Mb1-cre cKO model (Mb1 is expressed at the pre-proB cell 
stage), which will be the reason for the difference observed in the stage at 
which B cell development is blocked. Additionally, mTORC1 deficiency, and not 
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mTORC2, is responsible for a decrease in 18 genes encoding for electron 
transport chain (ETC) proteins together with a decrease in oxidative 
phosphorylation(302). While assessing the model with Raptor-deficiency in B 
cells (CD19-cre+/-Raptor KO) for early B cell progenitors, we observed an 
increase in LSK and pre-proB cells with a decrease in proB cells with Raptor-
deficiency (data not shown), thereby blocking B cell development at the pre-
proB cell stage as opposed to at the LSK stage in mice lacking Raptor at the HSC 
stage (Vav-cre) or in adult mice (Mx1-cre). This suggests that sufficient Raptor 
expression is required throughout the early stages of B cell development to 
support maturation of the B cell lineage. Interestingly, Tze et al., demonstrated 
that a conditional BCR deletion or inhibition of PI3K resulted in a de-
differentiation of mature B cells to having early B cell characteristics(303).  
Whether mTORC1 inactivation leads to the reversal or depletion of B cells is 
currently unknown. 
Rictor-deficiency in Vav-cre (HSC stage) or Mx1-cre (adult mice) mice did not 
affect B cell lineage commitment suggesting mTORC2 does not play a role in 
early B cell lineage commitment. However, previous literature has shown that 
Mx1-Rictor cKO mice exhibit an increase in proB cells with a decrease in mature 
B cells 6 months post poly(I:C) with an increase Rag1 expression and an increase 
in cell cycling as there was a significant increase in B cells in G2/S phase with a 
decrease in cells in G0 phase which was Foxo1 dependent(92). As our conditional 
mouse model is assessed 5 wk post poly(I:C) inoculation, it is possible that this 
phenotype has not become evident after about 1 month and needed to be 
assessed 6 months post inoculation. Additionally, B cells lacking mSIN1 (a 
component of mTORC2 which is known modulate activity of mTORC2) led to an 
increase in Rag and Il7r expression (also causing augmentation in V(D)J activity) 
via the regulation of Foxo1, which is mediated by Akt(112). Our data show that 
Rictor-deficiency solely in B cells leads to a significant decrease in B cells with 
an increase in pre-proB cells alluding to a potent role of mTORC2 in B cell 
maturation. However, as cre excision is not as efficient in CD19 models (206), a 
more potent Rictor KO in B cells in the BM, such as the Mb1-cre models, may 
have shown deregulated mTORC1 and Foxo1 activity (via upstream mTORC2 
activity).  
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Given that B cell development is blocked with mTORC1 deficiency, it was not 
surprising to see aberrations in late B cell populations. Significant reductions in 
T2 B cells with reductions in MZP, MZ and fol2 populations in the spleen of Mx1-
Raptor cKO mice with similar reductions in T2, fol1 and fol2 B cell subsets in 
CD19-cre+/-Raptor KO mice. Interestingly, Rictor-deficiency was also associated 
with a decrease in T1 and T3 B cells and reductions in MZP, MZ and fol1 B cells. 
These results were in agreement with previous literature determining the 
function of late B cell populations. T1 cells transition into T2 cells leading to 
subsequent fol2 B cells. Fol2 B cells are more primitive, quiescent and less 
abundant compared to fol1 cells, which form the majority of the recirculating 
pool. MZP B cells arise from fol2 cells leading to MZ B cells. Fol2 cells also 
generate fol1 cells(44). Therefore, it is appropriate to observe a significant 
decrease in T2 and the primitive fol2 cells and a concomitant decrease in MZP 
and MZ cells in Mx1-Raptor mice due to the fundamental role of mTORC1 in B 
cell development as discussed previously. Rictor-deficiency is associated with 
disruption in migration and cell cycling, which explains the observed reduction in 
T1, T3 cells which give rise to the recirculating fol1 B cell population. There 
were no significant changes observed in fol2 B cells suggesting that mTORC2 
plays a role in the ability of fol2 B cells to further develop into fol1, MZP and MZ 
cells. Lee et al., demonstrate a block in late B cell populations in mice with 
Rictor-deficiency at the HSC stage with similar results in adult mice via a 
decrease in T3 B cells and an increase in T1/T2 ratio together with a decrease in 
MZ cells. They also observe a modest decrease in follicular cells(111), however 
they did not distinguish between fol1 and fol2 cells. All these data support our 
results thereby confirming a role for mTORC2 in late B cell development. 
Although, there is a decrease in MZ population in Vav-Rictor KO mice, there is a 
trend in increase in MZ and MZP populations when Rictor-deficiency is induced in 
adult mice (Mx1-Rictor cKO) seen from H&E staining and from phenotypic 
analysis by flow cytometry. This suggests an accumulation of MZ cells with 
induced Rictor-deficiency in adult mice, as there is a decline in fol2 cells.  
4.3.5.2 Other haemopoietic lineages 
A significant reduction in the mature myeloid (CD11b+Gr1+) population was 
observed in the BM and blood but an increase in percentage of mature myeloid 
cells in the secondary lymphoid organs: spleen and LN, in Mx1-Raptor cKO mice. 
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As lymphopoiesis takes place in the BM, it is possible that there was an 
accumulation of CD11b+ myeloid cells (as seen in the BM) blocking the 
maturation into CD11b+Gr1+ myeloid cells with Raptor-deficiency in adult mice. 
Therefore, there was an increase in the remaining CD11b+Gr1+ myeloid cells in 
the secondary lymphoid organs. Additionally, secondary lymphoid organs would 
have a reduced population of B and T cells thereby increasing the percentage of 
myeloid cells. It would be interesting to analyse this population at later 
timepoint (6 months) post poly(I:C) inoculation and to determine whether there 
is a decrease in mature myeloid population with induced Raptor-deficiency in 
adult mice. Indeed, mTOR-deficiency leads to a block in myeloid development in 
vivo and in vitro via the reduction of M-CSF(102) receptor CD115 and the 
overactivation of STAT5 leading to the downregulation of IRF8(101). Rictor KO in 
myeloid cells has been shown to result in a bias towards an M1, and not M2, 
population and increased their sensitivity to apoptotic stimuli(304) and 
promoted pro-inflammatory M1 genes in response to TLR ligands in a FOXO1/3 
dependent manner(106), suggesting a role of mTORC2 in myeloid viability and 
inflammatory responses. Our data was not focussed on the role of mTORC2 in 
myeloid lineages. However, assessing the viability of this lineage in the three 
different models would give us a better insight on the cycling and underlying 
mechanisms behind this characteristic caused due to mTORC2 abrogation. 
Raptor-deficiency also affected NK cell populations and T cell lineages. The 
earliest thymocytes within the thymus lacking CD4 and CD8 expression and are 
termed as double negative (DN) thymocytes. About 95% of DN cells give rise to 
αβ-T cells via successful rearrangement of αβ-TCR via a process known as beta-
selection. It is during this proliferative period of selection that T cells either die 
of apoptosis or express both CD4 and CD8 to become DP. These cells 
subsequently down-regulate a co-receptor to fully differentiate into either CD4+ 
or CD8+ T cells(305).  We demonstrate a decrease in CD4+CD8+ DP thymocytes 
with a concomitant increase in CD8+ and CD4-CD8- DN thymocytes with Raptor-
deficiency. Although reduced, there is a generation of DP T cells suggesting a 
role of mTORC1 in the proliferation of naïve cells, which is consistent with 
previously published data(306). In agreement with our data, rapamycin (mTORC1 
inhibitor) treatment of mice with lymphocytic choriomeningitis virus (LCMV) has 
shown to increase the quantity and quality of CD8+ T cells(306) demonstrating a 
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role of mTORC1 in the proliferation with redundant roles in T cell development. 
Nevertheless, there remain discrepancies in the field as Pollizzi et al., have 
shown a potent role of mTORC1 in effector cells as RHEB mediated deletion of 
mTORC1 in CD8+ T cells did not differentiate into effector cells, but retained 
ability to differentiate into memory T cells, but were dysfunctional due to 
metabolic defects(120). Rictor-deficiency in the Vav- and Mx1-cre mouse models 
strongly affected T cell development with a decrease in CD4+CD8+ DP T cells 
together with an increase in the CD4-CD8- DN T cell populations with a modest 
increase in NK cell population in the spleen of adult mice with Rictor-deficiency. 
mTORC2 has been shown to regulate T cell development as Mx1-Rictor cKO 
partially blocks T cell development at the DN3 (CD3+CD44-CD25+) stage(115) and 
involves NFκB and FOXO1 pathways(116). Mice with mTOR-deficiency exhibit a 
block in Th1, Th2, and Th17 cells due to abrogation in the STAT signalling and 
differentiate towards T-regulatory (T-reg) cells which is independent of mTORC1 
suggesting an important role of mTORC2 in T-reg development(307). 
Additionally, Rictor deficiency in T cells causes a block in Th1 and Th2 CD4+ T 
cell development which is rescued by AKT (via increased expression of Tbet TF) 
and PKC-θ (via reverting Gata3 expression)(123). Conditional deletion of Rictor 
in CD8+ T cells demonstrates an increased ability of CD8+ T cells to commit to 
memory precursor effector cells (MPECs) together with more potent recall 
responses and CD8+ T cells also exhibited a reduction in short-lived effector cell 
(SLECs) commitment in a Foxo1 dependent manner(125) suggesting mTORC2 
regulates effector cell commitment. These published papers suggest a vital role 
of mTORC2 in T cell development. As the CD19-cre model should only effect 
CD19+ B cells, is was reassuring to see the majority of effects on B cells with 
Raptor and Rictor-deficiency. Nevertheless, there were slight increases in NK 
and myeloid lineages in the spleen and blood of transgenic mice lacking Raptor 
and Rictor, which could be attributed to the significant decrease in B cell 
lineage in these mice.  
Taken together, upon successful deletion of Raptor and Rictor, our data show an 
important role of mTORC1 predominantly in B and T cell development. mTORC1 
inactivation blocks B cell development at the LSK or the pre-proB cell stage 
(depending on the individual models used). Additionally, we demonstrate that 
mTORC2 is not vital for early B cell development but plays a role in late B cells 
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by blocking fol2 development into MZ and fol1 cells. mTORC2 also plays an 
important role in T cell development. Therefore, we demonstrate that although 
there is a cross-talk between both the complexes, mTORC1 and mTORC2 have 
unique roles during haemopoiesis. 
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4.4 Figures 
 
Figure 4.1:Optimization of the Mx1-cre Raptor cKO model. 
Mx1-cre- (cre-, Mx1-Raptor control) and Mx1-cre+Raptorfl/fl  (cre+, Mx1-Raptor cKO) mice were 
inoculated with either 3 or 5 doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 
(n=4) or 10 (n=3) wk or 5 wk post inoculations respectively. Spleen weight (mg) (A) and cellularity 
(log10) (B) of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and 
assessed at either 3, 5, 8 or 10 wk post inoculation. BM (C), LN (D), and thymus (E) cellularity 
(log10) of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and 
assessed at either 3, 5, 8 or 10 wk post inoculation. Spleen weight (mg) (F) and cellularity (log10) of 
BM, spleen, thymus and LN (G) of Mx1-Raptor control (n=3) and Mx1-Raptor cKO (n=3) mice 
inoculated with 5 poly(I:C) doses and assessed 5 wk post inoculation. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001). 
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Figure 4.2: Optimization of the Mx1-cre Raptor cKO model assessing stem and early B cell 
progenitors in vivo. 
Mx1-Raptor control (cre-) and Mx1-Raptor cKO (cre+) mice were inoculated with either 3 or 5 
doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=2) or 10 (n=3) wk or 5 wk 
post inoculation respectively. Bar graphs demonstrating the percentage (A) and cellularity (log10) 
(B) of LSK (lin-sca-1+CD117+) cells in the BM along with percentage (C) and cellularity (log10) (D) of 
pre-proB cells (lin-B220+CD19-) in the BM and spleen of Mx1-Raptor control and Mx1-Raptor cKO 
mice inoculated with 3 poly(I:C) doses and assessed at either 3, 5, 8 or 10 wk post inoculation. 
Percentage (E) and cellularity (log10) (F) of LSK cells in the BM (n=3) along with percentage (G) 
and cellularity (log10) (H) of pre-proB cells in the BM (n=1) and spleen of Mx1-Raptor control and 
Mx1-Raptor cKO mice inoculated with 5 poly(I:C) doses and assessed 5 wk post inoculation. Data 
are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 4.3: Optimization of the Mx1-cre Raptor cKO model assessing B cell lineages in vivo. 
Mx1-Raptor control (cre-) and Mx1-Raptor cKO (cre+) mice were inoculated with either 3 or 5 
doses of 10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=2) or 10 (n=3) wk or 5 wk 
(n=3) post inoculation respectively. Percentage of B cell lineage (CD19+CD11b-) in the BM, spleen, 
thymus, LN and blood of Mx1-Raptor control and Mx1-Raptor cKO mice inoculated with 3 doses of 
poly(I:C) and analyzed at either 3, 5, 8 or 10 wk post inoculation (A) or with 5 doses of poly(I:C) 
and assessed 5 wk post inoculation (B). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, 
p ***≤0.0001, p ****≤0.00001). 
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Figure 4.4: Optimization of the Mx1-cre Raptor cKO model assessing late B cell lineages in 
vivo. 
Mx1-Raptor control (cre-) and Mx1-Raptor cKO (cre+) mice were inoculated with either 3 doses of 
10 mg/kg poly(I:C) and analyzed at either 3 (n=5), 5 (n=5), 8 (n=2) or 10 (n=3) wk post inoculation 
or with 5 doses (n=3) of poly(I:C) and assessed 5 wk post inoculation. Bar graphs demonstrating 
the percentage of T1 (CD19+CD23-IgM+CD21-), T2 (CD19+CD23+CD21-CD1dloIgD+IgM+AA4.1+), T3 
(CD19+CD23+CD21-CD1dloIgD+IgM-AA4.1+), MZP (CD19+CD23+CD21+CD1d+) and MZ 
(CD19+CD23-IgM+CD21+) B cells (A), and percentage of fol1 (CD19+CD23+CD21-CD1dloIgD+IgM-
AA4.1-) and fol2 (CD19+CD23+CD21-CD1dloIgD+IgM+AA4.1-) B cells (B) in the spleen of Mx1-
Raptor control and Mx1-Raptor cKO mice inoculated with 3 poly(I:C) doses and assessed at either 
3, 5, 8 or 10 wk post inoculation. Percentage of T1, T2, T3, and MZP B cells (C), and percentage of 
MZ, fol1 and fol2 B cells (D) in the spleen of Mx1-Raptor control and Mx1-Raptor cKO mice 
inoculated with 5 doses of poly(I:C) and assessed 5 wk post inoculation. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001). T – transitional 1 B cells, MZP – marginal zone B cells, fol – 
follicular B cells. 
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Figure 4.5: Control experiment showing no difference between WT mice and mice 
expressing cre- on alleles. 
Comparison of spleen weight (mg) (A) and total organ counts (BM, spleen, and thymus) in 
logarithmic axis (B) between wild type (Wt) (n=8) mice and cre- (n=9, Mx1-Raptor control) mice 
assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculation. Bar graphs demonstrating the percentage (C) 
and cellularity (log10) (D) of B cells in the BM, spleen, and thymus of Wt (n=8) and cre- (n=6) mice 
assessed 5 wk post 10 mg/kg 4 poly(I:C) inoculation. Percentage (E) and cellularity (log10) (F) of 
CD4+CD8+ DP and CD4-CD8- DN T cells in the thymus of wild type (Wt) and cre- mice assessed 5 
wk post 4 poly(I:C) inoculation. Percentage (G) and cellularity (log10) (H) of CD11b+Gr1+ mature 
myeloid cells in the BM, spleen and thymus of wild type (Wt) (n=8) and cre- (n=6) mice assessed 5 
wk post 10 mg/kg 4 poly(I:C) inoculation. Data are expressed as mean±SEM. 
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Figure 4.6: Characterization of lymphoid organs in Raptor KO models.  
A. Spleen weights (mg) of Mx1-Raptor control (cre-) or Mx1-Raptor cKO (cre+) mice inoculated 
with 3 (n=5), 4 (n=6) or 5 (n=3) doses of 10 mg/kg poly(I:C) were assessed 5 wk post-inoculation to 
induce the cKO. B. Total organ counts (log10; BM, spleen, thymus and LN) of Mx1-Raptor control or 
Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation. C. Histology slides showing 
haematoxylin and eosin (H&E) staining (top row) and Ki67 staining (bottom row) of spleen section 
of Mx1-Raptor control or Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation.  Spleen 
weights (D) and organ cellularity (log10) (E) of CD19-cre-/-Raptorfl/fl (cre-, CD19-Raptor control, 
n=5), CD19-cre+/-Raptorfl/fl (cre+, CD19-cre+/-Raptor KO, n=7) or CD19-cre+/+Raptorfl/fl (cre++, 
CD19-cre+/+Raptor KO, n=6) mice. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p 
***≤0.0001, p ****≤0.00001). GC – germinal centre, MZ – marginal zone. 
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Figure 4.7: Confirmation of Raptor cKO at the protein, gene and at the substrate level for 
mTOR pathway members in Mx1-Raptor cKO mice. 
Representative western blot showing protein expression of RAPTOR and RICTOR, and 
downstream mTOR proteins: t4EBP1, pS6S235/S236, tS6, pAKTS473, tAKT and loading controls 
βACTIN and GAPDH in the BM, spleen, thymus and liver from Mx1-Raptor control and Mx1-Raptor 
cKO mice 5 wk post 4 poly(I:C) inoculation (A). Densitometry of protein expression of 
RAPTOR/tAKT (n=5 Mx1-Raptor control, n=7 Mx1-Raptor cKO) (B) and RICTOR/tAKT (n=4) in the 
spleen and thymus Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation 
(C). MFI ratios of p4EBP1T37/T46/isotype control (n=3) (D) and pAKTS473/isotype control (n=5) (E) in 
the BM, spleen and thymus of Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) 
inoculation. Gene expression of Raptor (F) and Rictor (G) in the BM (n=4), spleen (n=5) and liver 
(n=4) of Mx1-Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation. Data is 
shown relative to Mx1-Raptor controls with Tbp as the reference gene. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001). 
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Figure 4.8: Gating strategy of haemopoietic lineages in Mx1-cre and CD19-cre Raptor mouse 
models.  
Representative flow cytometry plots demonstrating the proportion of B cells (CD19+CD11b-) in the 
BM, CD4+ (CD19-CD4+CD8-), CD8+ (CD19-CD8+CD4-), CD4+CD8+ (CD19-CD4+CD8+) T cells in the 
thymus, mature myeloid cells (CD19-CD11b+Gr1+) in the BM, and NK cells (CD19-CD4-NK1.1+) in 
the spleen in Mx1-Raptor control (A) Mx1-Raptor cKO 5 wk post 4 poly(I:C) inoculation (B), CD19-
Raptor control (C) CD19-cre+/-Raptor KO (D), and CD19-cre+/+Raptor KO (E) mice. Plots are live 
and size (FSC-A/SSC-A) gated prior to the gating shown. RCN – relative cell number. 
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Figure 4.9: Raptor cKO in adult mice leads to significant aberrations in haemopoietic 
lineages in vivo.  
Bar graphs showing the percentage of B cells (A), CD11b+Gr1+ mature myeloid cells (C), NK cells 
(E) in the BM, spleen, LN, thymus and blood and cellularity of B cells (B), CD11b+Gr1+ mature 
myeloid cells (D), NK cells (F) in the BM, spleen, LN and thymus of Mx1-Raptor control (n=6) and 
Mx1-Raptor cKO (n=3) mice 5 wk post 4 poly(I:C) inoculation. Percentage (G) and cellularity (H) of 
CD4+CD8+ DP and CD4-CD8- DN thymocytes in the thymus of Mx1-Raptor control (n=6) and Mx1-
Raptor cKO (n=3) mice 5 wk post 4 poly(I:C) inoculation. Data are expressed as mean±SEM (p 
*≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
 
  
 144 
 
 
Figure 4.10: Raptor-deficiency in B cells leads to a decline in B cell lineage in vivo. 
Bar graphs showing the percentage of CD19+ B cells (A), CD11b+Gr1+ mature myeloid cells (C), 
NK cells (E) in the BM, spleen, LN, thymus and blood and cellularity of CD19+ B cells (B), 
CD11b+Gr1+ mature myeloid cells (D), NK cells (F) in the BM, spleen, LN and thymus of CD19-
Raptor control, CD19-cre+/-Raptor KO, and CD19-cre+/+Raptor KO mice. Percentage (G) and 
cellularity (H) of CD4+CD8+ and CD4-CD8- T cells in the thymus in CD19-Raptor control (n=5), 
CD19-cre+/-Raptor KO (n=7), and CD19-cre+/+Raptor KO (n=6) mice. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 4.11: Gating strategy of late B cell lineages in Mx1-cre and CD19-cre Raptor models.  
Representative flow cytometry plots showing the proportion of late B cells comprising transitional 1 
(T1) cells (CD19+CD21intCD23-IgMhi); T2 (CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMhi); T3 
(CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMlo); marginal zone precursor (MZP): 
(CD19+CD21hiCD23+CD1dhi); marginal zone (MZ) (CD19+CD21hiCD23-IgMhi); Fol1 (CD19+AA4.1-
CD21loCD23+CD1dintIgDhiIgMlo) Fol2 (CD19+AA4.1-CD21loCD23+CD1dintIgDhiIgMhi) in the spleen in 
Mx1-Raptor control (A), Mx1-Raptor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (B), 
CD19-Raptor control (C) and CD19-cre+/-Raptor KO (D) mice. Plots are live and size (FSC-A/SSC-
A) gated. RCN – relative cell number. 
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Figure 4.12: Raptor-deficiency in adult mice leads to aberrations in late B cells in vivo. 
Bar graphs showing the percentage (A) and cellularity (log10) (B) of T1, T2 and T3 B cells, and 
percentage (C) and cellularity (log10) (D) of MZP, MZ, Fol1, and Fol2 cells in the spleen in Mx1-
Raptor control and Mx1-Raptor cKO mice 5 wk post 4 poly(I:C) inoculation. Percentage (E) and 
cellularity (log10) (F) of T1, T2 and T3 B cells, along with percentage (G) and cellularity (log10) (H) of 
MZP, MZ, Fol1, and Fol2 cells in the LN of Mx1-Raptor control (n=6) and Mx1-Raptor cKO (n=3) 
mice 5 wk post 4 poly(I:C) inoculation. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001). 
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Figure 4.13: Raptor-deficiency in B cells leads to aberrations in late B cells in vivo. 
Bar graphs showing the percentage (A) and cellularity (log10) (B) of T1, T2 and T3 B cells, and 
percentage (C) and cellularity (log10) (D) of MZP, MZ, Fol1, and Fol2 cells in the spleen of CD19-
Raptor control and CD19-cre+/-Raptor KO mice. Percentage (E) and cellularity (log10) (F) of T1, T2 
and T3 B cells, and percentage (G) and cellularity (log10) (H) of MZP, MZ, Fol1, and Fol2 cells in 
the LN in CD19-Raptor control (n=5) and CD19-cre+/-Raptor KO (n=7) mice. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
  
 148 
 
 
Figure 4.14: Gating strategy for determining live, early apoptosing and apoptotic cells in 
Mx1-cre and CD19-cre Raptor models.  
Representative flow cytometry plots showing B cells (CD19+) and the proportion of live B cells 
(CD19+AnnV-7AAD-), early apoptosing B cells (CD19+AnnV+7AAD-) and apoptotic B cells 
(CD19+AnnV+7AAD+) in BM of Mx1-Raptor control (A) Mx1-Raptor cKO mice assessed 5 wk post 4 
poly(I:C) inoculation (B), CD19-Raptor control (C) CD19-cre+/-Raptor KO (D) mice. Plots are live 
and size (FSC-A/SSC-A) gated as shown. RCN – Relative cell number. 
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Figure 4.15: Raptor-deficiency in adult mice leads to increased apoptosis in B cells in vivo. 
Bar graphs demonstrate the percentage (A) and cellularity (log10) (B) of CD19+ B cells (n=4) along 
with the percentage (C) and cellularity (log10) (D) of all haemopoietic lineages which are live (AnnV-
7AAD-), early apoptotic (AnnV+7AAD-), necrotic (AnnV-7AAD+) or apoptotic cells (Apop; 
AnnV+7AAD+) in BM of Mx1-Raptor control (n=6) and Mx1-Raptor cKO (n=3) mice assessed 5 wk 
post 4 poly(I:C) inoculation. Percentage (E) and cellularity (log10) (F) of CD19+ B cells along with 
the percentage (G) and cellularity (log10) (H) of all haemopoietic cells which are live (AnnV-7AAD-), 
early apoptotic (AnnV+7AAD-), necrotic (AnnV-7AAD+) or dead by apoptosis (AnnV+7AAD+) in BM 
of CD19-Raptor control (n=5) and CD19-cre+/--Raptor KO (n=7) mice. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001). 
  
 150 
 
 
Figure 4.16: Optimization of the Vav-cre Rictor KO model. 
Vav-cre- (cre-, Vav-Rictor control) and Vav-cre+Rictorfl/fl (cre+, Vav-Rictor KO) mice were analyzed 
after 2 (n=3), 8 (n=3), or 24 (n=5) wk to assess the KO at different time points. A. Picture showing 
differences in spleen size of Vav-Rictor control (left) and Vav-Rictor KO (right) mice 8 wk of age. 
Spleen weight (mg) (B) and organ cellularity (log10) of BM, spleen, thymus and LN (C) of Vav-Rictor 
control and Vav-Rictor KO mice assessed after 2, 8, or 24 wk. B cell percentage in the BM, spleen 
LN and blood (D) and B cell lineage cellularity (log10) in the BM, spleen, thymus and LN (E) of Vav-
Rictor control and Vav-Rictor KO mice assessed after 2, 8, or 24 wk. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001, p***≤0.0001). 
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Figure 4.17: Optimization of the Vav-cre Rictor KO model age for phenotypic analysis of 
haemopoietic lineages. 
Vav-Rictor control (cre-) and Vav-Rictor KO (cre+) mice were analyzed after 2 (n=3), 8 (n=3), or 24 
(n=5) wk to assess the KO at different time-points. Percentage (A) and cellularity (log10) (B) of 
CD4+CD8+ DP and CD4-CD8- DN thymocytes in the thymus of Vav-Rictor control and Vav-Rictor 
KO mice analysed at 2, 8, or 24 wk of age. Percentage (C) and cellularity (log10) (D) of CD11b+Gr1+ 
mature myeloid cells in the BM, spleen, blood and LN as indicated of Vav-Rictor control and Vav-
Rictor KO mice analysed aged 2, 8, or 24 wk. Percentage (E) and cellularity (log10) (F) of NK cells 
in the BM, spleen and blood as indicated of Vav-Rictor control and Vav-Rictor KO mice analysed 
aged 2, 8, or 24 wk. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001). 
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Figure 4.18: Characterization of Rictor KO models.  
Spleen weight (mg) (A) and total organ counts (log10) (BM, spleen, thymus and LN) (B) of Vav-
Rictor control and Vav-Rictor KO mice at 8 wk (n=3); Mx1-Rictor control and Mx1-Rictor cKO mice 
assessed 5 wk post 4 poly(I:C) inoculation (n=5); and CD19-Rictor control and CD19-Rictor KO 
mice (n=6) ≥18 wk of age. Histology slides showing H&E staining (top row), Ki67 staining (middle 
row), and pS6S235/S236 (bottom row) in spleens of Vav-Rictor control and Vav-Rictor KO mice at 8 wk 
of age (C) and of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) 
inoculation (D). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001). 
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Figure 4.19: Confirming Rictor cKO by assessing protein and gene expression of mTOR 
pathway members. 
Representative western blot showing protein expression of mTOR pathway proteins: RICTOR, 
RAPTOR, pAKTS473, tAKT, pS6S235/S236, tS6, βACTIN and GAPDH in the BM, spleen, thymus and 
liver of Vav-Rictor control and Vav-Rictor KO mice 8 wk of age (A) and of Mx1-Rictor control and 
Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (B). Densitometry showing protein 
expression (log fold change) of RICTOR/βACTIN  in the spleen and thymus (C), RAPTOR/βACTIN 
in the spleen, thymus and liver (D), and of pAKTS473/tAKT in the BM, spleen, thymus (E) of Vav-
Rictor control and Vav-Rictor KO mice 8 wk of age (n=3), and densitometry showing protein 
expression (log fold change) of RICTOR/βACTIN  in the spleen (n=5), thymus (n=3) and liver (n=4) 
(F), of RAPTOR/βACTIN  in the spleen (n=5), thymus (n=3) and liver (n=4) (G), and of 
pAKTS473/tAKT in the BM (n=4), spleen (n=5), thymus (n=2) (H) of Mx1-Rictor control and Mx1-
Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation. Gene expression (log fold change) of 
Rictor (I) and Raptor (J) in the BM, spleen and thymus of Vav-Rictor control and Vav-Rictor KO 
mice 8 wk (n=3) of age, along with gene expression (log fold change) of Rictor (K) and Raptor (L) 
in the BM (n=8), spleen (n=6) and liver (n=5) of Mx1-Rictor control and Mx1-Rictor cKO mice 
assessed 5 wk post 4 poly(I:C) inoculation. Data are expressed as mean±SEM (p *≤0.05, p 
**≤0.001, p ***≤0.0001). 
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Figure 4.20: Gating strategy of haemopoietic lineages in Vav-cre and Mx1-cre Rictor models.  
Representative flow cytometry plots demonstrating the proportion of B cells (CD19+CD11b-) in the 
spleen, CD4+ (CD19-CD8-CD4+), CD8+ (CD19-CD4-CD8+), CD4+CD8+ (CD19-CD4+CD8+) T cells in 
the thymus, mature myeloid cells (CD19-CD11b+Gr1+) in the BM, and NK cells (CD19-CD4-NK1.1+) 
in the spleen in Vav-Rictor control (A) Vav-Rictor KO aged 8 wk (B), Mx1-Rictor control (C), and 
Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation (D). Plots are live and size (FSC-
A/SSC-A) gated prior to the gating shown. RCN – relative cell number. 
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Figure 4.21: Rictor-deficiency leads to B and T cell aberrations in vivo. 
Bar graphs showing the percentage of B cells in the BM, spleen, LN, and blood of Vav-Rictor 
control and Vav-Rictor KO mice aged 8 wk (n=3) (A), Mx1-Rictor control and Mx1-Rictor cKO mice 
assessed 5 wk post 4 poly(I:C) inoculation (n=6) (B), and CD19-Rictor control and CD19-Rictor KO 
mice (n=6) (C). Percentage of CD4+CD8+ DP and CD4-CD8- DN T cells in the thymus of Vav-Rictor 
control and Vav-Rictor KO mice aged 8 wk (n=3) (D), Mx1-Rictor control and Mx1-Rictor cKO mice 
assessed 5 wk post 4 poly(I:C) inoculation (n=6) (E), and CD19-Rictor control and CD19-Rictor KO 
mice (n=6) (F). Percentage of CD11b+Gr1+ mature myeloid cells in the BM, spleen and blood of 
Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=3) (G), Mx1-Rictor control and Mx1-Rictor 
cKO mice assessed 5 wk post 4 poly(I:C) inoculation (n=6) (H), and CD19-Rictor control and 
CD19-Rictor KO mice (n=6) (I). Percentage of NK cells in the BM, spleen and blood of Vav-Rictor 
control and Vav-Rictor KO mice aged 8 wk (n=3) (J), Mx1-Rictor control and Mx1-Rictor cKO mice 
assessed 5 wk post 4 poly(I:C) inoculation (n=6) (K), and CD19-Rictor control and CD19-Rictor KO 
mice (n=6) (L). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001). 
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Figure 4.22: Gating strategy for determination of cell viability in Vav-cre and Mx1-cre Rictor 
models.  
Representative flow cytometry plots showing the proportion of live (AnnV-7AAD-), early apoptosing 
(AnnV+7AAD-) and apoptotic (AnnV+7AAD+) cells in BM of Vav-Rictor control (A) Vav-Rictor KO 
mice aged 8 wk (B), Mx1-Rictor control (C) and Mx1-Rictor cKO mice assessed 5 wk post 4 
poly(I:C) inoculation (D). Plots are live and size (FSC-A/SSC-A) gated as shown. 
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Figure 4.23: Rictor-deficiency does not cause apoptosis in vivo. 
Bar graphs showing the percentage of CD19+ B cells in the BM (A) and spleen (B), and percentage 
of all cells in the BM (C) and spleen (D) which are live, early apoptotic (AnnV+), necrotic (7AAD+) or 
dead by apoptosis (Apop) in BM of Vav-Rictor control and Vav-Rictor KO mice aged 8 wk (n=5). 
Percentage of CD19+ B cells in the BM (E) and spleen (F), and percentage of all cells in the BM (G) 
and spleen (H) which are live, early apoptotic (AnnV+), necrotic (7AAD+) or dead by apoptosis in 
BM of Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 wk post 4 poly(I:C) inoculation 
(n=5). Bar graphs demonstrating the percentage of CD19+ B cells in the BM (I) and spleen (J) 
which are live, early apoptotic (AnnV+), necrotic (7AAD+) or dead by apoptosis in BM of CD19-
Rictor control and CD19-Rictor KO mice (n=6). Data are expressed as mean±SEM (p *≤0.05). 
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Figure 4.24: Gating strategy of early B cell lineages in Vav-cre and Mx1-cre Rictor models. 
Representative flow cytometry plots showing the proportion of proB cells (Lineage-B220+CD19+), 
pre-proB cells (Lineage-B220+CD19-), LSK cells (Lineage-B220-CD19-Sca-1hiCD117hi), and sca-
1loCD117hi (Lineage-B220-CD19-Sca-1loCD117hi) cells in the BM of Vav-Rictor control (A) and Vav-
Rictor KO mice of 8 wk (B), Mx1-Rictor control (C) and Mx1-Rictor cKO 5 wk post 4 poly(I:C) 
inoculation (D). Lineage peak is shown in red and lineage negative subset was gated based on the 
unstained population (blue peak). Plots are live and size (FSC-A/SSC-A) gated as shown. RCN – 
relative cell number. 
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Figure 4.25: Gating strategy of late B cell lineages in Vav-cre and Mx1-cre Rictor models. 
Representative flow cytometry plots demonstrating the proportion of late B cells which comprise 
transitional 1 (T1) cells (CD19+CD21intCD23-IgMhi); T2 
(CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMhi); T3 (CD19+AA4.1+CD21intCD23+CD1dintIgDhiIgMlo); 
marginal zone precursor (MZP): (CD19+CD21hiCD23+CD1dhi); marginal zone (MZ) 
(CD19+CD21hiCD23-IgMhi); Fol1 (CD19+AA4.1-CD21loCD23+CD1dintIgDhiIgMlo) Fol2 (CD19+AA4.1-
CD21loCD23+CD1dintIgDhiIgMhi)  in the spleen of Vav-Rictor control (A) and Vav-Rictor KO mice of 
8 wks (B), Mx1-Rictor control (C) and Mx1-Rictor cKO 5 wks post 4 poly(I:C) inoculation (D). Plots 
are live and size (FSC-A/SSC-A) gated as shown. 
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Figure 4.26: Rictor-deficiency at the HSC stage, in adult mice, and in B cells leads to 
aberrations in late B cells in vivo. 
Bar graphs showing the percentage of LSK, pre-proB and proB cells in the BM of Vav-Rictor 
control and Vav-Rictor KO mice aged 8 wk (n=5) (A), Mx1-Rictor control and Mx1-Rictor cKO mice 
assessed 5 wk post 4 poly(I:C) inoculation (n=6) (B), and CD19-Rictor control and CD19-Rictor KO 
mice (n=6) (C). Percentage of T1, T2 and T3 B cells in the spleen and LN of Vav-Rictor control and 
Vav-Rictor KO mice aged 8 wk (n=5) (D), Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 
wk post 4 poly(I:C) inoculation (n=6) (E), and CD19-Rictor control and CD19-Rictor KO mice (n=6) 
(F). Percentage of MZP, MZ, Fol1, and Fol2 cells in the spleen and LN of Vav-Rictor control and 
Vav-Rictor KO mice aged 8 wk (n=5) (G), Mx1-Rictor control and Mx1-Rictor cKO mice assessed 5 
wk post 4 poly(I:C) inoculation (n=6) (H), and CD19-Rictor control and CD19-Rictor KO mice (n=6) 
(I). Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Role of mTORC1 and mTORC2 in CLL 
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5 Role of mTORC1 and mTORC2 in CLL 
5.1 Introduction 
This chapter focusses on the role of mTORC1 and mTORC2 in leukaemia initiation 
and/or maintenance. As the Vav-cre+Raptorfl/fl model is lethal at the perinatal 
stage, we did not use this model. As such, two mTORC1 KO models – Mx1-cre 
Raptorfl/fl (Mx1-Raptor) and CD19-cre Raptorfl/fl (CD19-Raptor) were used. To 
assess the role of mTORC2 in leukaemia initiation/development, the CD19-cre 
Rictorfl/fl (CD19-Rictor), Vav-cre Rictorfl/fl (Vav-Rictor) and Mx1-cre Rictorfl/fl 
(Mx1-Rictor) mice models were used. Our lab has previously generated a murine 
CLL-like disease by retrovirally transducing lymphocyte-progenitors obtained 
from FLs of wildtype mice with a GFP-tagged kinase dead PKCα (PKCαKR) (229). 
We utilised a similar technique to generate a murine CLL-like disease from the 
BM of Raptor and Rictor KO mouse models to assess the role of mTORC1 and 
mTORC2 respectively in CLL initiation and/or development in vitro and in vivo. 
  
 163 
 
5.2 Results 
5.2.1 Ablation of mTORC1 blocks CLL initiation in vitro. 
In order to assess the role of mTORC1 in CLL initiation/development in vitro, the 
Mx1-Raptor mouse model was used. To generate a CLL-like disease with Raptor 
cKO, mice were inoculated with either 3 or 4 rounds of poly(I:C) as indicated, 
and BM from either Mx1-Raptor control (cre-/-) or Mx1-Raptor cKO (cre+/-) mice 
was dissected. Purified CD117+ lymphoid progenitors from the BM were then 
retrovirally transduced with either GFP+-MIEV (for generation into B cells as a 
control) or GFP+-PKCαKR, to induce a murine CLL-like disease, in both Mx1-
Raptor control or Mx1-Raptor cKO models, upon co-culture with OP9 cells 
(229,231).  
Mx1-Raptor cKO MIEV and PKCαKR co-cultures (derived from mice dissected 3 wk 
post 3 poly(I:C) inoculation) failed to generate a CD19+GFP+ population compared 
to Mx1-Raptor controls over D7, 11, 14 and 18 in vitro (Figure 5.1).  Data 
demonstrated the inability of the PKCαKR construct to rescue the B cell lineage 
commitment block caused by Raptor-deficiency. Additionally, BM derived from 
Mx1-Raptor cKO mice with 4 poly(I:C) inoculation and dissected 5 wk post 
treatment, and then retrovirally transduced with MIEV or PKCαKR constructs 
showed a significant decrease in cellularity of GFP+CD19+ MIEV cells over D3 and 
D7, coupled with a decrease in percentage of GFP+CD19+ cells at D7, 11, and 14 
as compared to Mx1-Raptor control MIEV cells (Figure 5.1A,B, Figure 5.2A,C). 
Similarly, Mx1-Raptor cKO PKCαKR cells had a significant decrease in cellularity 
of GFP+CD19+ cells at D3 and D11 with a significant decrease in the percentage 
of GFP+CD19+ PKCαKR cells over all culture days compared to Mx1-Raptor control 
PKCαKR cells (Figure 5.1C,D, Figure 5.2B,D). A significant increase in the 
percentage of GFP+CD11b+ population in Mx1-Raptor cKO MIEV cells at D14 and in 
Mx1-Raptor cKO PKCαKR cells at D11 and D14 was observed compared to Mx1-
Raptor control MIEV and PKCαKR cells (Figure 5.2E,F). These data suggest a lack 
in B cell lineage commitment with Raptor-deficiency regardless of the viral 
construct. In addition, there is an increase in GFP+CD11b+ population over time 
suggesting a block in B cell differentiation compared to Mx1-Raptor control cells 
and block in CLL-like development with Raptor-deficiency compared to controls. 
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To further assess the role of mTORC1 in CLL cells, the CD19-Raptor KO model 
was used as it specifically excises Raptor in B-cells, as described previously 
(Section 1.7.1.3). Unlike, Mx1-Raptor cKO PKCαKR cells, CD19-Raptor KO 
PKCαKR cells developed a CLL-like phenotype. CD19-Raptor control and KO MIEV 
and PKCαKR cells were cultured until D18 to mimic later stages of disease 
development, then cell proliferation, viability and migration assays were carried 
out. No changes were observed in MIEV cells derived from CD19-cre- or CD19-
cre+/- Raptor mice, but there was an increase in the cell trace violet (CTV) ratios 
comparing to D0, which was significant in D1/D0 ratio of CD19-Raptor KO 
PKCαKR cells compared to CD19-Raptor control PKCαKR cells (Figure 5.3A-C). 
This suggests a decrease in proliferation in PKCαKR cells with Raptor-deficiency 
as compared to controls. CD19-Raptor KO PKCαKR cells displayed a significant 
decrease in the percentage of early (AnnV+) and late apoptosis (AnnV+7AAD+) 
with a significant increase in percentage of live cells (AnnV-7AAD-) compared to 
CD19-Raptor control PKCαKR cells (Figure 5.3D,E) suggesting Raptor-deficiency 
reduces apoptosis in CLL-like cells. To assess whether the CD19-Raptor KO 
PKCαKR cells migrate to the same extent as controls, a migration assay was 
performed where the cells were serum-starved for 2 hr and then allowed to 
migrate towards SDF-1 in transwell plates. There was a significant decrease in 
the cellularity and percentage of PKCαKR migrating cells in the absence of 
Raptor, with ~50% decrease in migration in CD19-Raptor KO PKCαKR cells 
compared to CD19-Raptor control PKCαKR cells (Figure 5.3F,G). Lastly, Raptor-
deficient CLL-like cells displayed a trend in increase in G0/G1 phase with a 
decreasing trend in the G2 phase compared to CD19-Raptor control PKCαKR cells 
(Figure 5.3H), further suggesting a block in proliferation with Raptor-deficiency. 
As inducing Raptor-deficiency in all haemopoietic populations (Mx1-Raptor cKO 
model) leads to a block in B cell lineage commitment and a lack in CLL-like 
disease initiation, we assessed the role of mTORC1 in CLL maintenance. 
Therefore, GFP+-PKCαKR cells were generated from BM of Mx1-Raptor control 
and cKO mice in the absence of poly(I:C) inoculation. There was no significant 
difference between the percentage of GFP+CD19+ cells generated from Mx1-
Raptor cKO MIEV compared to control and Mx1-Raptor cKO PKCαKR cells 
compared to their respective control (Figure 5.4A,B). Mx1-Raptor control and 
cKO (no poly(I:C)) PKCαKR cells were cultured in vitro until D10 to mimic disease 
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development. To assess role of Raptor in disease maintenance, these cells were 
treated with 200 units (U) IFNβ for 24 hr, stimulating a TLR3 response and cre 
expression, to induce cKO in vitro. PCR analysis showed successful excision of 
Raptor in Mx1-Raptor cKO PKCαKR cells compared to controls (Figure 5.4C). 
Moreover, there was a decrease in the protein expression of RAPTOR in Mx1-
Raptor cKO MIEV and PKCαKR cells compared to Mx1-Raptor controls with IFNβ 
treatment suggesting successful KO in vitro (Figure 5.4D,E). In addition, there 
were trends in decrease in pS6S235/S236 expression with no changes in RICTOR and 
pAKTS473 expression in Mx1-Raptor cKO PKCαKR cells treated with IFNβ compared 
to controls (Figure 5.4D,G,H) suggesting mTORC1 downstream targets were 
reduced upon Raptor excision with no effect on mTORC2 signalling.  
To assess the effect of Raptor-deficiency in CLL maintenance in vitro, Mx1-
Raptor cKO PKCαKR CLL-like cells treated with IFNβ were assessed for 
proliferation and cell cycling. There was a significant decrease in the cellularity, 
with a similar trend in the percentage, of GFP+CD19+ population in the co-
cultures of Mx1-Raptor cKO PKCαKR cells treated with 50U IFNβ for 3 days and 
200U for 24 hr, compared to Mx1-Raptor controls (Figure 5.5A,B). As 200U IFNβ 
treatment for 24 hr was more robust compared to other treatment arms, 200U 
IFNβ treatment was carried out on all future experiments. Interestingly, there 
was also a significant decrease in the cellularity of GFP+CD19+ Mx1-Raptor cKO 
PKCαKR cells receiving no IFNβ treatment (pink bars) (Figure 5.5A) compared to 
untreated Mx1-Raptor control PKCαKR cells (light blue bars). While this effect 
was significant, it did not occur to the same extent as with higher IFNβ 
treatments. Indeed, a significant decrease in the GFP+CD19+ cellularity was 
observed in Mx1-Raptor cKO PKCαKR cells with IFNβ treatment compared to 
untreated cells, with no reductions in cell populations in Mx1-Raptor control 
PKCαKR cells with or without IFNβ treatment (Figure 5.5C). IFNβ treatment of 
Mx1-Raptor cKO PKCαKR cells slightly increased G0 phase, with a decreasing 
trend in S/G2 phase compared to the untreated Mx1-Raptor cKO PKCαKR cells 
and Mx1-Raptor control PKCαKR cells treated and untreated with IFNβ (Figure 
5.5D). Moreover, there is a significant increase in the CTV MFI of D2 in IFNβ 
treated Mx1-Raptor cKO PKCαKR cells compared to treated controls suggesting a 
block in proliferation due to an increase in CTV MFI (Figure 5.5E,F). These data 
suggest a similar role for Raptor in disease maintenance as in disease initiation, 
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whereby there is a block in proliferation with induced Raptor-deficiency after 
mimicking disease development in vitro. 
5.2.2 mTORC2 plays a role in CLL-like phenotype maintenance at 
later stages in vitro. 
To determine the role of mTORC2 in CLL initiation/development, the Vav-Rictor, 
Mx1-Rictor and CD19-Rictor mouse models were used. BM was derived from Vav-
, Mx1- (dissected 5 wk post 4 poly(I:C) inoculation), and CD19-Rictor control or 
KO mice, and retrovirally transduced with either GFP+-MIEV or GFP+-PKCαKR 
constructs to induce a CLL-like phenotype. Unlike Raptor-deficient cells, PKCαKR 
cells derived from all the Rictor KO models developed a CLL-like phenotype in 
vitro. There was little difference in the cellularity of GFP+CD19+ population 
earlier in the co-cultures, with a slight decrease in cellularity of GFP+CD19+ 
population at D28 in Vav-, and CD19-Rictor KO MIEV and PKCαKR cells compared 
to their respective controls (Figure 5.6A-C,E,F,H). There was a trend in increase 
in the cellularity of GFP+CD19+ population of Mx1-Rictor cKO MIEV cells with 
decreasing trends in Mx1-Rictor cKO PKCαKR cells at D21 (Figure 5.6D,G). These 
data suggest Rictor is not fundamental for CLL-like disease initiation but may 
play a role in disease maintenance. Similarly, there was no difference in the 
percentage of GFP+CD19+ population, but a decreasing trend in the percentage 
of GFP+CD19+ population was observed at D21 and later days in Vav-, Mx1- and 
CD19- Rictor KO MIEV and PKCαKR cells, compared to their respective controls 
(Figure 5.7A-F). This suggests there may be a role of Rictor in CLL-like disease 
maintenance, similar to that played in late B cell maintenance (Chapter 4). 
Additionally, no changes were observed in GFP+CD11b+ population in Vav-, Mx1-, 
or CD19-Rictor KO MIEV and PKCαKR cells compared to their respective controls 
suggesting mTORC2 does not play a role in B cell lineage commitment, further 
reiterating the redundant role of mTORC2 in CLL-like phenotype initiation in 
vitro (Figure 5.7G-L). 
As there was a decreasing trend in GFP+CD19+ cellularity and percentage in later 
stages of both MIEV and PKCαKR co-cultures with Rictor-deficiency, Vav- and 
Mx1-Rictor cKO and control PKCαKR cells at D21 were further assessed. 
Successful KO, confirmed by a significant decrease in Rictor expression, was 
associated with an increasing trend in Ccnd1 expression and no changes in 
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Cdkn1a and Cdkn1b in Vav-Rictor KO PKCαKR cells compared to Vav-Rictor 
control PKCαKR cells, with no changes in Ccnd1, Cdkn1a and Cdkn1b expression 
in Vav-Rictor KO MIEV cells compared to Vav-Rictor control MIEV cells (Figure 
5.8A). A similar trend was seen in Mx1-Rictor cKO PKCαKR cells (4 poly(I:C) 
inoculation), with a strong trend in increase in Ccnd1 with a significant decrease 
in Rictor expression compared to Mx1-Rictor control PKCαKR cells cultured till 
D21 (Figure 5.8B) alluding to a potential role of mTORC2 in regulating cell 
cycling in CLL-maintenance in vitro. At the protein level, there was a significant 
decrease in RICTOR expression with a slight decrease in pAKTS473 expression in 
Mx1-Rictor cKO PKCαKR cells compared to Mx1-Rictor control PKCαKR cells at 
D21 of culture (Figure 5.8C-E). This confirmed a lack of Rictor at the later co-
culture stages mimicking CLL-disease, suggesting that the Mx1-Rictor cKO model 
is not ‘leaky’. To further assess the role of mTORC2 in CLL, migration, 
proliferation and cell cycle assays were carried out. An increasing trend in the 
cellularity and percentage of migrating cells towards SDF-1 was observed at D15 
of Vav-Rictor KO PKCαKR cells (Figure 5.9A,B), which was significant at D21 of 
Vav-Rictor KO PKCαKR cells compared to controls (Figure 5.9C,D), alluding to a 
role at later stages of disease development. Nevertheless, there were no 
changes in the MFI ratios of CTV values in Vav-Rictor KO PKCαKR cells at D14 or 
at D21 compared to controls suggesting no changes in proliferation (Figure 
5.9E,F). However, at both D14 and D21 of culture, there was an increasing trend 
in the percentage of Mx1-Rictor cKO (4 poly(I:C) inoculation) PKCαKR cells in S 
phase with a decreasing trend of cells in G0/G1 phase compared to Mx1-Rictor 
control PKCαKR cells (Figure 5.9G,H) suggesting a potential increase in cell 
cycling in PKCαKR cells with Rictor-deficiency. 
5.2.3 mTORC1 affects CLL maintenance in vivo. 
As mTORC1 plays a fundamental role in disease initiation and maintenance in 
vitro, the role of mTORC1 in disease maintenance was assessed in vivo. 
Immunocompromised NSG mice were transplanted with 5x105 Mx1-Raptor control 
or cKO (no poly(I:C) inoculation) PKCαKR cells co-cultured till D7-10. Upon 
disease development, classified as ≥ 10% GFP+CD19+ CLL-like disease assessed by 
weekly tail bleeds, half the cohort of mice were inoculated with poly(I:C) to 
induce Raptor cKO in the CLL-like cells transplanted into NSG mice. Screening 
for CLL-like disease in weekly blood samples of NSG mice showed a drastic 
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reduction, from ≥89.3% in an untreated mouse and other two mice transplanted 
with Mx1-Raptor control PKCαKR cells with or without poly(I:C) treatment to 
3.45% in GFP+CD19+ CLL-like disease in a mouse transplanted with Mx1-Raptor 
cKO PKCαKR cells and poly(I:C) treated (Figure 5.10A-D). Although there were no 
changes in splenic weight (Figure 5.11A), there was a decreasing trend in splenic 
cellularity in mice transplanted with Mx1-Raptor cKO PKCαKR cells with poly(I:C) 
treatment compared to untreated and Mx1-Raptor control with or without 
poly(I:C) treatment in vivo (Figure 5.11B). There was also a decreasing trend in 
BM cellularity in mice transplanted with Mx1-Raptor cKO PKCαKR cells treated 
with poly(I:C) compared to mice treated with poly(I:C) and transplanted with 
Mx1-Raptor control PKCαKR cells (Figure 5.11C). Weekly bloods taken from mice 
to assess disease progression after inducing Raptor-deficiency showed a trend in 
increase in the percentage of GFP+CD19+ population in mice transplanted with 
Mx1-Raptor control and cKO PKCαKR cells (no poly(I:C)) (Figure 5.11D). 
Interestingly, there was a delay in increase in the percentage of GFP+CD19+ cells 
in mice transplanted with Mx1-Raptor control PKCαKR cells after treatment with 
poly(I:C) suggesting that poly(I:C) alters disease progression (Figure 5.11D). Mice 
transplanted with Mx1-Raptor cKO PKCαKR cells and then treated with poly(I:C) 
had a decreased percentage of disease load in the blood (GFP+CD19+ population) 
compared to the other arms (Figure 5.11E). Whilst assessing the organs, there 
was a significant decrease in GFP+CD19+ cellularity in the spleen, and a 
significant decrease in the percentage of GFP+CD19+ population in the BM and 
spleen of poly(I:C) treated mice transplanted with Mx1-Raptor cKO PKCαKR cells 
compared to those transplanted with Mx1-Raptor cKO PKCαKR cells (untreated) 
and Mx1-Raptor control PKCαKR cells respectively (Figure 5.11F,G). No 
significant difference was noted between the percentage of survival in poly(I:C) 
treated or untreated mice transplanted with Mx1-Raptor control PKCαKR cells 
(Figure 5.11H) suggesting poly(I:C) inoculation does not increase survival in mice 
with a CLL-like disease in vivo. However, there was a significant  increase in 
survival of poly(I:C) treated mice transplanted with Mx1-Raptor cKO PKCαKR 
cells compared to untreated mice transplanted with Mx1-Raptor cKO or control 
PKCαKR cells (Figure 5.11I,J), which suggests that Raptor-deficiency increases 
survival in mice with a CLL-like disease in vivo.  
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Interestingly, there was no significant difference in pAKTS473 phosphorylation, 
but a significant increase in RAPTOR expression, together with a strong trend in 
increase downstream targets p4EBP1T36/T47 expression in poly(I:C) treated mice 
transplanted with Mx1-Raptor cKO PKCαKR cells compared to Mx1-Raptor control 
PKCαKR cells (Figure 5.12A-D). Additionally, there was a trend in increase in 
pS6S235/S236 expression with a significant decrease in the downstream expression 
of RICTOR (Figure 5.12E-F). These data suggest a possible re-population of a 
CLL-like disease clone with increased RAPTOR expression which escaped 
poly(I:C) dependent Raptor-excision. It is important to note here that all the 
transplanted mice were sacrificed at disease end and not after a single time 
point, therefore most of the mice transplanted with Mx1-Raptor cKO PKCαKR 
cells + poly(I:C) treated were sacrificed at a later time than the other arms due 
to a delay in disease (Figure 5.11I,J). We would have expected to see a decrease 
in RAPTOR if the mice would have been sacrificed at the same time point. 
To further assess the role of mTORC1 in leukemogenesis, CD19-Raptor control or 
KO BM cells were transduced with GFP+-PKCαKR and transplanted into NSG mice 
between D7-10 of culture. There was a decreasing trend of GFP+CD19+ CLL-like 
disease percentage in the bloods of NSG mice transplanted with CD19-Raptor KO 
cells as compared to controls (Figure 5.13) suggesting a non-redundant role of 
Raptor in CD19+ cells in disease progression. Although there were no changes in 
the spleen weight, BM and spleen organ cellularity, there was a clear delay in 
disease onset, observed by a delay in GFP+CD19+ CLL-like cells in the bloods, 
along with a significant increase in survival of mice transplanted with CD19-
Raptor KO PKCαKR cells compared to controls (Figure 5.14A-D). As all mice were 
sacrificed at disease end, most of the mice transplanted with CD19-Raptor KO 
PKCαKR cells survived longer than the controls allowing disease to accumulate 
eventually compromising the health of the mouse leading to end point. At end 
point, no change was observed in the cellularity of GFP+CD19+ CLL-like cells in 
the BM and spleen, but there was a significant decrease in percentage of 
GFP+CD19+ CLL-like cells in the BM with a similar trend in the LN of mice 
transplanted with CD19-Raptor KO PKCαKR cells compared to controls (Figure 
5.14E,F). Moreover, there were no changes in RAPTOR, pAKTS473, and pS6S235/S236 
expression in the spleens of mice transplanted with CD19-Raptor KO PKCαKR 
cells compared to controls (Figure 5.14G-J), suggesting a re-population of Raptor 
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in CD19+ cells thereby leading to an increase in GFP+CD19+ cell population in 
mice treated with CD19-Raptor KO PKCαKR cells over time. 
5.2.4 Using mTOR inhibitors and current clinical drugs to combat 
CLL in vivo. 
To compare the effect of mTOR inhibitors and current clinical drugs for CLL in 
mice transplanted with a CLL-like disease, CD117+ lymphocytes purified from BM 
of B6.SJL mice were retrovirally transduced with GFP+-PKCαKR to generate a 
CLL-like disease and 5x105 cells were transplanted into NSG mice after D7-10 of 
co-culture. Once the mice had established disease (≥0.4% GFP+CD19+ CLL-like 
disease), the mice were treated with either vehicle control 
(captisol+0.5%methylcellulose), AZD2014 (dual mTOR complex inhibitor), 
ibrutinib (BTK inhibitor used in clinics), or a combination of AZD2014+Ibrutinib 
(combo). AZD2014 and ibrutinib were administered at 15 mg/kg and 12 mg/kg by 
OG daily for 2 wk, after which mice were sacrificed and analyzed for disease. A 
drastic reduction in the percentage of GFP+CD19+ CLL-like cells was observed in 
the bloods, from 93.6% in mice treated with vehicle control to 3.68% and 5.92% 
in mice treated with AZD2014 and ibrutinib respectively (Figure 5.15A-C). 
Additionally, mice treated with the combo showed a greater decrease in 
GFP+CD19+ percentage, from 3.68% in AZD2014 treated mice and 5.92% in 
ibrutinib treated mice to 0.57% in mice treated with combination (Figure 5.15B-
D). These data suggest that mice treated with a combination therapy have a 
greater reduction in disease load in the blood compared to single agents. There 
was a clear reduction in the spleen size and a significant reduction in 
spleen/body weight ratio and spleen cellularity, with no changes in BM 
cellularity in mice treated with either AZD2014, ibrutinib, or combination 
compared to vehicle control (Figure 5.16A-C). These findings suggest a reversal 
of splenomegaly observed in CLL with no changes in BM cellularity with single 
agents or combination therapy. There was a clear decrease in percentage of 
GFP+CD19+ CLL-like disease in mice in weekly tail bleeds post treatment with 
AZD2014, ibrutinib or combination compared to vehicle controls (Figure 5.16D). 
Moreover, a significant decrease in cellularity and percentage of the GFP+CD19+ 
CLL-like population in the BM, together with a significant decrease in the 
cellularity and a similar decreasing trend in the percentage of GFP+CD19+ cells in 
the spleen were observed in mice treated with AZD2014, ibrutinib or 
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combination compared to controls (Figure 5.16E-H). GFP+CD19+ CLL-like cells 
were assessed for the expression of CD5+ marker, which is a subset of CLL cells 
associated with increased migration as described in the Calissano model (156). A 
significant decrease in the cellularity of GFP+CD19+CD5+ CLL-like cells was 
observed in the BM and spleen of mice treated with single agents or with 
combination compared to controls (Figure 5.16I). These data suggest a potent 
role of the dual mTOR complex inhibitor, AZD2014, as a promising therapeutic 
compound for CLL as it has similar results as ibrutinib, a drug currently used as 
first-line therapy for CLL patients with TP53 mutation/17p deletion. However, 
combination of ibrutinib and AZD2014 did not have any additive effect with little 
evidence for synergy. 
To assess the ability of mTOR inhibitors to treat advanced CLL-like disease, we 
performed secondary transplants, where 4x105 cells from the spleen of mice 
carrying a CLL-like disease (≥95%) was transplanted into NSG or NRG host mice. 
Once disease was established (≥10% GFP+CD19+ CLL-like disease), mice were 
treated with either rapamycin (administered by ip injection at 4 mg/kg) or 
AZD2014 (administered by OG at 15 mg/kg) once daily for 3 wk and disease 
progression was assessed. A reduction in the percentage of GFP+CD19+ CLL-like 
cells in the bloods of mice treated with AZD2014 and rapamycin was seen, from 
90.1% to 77.9% and 0.69% respectively compared to vehicle control (Figure 
5.17A-C). There was a clear reduction in the spleen size and a strong decreasing 
trend in spleen/body weight ratio, with no changes in BM and splenic cellularity 
in mice treated with rapamycin. These findings are coupled with no change in 
the spleen size and weight, or BM or spleen cellularity in mice treated with 
AZD2014 compared to vehicle controls, suggesting rapamycin is more potent at 
decreasing disease load in mice that have undergone secondary transplants 
(Figure 5.18A-C). In addition, there was a clear decrease in percentage of 
GFP+CD19+ CLL-like disease in the blood post rapamycin treatment, but not with 
AZD2014 compared to vehicle controls (Figure 5.18D). Moreover, there was a 
significant decrease in the percentage of GFP+CD19+ CLL-like cells in the BM and 
blood with a similar trend in the spleen and LN, and a decreasing trend in 
cellularity of GFP+CD19+ CLL-like cells in the BM and spleen in mice treated with 
rapamycin compared to AZD2014 or controls (Figure 5.18E-G). These data 
indicate a potential decrease in disease load with rapamycin and not with 
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AZD2014. As expected, no changes in RAPTOR and RICTOR expression was noted 
in spleens of mice treated with AZD2014 or rapamycin, despite the more potent 
effect of rapamycin in decreasing disease load, as this was not a KO model 
(Figure 5.19A-C). No significant changes in pAKTS473 and pS6S235/S236 levels were 
noted in drug treated spleens (Figure 5.19A,D,E). Furthermore, spleens of mice 
treated with AZD2014, and not with rapamycin, had an increasing trend in cyclin 
genes Ccnd1, Ccnd2 and Ccnd3, with trends in increase in the pro-apoptotic 
target Bid and no changes in Prkcb (Figure 5.19F,G), suggesting possible increase 
in cell cycling with AZD2014 treatment compared to vehicle controls. These data 
suggest that rapamycin is more potent in targeting a CLL-like disease in 
secondary transplants of mice than AZD2014, which could have a potential effect 
on cell cycling of CLL-like disease in vivo.  
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5.3 Discussion 
To assess the role of the mTOR complexes in leukaemia initiation and/or 
development, cre-loxP models were used for both in vitro and in vivo studies. 
CLL is characterised by having increased BCR signalling where CLL is driven by 
antigen-independent autonomous signalling(308). Moreover, it is known that BCR 
signalling in CLL cells which are anergic internalise and accumulate ligand in 
exosomes more than in normal B cells. Additionally, ligation of CD79b or IgM has 
shown independent internalisation in CLL cells but not in healthy B cells. 
Ibrutinib, a BTK inhibitor has been shown to reduce BCR signalling capacity and 
induce efficient internalisation(309). Several other inhibitors have been tested 
to reduce this chronic BCR signalling. Once such drug, Fostamatinib, a partial 
spleen tyrosine kinase (SYK) inhibitor, although effective in causing CLL-
apoptosis, was deemed toxic to certain cell lines and clinical development was 
discontinued(310). Dasatinib, a tyrosine kinase inhibitor, blocking LYN, BTK and 
other kinases inhibits BCR signalling and block BCR mediated survival of CLL 
cells, together with decreasing migration towards SDF-1(311). Although there 
are very efficient drugs in clinics for CLL, it currently remains incurable and 
therefore there is a need for curative therapy. The mTOR pathway has 
previously shown to be upregulated in CLL(312), and here we target this 
pathway downstream the BCR as a potential therapeutic strategy. We used cre-
loxP mouse models to generate a CLL-like disease and assess the role of mTORC1 
and mTORC2 in CLL in vitro and in vivo. Our laboratory has previously developed 
a CLL mouse model by the retroviral transduction of a kinase-dead PKCα 
(PKCαKR) into lymphocytes isolated from FL of mice(230). We used a similar 
technique, but we induced a CLL-like disease from the BM of mice enabling us to 
utilize the KO mouse models. For all the experiments, the BM was purified for 
CD117+ lymphocytes and retrovirally transduced with either GFP tagged MIEV to 
assess B cell development, or PKCαKR to induce a CLL-like disease. These cells 
were cultured in vitro for experiments or were transplanted into NSG host mice 
after D7-10 of culture to introduce a CLL-like disease in vivo. 
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5.3.1 Role of mTORC1 and mTORC2 in leukaemia initiation and/or 
progression in vitro 
CD117+ lymphocytes retrovirally transduced with GFP+-PKCαKR from the BM of 
Mx1-Raptor cKO mice with 4 poly(I:C) inoculation failed to initiate a CLL-like 
disease as compared to Mx1-Raptor controls in vitro. Mx1-Raptor control MIEV 
and PKCαKR cells are driven to a B cell lineage in culture, however, Mx1-Raptor 
cKO MIEV cells failed to commit to a B cell lineage alluding to the role of 
mTORC1 not only in B cell development (Chapter 4), but also in CLL initiation. 
Our results highlight that the PKCαKR retroviral construct was unable to rescue 
the lineage commitment block caused due to Raptor-deficiency. The increased 
percentage of GFP+CD11b+ cells with a concomitant decline in B cell/CLL-like 
cell population in Mx1-Raptor cKO MIEV and PKCαKR cells does not allude to an 
increase in myeloid population with Raptor-deficiency. As there is a block in B 
cell development, there is increased GFP+CD11b+ population as myeloid lineage 
development is not completely compromised with Raptor-deficiency. 
Nevertheless, due to the OP9-system(231), there is a bias for B-cell development 
with the addition of Flt3 ligand and IL7 (33,313), and a lack of M-CSF, which 
hinders myeloid lineage development and proliferation. Therefore, there is an 
initial increase in CD11b+ population and subsequent decline in this population 
by D7 in Mx1-Raptor control MIEV and PKCαKR cells but this trend is 
compromised with Raptor deficiency leading to an increase in percentage of 
GFP+CD11b+ population. 
Whilst assessing the role of mTORC1 in CLL progression, the CD19-Raptor KO 
model was used. Unlike the Mx1-Raptor cKO model, there was successful CLL-
like disease initiation with Raptor-deficiency in CD19+ cells. As CD19 is expressed 
at the preB cell stage (205), retroviral transduction is done at an earlier stage in 
CD117+ lymphocytes thereby leading to disease initiation. However, the model 
would KO Raptor in CLL-CD19 expressing cells thereby enabling the assessment 
of the role of Raptor in CLL in vitro. CD19-Raptor KO PKCαKR cells demonstrated 
a similar block in proliferation and migration with an increasing trend in G0/G1 
phase. It was interesting to observe a maintenance of disease till later stages in 
vitro as opposed to a rapid decrease in disease, as Raptor-deficiency in B cells 
leads to a block in B cell development altogether (Chapter 4). One of the 
reasons for this could be due to the microenvironmental factors due to the co-
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culture. Unlike the Mx1-Raptor cKO model, Raptor-deficiency is induced solely 
in CD19+ cells and not in other haemopoietic lineages in the CD19-Raptor KO 
model. To induce a CLL-like disease in CD19-Raptor KO model, CD117+ 
lymphocytes are retrovirally transduced with GFP+-PKCαKR construct. These 
retrovirally cells are co-cultured with murine derived OP9 stromal cells to aid B-
cell/PKCαKR cells generation(314). Additionally, other lymphocytes such as NK 
cells and a low percentage of macrophages could be present at early stages of 
culture. Besides the role of OP9 stromal cells in aiding B cell development, it is 
possible that these other cells release cytokines which aid disease progression 
till a later stage of disease progression after Raptor KO in B cells. Indeed, 
chemokines released by BMSCs and NLCs including SDF-1 lead to increased 
chemotaxis and decreased apoptosis in CLL(315). NLCs also activate the BCR 
through antigens such as vimentin and calreticulin(316). Although tumour 
associated macrophages (TAMs) and T cells play critical roles in CLL 
maintenance, BM cells which are retrovirally transduced do not have a high 
percentage of T cells. They contain macrophages but not TAMs. With the 
induction of a CLL-like disease there is a decrease in macrophages. However, it 
has previously been shown that secretion of CD14 by monocytes has shown to 
protect CLL by decreasing apoptosis and activating NFκB-mediated signals (317), 
which could potentially increase the disease progression in CD19-Raptor PKCαKR 
cells. 
It was reassuring to see that BM of Mx1-Raptor cKO mice not treated with 
poly(I:C) developed a CLL-like disease, confirming that it is indeed Raptor-
deficiency causing the block in disease initiation. Optimization of the dosage and 
time of IFNβ treatment, a TLR receptor agonist used to induce cKO in vitro, was 
carried out: 200U IFNβ for 24 hr was optimal and was used in all experiments in 
vitro. However, there was a significant decrease in cellularity in Mx1-Raptor cKO 
PKCαKR cells (without prior poly(I:C) treatment) without IFNβ treatment 
compared to Mx1-Raptor controls. This was interesting as no changes were 
observed in Mx1-Raptor cKO PKCαKR cells treated with 50U IFNβ suggesting this 
result is not due to cre toxicity(208). However, it suggests an activation of TLR 
signalling in Mx1-Raptor cKO PKCαKR cells with no prior drug treatment. The 
reason for this potential TLR activation is not known and requires further 
assessment. Indeed, it has been demonstrated that there can be spontaneous cre 
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expression prior to induction of cre expression(203). It is possible that such 
spontaneous cre expression caused the significant decrease in Mx1-Raptor 
PKCαKR cellularity with no prior drug treatment. 
TLRs are present on innate cells and act a bridge between innate and adaptive 
immunity. In murine B cells, TLR4 and TLR10 have shown to be prevalently 
expressed(318). In humans, TLR expression in CLL is similar to that on normal B 
lymphocytes. However, Dadashian et al., have recently demonstrated an 
increased cooperation of TLR signalling with BCR signalling leading to 
downstream NFκB signalling thereby increasing survival of CLL cells residing in 
LN of patients, which was partially inhibited with ibrutinib treatment(319). 
However, expression of various TLRs on the PKCαKR mouse model of CLL has not 
yet been assessed. Therefore, it is possible that there is an increase in stochastic 
TLR signalling with our murine CLL model leading to cre expression and 
subsequent Raptor-excision. Nevertheless, there was a clear excision of Raptor 
in Mx1-Raptor cKO (no poly(I:C) treatment) PKCαKR cells with IFNβ treatment 
which led to a decrease in CLL-disease load with an increasing trend in G0/G1 
phase with a decrease in proliferation in vitro. These data suggest Raptor-
deficiency in B cells and in haemopoietic cells affects CLL progression in a 
similar manner as its role in CLL initiation. 
On the other hand, Rictor-deficiency at the HSC stage, in haemopoietic lineages 
in adult mice, and solely in CD19+ cells in PKCαKR cells led to a CLL-like disease 
with a decline in GFP+CD11b+ myeloid cells in vitro suggesting a redundant role 
of mTORC2 in CLL initiation and lineage commitment. PKCαKR cells with Rictor-
deficiency displayed an increase in migration, a trend in increased cell cycling 
(increased percentage of cells in the S phase), with an increasing trend in Ccnd1 
expression at later stages of disease progression (D21 of culture) compared to 
controls alluding to a role of mTORC2 in disease maintenance. A similar trend 
has been observed in previous studies where there was a decrease in Notch-
driven T-acute lymphocytic leukaemia (T-ALL) progression with Rictor-
deficiency, with an increase in CXCR4 expression causing increased migration 
and homing in the spleen and not the BM, together with an arrest in proliferation 
and cell cycling at the G0 phase via FoxO3 activation(123,320). As our data 
demonstrate an increasing trend in cell cycling and proliferation, this opposing 
trend could be due to the anti-proliferative role of mTORC2 in T cells as 
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compared to in B cells. As chronic BCR activation in CLL has been shown to 
increase RNA translation along with the upregulation of MYC(321), future 
directions of assessing Rictor-deficiency in CLL should include assessing MYC 
levels, a downstream target. 
5.3.2 Role of mTORC1 and mTORC2 in leukaemia progression in 
vivo 
As Mx1-Raptor cKO PKCαKR cells (with prior poly(I:C) inoculation) failed to 
develop disease in vitro, NSG mice were transplanted with Mx1-Raptor control 
or cKO PKCαKR cells (without poly(I:C) inoculation) cultured till D7-10. After 
disease was well established (≥10% disease), the mice were either left untreated 
or inoculated with poly(I:C) doses to induce Raptor-deficiency in the 
transplanted CLL-like disease to assess the role of mTORC1 in CLL progression in 
vivo. There was a significant decrease in disease percentage in the BM and 
spleen together with increased survival in diseased mice with Raptor cKO with 
poly(I:C) inoculation, compared to mice with Mx1-Raptor control PKCαKR cells 
(with no poly(I:C)) suggesting a decrease in disease maintenance with Raptor-
deficiency. However, there was an observed delay in GFP+CD19+ disease 
progression with mice transplanted with Mx1-Raptor control PKCαKR cells 
treated with poly(I:C) suggesting a potential role of poly(I:C) in initiating TLR 
response. TLR in normal B lymphocytes are responsible for identifying virus, 
bacteria and other agents. Therefore, it is possible that TLR activation delays 
disease progression. As TLR signalling in CLL has shown to phosphorylate STAT1 
and STAT3 and activate NFκB signalling and cause subsequent survival of 
CLL(319), it is also possible that poly(I:C) inoculation affects normal and 
leukaemic B cells thereby causing in initial delay in CLL progression, but also 
protecting the murine CLL disease in vivo to an extent. Nevertheless, it was 
reassuring to see no difference in survival between NSG mice transplanted with 
Mx1-Raptor control PKCαKR cells with and without poly(I:C) inoculation. 
Although host mice with Mx1-Raptor cKO PKCαKR cells (with poly(I:C)) had 
increased survival and decreased disease load, these mice did not have a 
complete abrogation in disease and eventually the mice succumbed to a CLL-like 
disease. All mice were sacrificed after their health was compromised due to 
disease progression, and not after a common time point thereby allowing us to 
determine the role of mTORC1 in disease maintenance. Analysis of spleens from 
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Mx1-Raptor cKO PKCαKR cells (with poly(I:C)) at disease end showed a 
significant increase in RAPTOR expression and an increase in p4EBP1T36/T47, 
compared to Mx1-Raptor control PKCαKR cells (no poly(I:C)). This suggests 
‘escaped deletion’(208) of Raptor in Mx1-Raptor cKO PKCαKR cells by poly(I:C), 
leading to a repopulation of disease with Raptor and eventual death of host 
mice. Interestingly, there was a drastic decrease in RICTOR expression in Mx1-
Raptor cKO PKCαKR cells with poly(I:C) inoculation compared to Mx1-Raptor cKO 
PKCαKR cells alluding to possible regulation of RICTOR by mTORC1. Brown et al., 
have shown that mTORC2 negatively regulates TLR response as Rictor-excision 
induces a hyperinflammatory response via TLR activation through FoxO1 
modulation(71). However, it is not known whether TLR activation modulates 
Rictor function via FoxO1 modulation thereby affecting RICTOR expression as 
observed in our results. A similar trend is observed in the Mx1-Raptor control 
PKCαKR cells with poly(I:C) where there is a significant decrease in RICTOR 
expression, suggesting TLR mediated modulation of mTORC2. However, as this 
experiment was performed once, it would be beneficial to perform this again to 
evaluate this further. 
CD19-Raptor control or KO PKCαKR cells were transplanted into NSG mice to 
address the role of mTORC1 solely in CD19+-CLL disease. As the Mx1-Raptor cKO 
PKCαKR cells with poly(I:C) treatment exhibit a decrease in disease load, we 
hypothesised a similar result would be seen in the CD19-Raptor KO PKCαKR 
transplanted mice in vivo. Indeed, we observed a more pronounced increase in 
survival in mice with CD19-Raptor KO PKCαKR cells compared to CD19-Raptor 
control PKCαKR cells. Although there was an increase in survival, these mice still 
died of disease at a later timepoint as seen with an increase in disease load in 
the blood of NSG mice with CD19-Raptor KO PKCαKR cells after 5 wk. When 
assessed further, this was due to re-emergence of RAPTOR expression. These 
data suggest that although Raptor excision can abrogate disease progression, the 
CD19-cre-loxP model was not very efficient in inducing a 100% knockout in CLL-
like cells leading to ‘escaped deletions’ and subsequent re-population of 
disease. This also reiterates that the CD19-cre KO model is not as efficient as 
the Vav- and Mb1-cre models, where CD19-cre model has ≥75% KO efficiency 
compared to Vav- and Mb1- cre with 95% KO efficiency(208), thereby not being 
the ideal KO model for these experiments. 
 179 
 
Previous studies have assessed the role of mTOR in leukaemic settings by 
inducing PTEN loss which leads to myeloproliferative neoplasms (MPN)(322). This 
could be a good model for CLL. Kalaitzidis et al., have demonstrated that Pten-
loss leads to MPN and inducing Raptor loss after MPN using the cre-loxP system 
leads to increased survival suggesting a fundamental role of mTORC1 in disease 
progression(91) as is also seen from our results. Additionally, Rictor deletion 
using the Mx1-cre system in PTEN loss evoked disease resulted in a disruption in 
disease maintenance and prevention of HSC exhaustion in adult, but not 
neonatal mice(93) suggesting a role of mTORC2 in later stages of normal 
haemopoiesis and in disease, similar to our data. 
To determine the therapeutic potential of targeting mTOR complexes 
pharmacologically in CLL, we transplanted a CLL like disease into mice and then 
treated mice with clinically relevant inhibitors of the PI3K/mTOR pathway in 
mice with an established disease to assess leukaemia progression in vivo. 
Ibrutinib, a BTK inhibitor, has been approved as the current first line therapy for 
patients with 17p deletion or TP53 mutation (patients displaying a more 
aggressive form of CLL) after the RESONATE-2 trial (323). AZD2014, the dual 
mTOR complex inhibitor is currently in phase II clinical trials for gastric 
carcinoma(324) and shown promise in other cancers such as breast cancer(325). 
AZD2014, in synergy with ibrutinib has been demonstrated to ablate diffuse large 
B-cell lymphoma (DLBL) cell lines (ABC subtype)(326) thereby making it an ideal 
drug for testing in our CLL model. Mice given combination therapy with AZD2014 
and ibrutinib had a better overall decrease in disease load in the BM and spleen 
as compared to the vehicle controls or single agents, suggesting synergy between 
ibrutinib and AZD2014 in combating CLL(128). Additionally, there was a decrease 
in CD5+ CLL-like cells with combination and with single agents in the BM and 
spleen of mice. CLL population with high levels of CD5 expression are classified 
as the migrating CLL population(156). A recent study has shown a population of 
CLL cells with high IgM expression residing in the LN as compared to those in the 
blood suggesting a functional difference between the two subtypes(309). 
Whether they correlate to the migrating subtype or are different to the 
Calissano model is unclear. However, our results highlight the importance of 
combination therapy in targeting different clonal subtypes of the heterogenous 
disease. 
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Although combination therapy was more efficient in decreasing disease load, 
secondary transplants were performed to assess the efficiency between 
rapamycin (mTORC1 inhibitor) or AZD2014 to assess whether combination 
therapy of ibrutinib with AZD2014 or rapamycin would yield a better outcome. 
We hypothesised that AZD2014, inhibiting both mTORC1 and mTORC2 would be a 
more potent inhibitor than rapamycin alone. However, secondary transplants 
showed a significant difference between the two agents where AZD2014 was 
inferior compared to rapamycin in decreasing disease load in vivo. Our results 
indicate a decreasing trend in splenic cellularity with rapamycin treatment 
compared to AZD2014 and controls. As there is a clear reduction in spleen size 
with rapamycin, it was surprising that this did not co-relate with a significant 
decrease in splenic cellularity. Splenomegaly in CLL is associated with an 
increase in red pulp(327) thereby increasing splenic cellularity. However, all 
total counts of the spleen were taken after enrichment of lymphocytes thereby 
depleting other cell types which could explain the lack of a significant decrease 
in the splenic cellularity of rapamycin treated mice compared to vehicle controls 
and those treated with AZD2014. The pharmacokinetics of both the drugs have 
shown fast absorption with the peak concentration in serum reaching between 
0.5-1 hr when both drugs are given orally. Nevertheless, rapamycin yielded best 
results when the drug was given daily for 2 weeks, whereas AZD2014 inhibited 
phosphorylation of 4EBP1 by -45% and -41% and phosphorylation of S6KS235/S236 by 
-62% and -37% at 2 and 6 to 8 hr after dose compared to baseline respectively. 
As rapamycin has a longer half-life compared to AZD2014 (30 hr compared to 3 
hr)(328,329) , it would have been interesting to test downstream signalling after 
one dose (preferably after 2 hr) of AZD2014 and rapamycin to determine the 
downstream mechanisms.  Our laboratory has recently shown that AZD8055 (a 
drug with the same pharmacophore as AZD2014) is superior to rapamycin at 
reducing CLL in primary transplants(128) thereby suggesting that the disease is 
more aggressive as a secondary transplant and potentially more dependent on 
mTORC1. 
Spleens with a CLL-like disease treated with AZD2014 or rapamycin had no 
changes in RAPTOR or RICTOR expression. However, the phosphorylation of these 
proteins was not tested making it difficult to comment upon the functionality of 
the proteins. Nevertheless, there was a trend in decrease in pAKTS473 with both 
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drugs compared to vehicle controls. It is known that continuous rapamycin 
treatment leads to mTORC2 inhibition in certain cells(330) suggesting that 
rapamycin inhibits mTORC2 as seen by the decrease in downstream AKT 
phosphorylation. Indeed, a phase II trial has shown similar results in patients 
with refractory renal cancer where patients given AZD2014 treatment had a 
shorter progression-free survival (PFS) with an increase in disease progression 
compared to patients given everolimus, a compound derived from 
rapamycin(331). Assessing the mechanism of action of the two drugs would allow 
a better understanding about these findings. Rapamycin binds to FKBP12 and this 
complex allosterically inhibits mTORC1. Rapamycin is known to be a potent 
immunosuppressant as it hinders T cell activity and proliferation along with 
inhibiting antibody production(332). As our host mice are immunocompromised, 
it is unlikely that rapamycin is compromising the microenvironment alluding to 
rapamycin inhibition of mTORC1 downstream the BCR in a CLL-like disease.  
Moreover, we observed a trend in increase in cell cycling genes in the spleens of 
AZD2014 treated mice whereas those treated with rapamycin do not show similar 
trends suggesting that the classical cell cycle arrest mechanism was not engaged 
with rapamycin treatment in decreasing disease load in vivo. Faller et al., have 
shown that in the murine intestinal cancer model, rapamycin treatment caused a 
decrease in cancer cell proliferation (not initiation) independent of the classical 
cell cycle arrest mechanism. They demonstrate a novel mechanism by which 
mTORC1 regulates translation elongation of malignant cells via the S6K-
elongation factor 2 kinase (EF2K)-EF2 axis which, after Raptor-deletion or 
rapamycin treatment, was reversed(333). It would be of great benefit to assess 
this S6K mediated translational elongation in our CLL-secondary transplants to 
determine whether this more aggressive form of disease is increasingly mTORC1 
dependent.  
Taken together, mTORC1 plays a fundamental role in CLL initiation and 
progression in vitro and in vivo whereas mTORC2 has roles in CLL maintenance 
at a later stage in vitro. Although the dual mTOR complex inhibitor, AZD2014 
significantly reduces disease load in mice in primary transplants, and is 
synergistic with ibrutinib in decreasing disease load, AZD2014 is inferior to 
rapamycin in decreasing disease load in secondary transplants. It will be 
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interesting to test whether rapamycin can also exhibit synergy with ibrutinib or 
other drugs in clinics to combat CLL. 
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5.4 Figures 
 
Figure 5.1 BM from adult mice with Raptor-deficiency does not develop into PKCαKR CLL-
like cells in vitro. 
Representative flow cytometry plots showing D7 post retroviral transduction of either GFP-tagged 
MIEV construct of purified CD117+ lymphocyte progenitors from the BM of Mx1-Raptor control (A) 
or cKO (B) mice, or GFP-tagged PKCαKR construct of purified CD117+ lymphocyte progenitors 
from the BM of Mx1-Raptor control (C) or cKO (D) mice dissected 5 wk post 4 poly(I:C) inoculation. 
Plots were live and size (FSC-A/SSC-A) gated, and doublet cells were excluded and were gated for 
GFP+CD45+ before assessing surface expression of CD19+ or CD11b+ populations. Percentage of 
GFP+CD45+CD19+ MIEV (n=2)(E) or PKCαKR CLL-like cells (n=2) (F) from Mx1-Raptor control 
(cre-, blue bars) or cKO (cre+, red bars) mice dissected 3 wk post 3 poly(I:C) inoculation and 
assessed D7, 11, 14, and 18 post retroviral transduction. Data are expressed as mean±SD. 
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Figure 5.2 Raptor-deficiency abrogates B cell lineage commitment and leads to the absence 
of PKCαKR CLL-like cells in vitro. 
Cellularity of GFP+CD19+ population of Mx1-Raptor control or cKO (4 poly(I:C)) MIEV (A) and Mx1-
Raptor control or cKO (4 poly(I:C)) PKCαKR (B) cells over D3 (n=3), 7 (n=6) and 11 (n=6) of 
culture, together with percentage of GFP+CD19+ population of Mx1-Raptor control or cKO (4 
poly(I:C)) MIEV (C) and Mx1-Raptor control or cKO (4 poly(I:C)) PKCαKR (D) cells over D3 (n=5), 
7 (n=9), 11 (n=8) and 14 (n=8) of culture. Percentage of GFP+CD11b+ population of Mx1-Raptor 
control or cKO (4 poly(I:C)) MIEV (E) and Mx1-Raptor control or cKO (4 poly(I:C)) PKCαKR (F) 
cells over D3 (n=5), 7 (n=8), 11 (n=10) and 14 (n=6) of culture. Cre-: Raptor-control samples, cre+: 
Raptor-cKO samples. Data are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p 
****≤0.00001). 
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Figure 5.3 Raptor-deficiency in CD19+ cells leads to decreased proliferation, migration and 
cell cycle arrest of PKCaKR CLL-like cells in vitro. 
A. Representative plot showing CTV proliferation assay performed every 24 hr for 72 hr on CD19-
Raptor control (left) or KO (right) PKCαKR cells at D18 of culture. Bar graphs demonstrating CTV 
MFI ratios of D1/D0 and D2/D0 of CD19-Raptor control (n=2) and CD19-Raptor KO MIEV (n=2) 
cells (B) and CD19-Raptor control (n=5) and CD19-Raptor KO PKCαKR cells (n=3) (C). 
Representative flow cytometry plots (D), together with percentage (E) of AnnV-7AAD- (Live), AnnV+ 
(early apoptotic), 7AAD+ (necrotic cells), and AnnV+7AAD+ (late apoptotic) populations of CD19-
Raptor control (n=3) (left) and CD19-Raptor KO (n=3) PKCαKR cells (right) at D18 of culture. 
Cellularity (F) and percentage (G) of migration of CD19-Raptor control (n=3) and CD19-Raptor KO 
(n=3) PKCαKR cells towards SDF-1 after serum starvation. Negative and positive controls 
represent migration without SDF-1 and 100% migration respectively. H. Percentage of CD19-
Raptor control (n=2) and CD19-Raptor KO (n=2) PKCαKR cells at D18 of culture in G0/G1, S, and 
G2 phases of cell cycling. Cre-: Raptor-control samples, cre+: Raptor-KO samples. Data are 
expressed as mean±SD/SEM (p *≤0.05, p **≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 5.4 The generation of an inducible model of Raptor-deficiency in vitro. 
Bar graphs showing percentage of CD19+GFP+ Mx1-Raptor control or Mx1-Raptor cKO MIEV (A) 
and Mx1-Raptor control or Mx1-Raptor cKO PKCαKR (B) cells at D7 (n=2), 14 (n=4), and 21 (n=3) 
with no poly(I:C) inoculation given to mice. C. DNA agarose gel of a PCR reaction showing 
expression of Raptor in Mx1-Raptor control or Mx1-Raptor cKO (no poly(I:C)) PKCαKR cells 
treated with or without 200U IFNβ for 24 hr and assessed 72 hr post treatment together with Mx1-
Raptor control BM as a reference for Raptor expression. Representative western blot (D) and bar 
graphs showing expression of RAPTOR/tAKT (E), pS6S235/S236/tS6 (F), RICTOR/tAKT (G), 
pAKTS473/tAKT (H) of Mx1-Raptor control or cKO MIEV (n=2) and Mx1-Raptor control or cKO 
PKCαKR (n=4) cells treated with IFNβ and assessed 72 hr post treatment. Cre-: Raptor-control 
samples, cre+: Raptor-cKO samples. Data are expressed as mean±SD/SEM (p *≤0.05). 
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Figure 5.5 CLL-like cells with induced Raptor-deficiency exhibit a block in proliferation in 
vitro. 
Cellularity (n=6) (A) and percentage (n=2) (B) of GFP+CD19+ Mx1-Raptor control or cKO (no 
poly(I:C)) PKCαKR cells, either untreated (UT, light blue and pink bars) or treated with 50U IFNβ 
for D2, D3 or 200U for 24 hr (blue and red bars) and assessed 72 hr post treatment. C. Cellularity 
(n=6) of Mx1-Raptor control or cKO (no poly(I:C)) PKCαKR cells either untreated or treated with 
200U IFNβ for 24 hr and assessed 72 hr post treatment. D. PI staining showing percentage of Mx1-
Raptor control and cKO (no poly(I:C)) PKCαKR cells (n=2), either untreated or treated with 200U 
IFNβ for 24 hr and assessed 72 hr post treatment, in G0/G1, S, and G2 phases of cell cycling. 
Representative plot (E) and bar graphs (F) showing CTV MFI of D0, D1 and D2 performed every 
24 hr for 3 days of Mx1-Raptor control (left) or cKO (no poly(I:C), right) PKCαKR cells (n=6) treated 
with 200U IFNβ for 24 hr (right) and assessed 72 hr post treatment. Cre-: Raptor-control samples, 
cre+: Raptor-cKO samples. Data are expressed as mean±SD/SEM (p *≤0.05, p **≤0.001, p 
***≤0.0001, p ****≤0.00001). 
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Figure 5.6 Rictor-deficiency does not abrogate CLL-initiation in vitro. 
Representative graphs showing proportion of GFP+CD19+ cells of Vav-Rictor control (A) and Vav-
Rictor KO (B) PKCαKR cells at D21 of culture. Plots were live and size (FSC-A/SSC-A) gated, and 
doublet cells were excluded and were gated for GFP+CD45+ before assessing surface expression 
of CD19+ or CD11b+ populations. Cellularity of GFP+CD19+ population of Vav-Rictor control or KO 
at D7 (n=6), 14 (n=3), 21 (n=5) and 28 (n=2) of culture (C), Mx1-Rictor control or cKO (4 poly(I:C) 
inoculation) at D7 (n=6), 14 (n=5) and 21 (n=4) of culture (D), and CD19-Rictor control (n=2) or KO 
(n=2) at D7, 14, 21 and 28 of culture (E) MIEV cells. Cellularity of GFP+CD19+ cells of Vav-Rictor 
control or KO at D7 (n=5), 14 (n=6), 21 (n=7) and 28 (n=3) of culture (F), Mx1-Rictor control or cKO 
(4 poly(I:C) inoculation) at D7 (n=8), 14 (n=7), and 21 (n=7) of culture (G), and CD19-Rictor control 
or KO at D7 (n=2), 14 (n=3), 21 (n=3) and 28 (n=3) of culture (H) PKCαKR cells. Cre-: Rictor-
control samples, cre+: Rictor-cKO/KO samples. Data are expressed as mean±SD/SEM. 
 
 
  
 189 
 
 
Figure 5.7 CLL-like cells with Rictor-deficiency exhibit a decreasing trend in cell count and 
percentage at later stages of culture in vitro. 
Percentage of GFP+CD19+ cells of Vav-Rictor control or KO at D7 (n=7), 14 (n=7), and 21 (n=6) of 
culture (A), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=9), 14 (n=9), 21 (n=5) and 
28 (n=3) of culture (B), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture 
(C) of MIEV cells. Percentage of GFP+CD19+ cells of Vav-Rictor control (n=7) or KO (n=7) at D7, 
14, and 21 of culture (D), Mx1-Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=8), 14 (n=8), 
21 (n=6) and 28 (n=2) of culture (E), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 
28 of culture (F) PKCαKR cells. Bar graphs showing percentage of GFP+CD11b+ cells of Vav-
Rictor control (n=6) or KO (n=6) at D7, 14, and 21 of culture (G), Mx1-Rictor control or cKO (4 
poly(I:C) inoculation) at D7 (n=9), 14 (n=9), 21 (n=5) and 28 (n=3) of culture (H), and CD19-Rictor 
control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture (I) MIEV cells. Percentage of 
GFP+CD11b+ cells of Vav-Rictor control (n=6) or KO (n=6) at D7, 14, and 21 of culture (J), Mx1-
Rictor control or cKO (4 poly(I:C) inoculation) at D7 (n=9), 14 (n=11), 21 (n=7) and 28 (n=5) of 
culture (K), and CD19-Rictor control (n=3) or KO (n=3) at D7, 14, 21 and 28 of culture (L) PKCαKR 
cells. Cre-: Rictor-control samples, cre+: Rictor-cKO/KO samples. Data are expressed as 
mean±SD/SEM. 
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Figure 5.8 Rictor-deficiency at the HSC stage and in adult mice plays a role at later stages of 
CLL in vitro.  
Gene expression of Rictor (n=7), Bcl-2 (n=7), Ccnd1 (n=5), Cdkn1a (n=4), Cdkn1b (n=4) in Vav-
Rictor KO MIEV (blue) and Vav-Rictor KO PKCαKR (pink) cells (A), along with gene expression of 
Rictor, Bcl-2 and Ccnd1 in Mx1-Rictor control (blue, n=3) and KO (pink, n=3) PKCαKR cells (B). 
ΔΔCT calculated by taking Tbp as a reference gene and Vav/Mx1-Rictor control MIEV/PKCαKR 
samples as reference where all samples were cultured till D21 in vitro. Representative western blot 
(C) along with bar graphs demonstrating protein expression ratio of RICTOR/GAPDH (D) and 
pAKTS473/tAKT (E) in Mx1-Rictor control (n=4) and cKO (n=4) PKCαKR cells cultured till D21. Cre-: 
Rictor-control samples, cre+: Rictor-cKO samples. Data are expressed as mean±SEM (p *≤0.05, p 
**≤0.001, p ***≤0.0001, p ****≤0.00001). 
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Figure 5.9 CLL cells with Rictor-deficiency at the HSC stage exhibit increased migration at 
later stages of culture. 
Cellularity (A) and percentage (B) of migration of Vav-Rictor control (cre-, n=2) and Vav-Rictor KO 
(cre+, n=2) PKCαKR cells at D15 together with the cellularity (C) and percentage (D) of migration 
of Vav-Rictor control (n=4) and Vav-Rictor KO (n=4) PKCαKR cells towards SDF-1 after serum 
starvation when cultured for D21 in vitro. Negative and positive controls represent migration without 
SDF-1 and 100% migration respectively. Bar graphs of Vav-Rictor control (n=4) and KO PKCαKR 
cells cultured up to D14 (n=3 Vav-Rictor KO) (E) and D21 (n=2 Vav-Rictor KO) (F) showing CTV 
MFI ratios of D0/D1 and D2/D0 performed every 24 hr for 3 days. Bar graphs of Mx1-Rictor control 
(n=4) and cKO (n=5) (4 poly(I:C) inoculation) PKCαKR cells cultured to D14 (G) and D21 in vitro 
(H) demonstrating percentage of G0/G1, S, and G2 phases of cell cycling. Cre-: Rictor-control 
samples, cre+: Rictor-cKO samples. Data are expressed as mean±SD/SEM (p *≤0.05, p **≤0.001, 
p ***≤0.0001, p ****≤0.00001). 
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Figure 5.10 Raptor-deficiency induced after disease development abrogates CLL-like 
disease in vivo. 
Immunocompromised NSG mice were transplanted with PKCαKR cells and developed disease. 
Representative flow cytometry plots showing proportion of GFP+CD45+CD19+ CLL-like PKCαKR 
cells in the blood of NSG mice which were transplanted with 5x105 Mx1-Raptor control PKCαKR 
cells (A), Mx1-Raptor control PKCαKR cells and given 4 inoculation of poly(I:C) after disease 
development (B), Mx1-Raptor cKO PKCαKR cells (C) and Mx1-Raptor cKO PKCαKR cells and 
given 4 inoculation of poly(I:C) after disease development (D). Plots are live and size (FSC-A/SSC-
A) gated prior to the gating shown. Doublet cells were excluded (FSC-A/FSC-H) and positively 
selected for CD45 before assessing surface expression of GFP+CD19+ population. 
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Figure 5.11 Mice with an established CLL-like disease exhibit a decrease in disease load 
with induced Raptor-deficiency in vivo.  
Data represents transplanted NSG mice with an established CLL-like disease. Spleen weight (mg) 
(A) and spleen (B) and BM (C) organ cellularity of mice transplanted with either 5x105 Mx1-Raptor 
control PKCαKR cells (light blue bar, n=11), Mx1-Raptor cKO PKCαKR cells (pink bar, n=2), Mx1-
Raptor control PKCαKR cells and given 4 inoculation of poly(I:C) after disease development (blue 
bar, n=3), or Mx1-Raptor cKO PKCαKR cells and given 4 inoculation of poly(I:C) after disease 
development (red bar, n=5). Percentage of GFP+CD19+ CLL-like disease (representative, n=3/arm) 
in bloods from weekly tail bleeds (D) and from bloods of sacrificed mice (E) which were 
transplanted with Mx1-Raptor control PKCαKR cells, Mx1-Raptor cKO PKCαKR cells, Mx1-Raptor 
control PKCαKR cells and given 4 inoculation of poly(I:C), or Mx1-Raptor cKO PKCαKR cells and 
given 4 inoculation of poly(I:C). Cellularity (F) and percentage (G) of GFP+CD19+ cells in BM and 
spleen of NSG mice transplanted with either Mx1-Raptor control PKCαKR cells (n=8), Mx1-Raptor 
cKO PKCαKR cells (n=3), Mx1-Raptor control PKCαKR cells + poly(I:C) (n=4) or Mx1-Raptor cKO 
PKCαKR cells + poly(I:C) (n=5). Kaplan-meier survival graphs comparing the percentage survival 
between NSG mice transplanted with Mx1-Raptor control PKCαKR cells with (n=4) or without 
(n=11) poly(I:C) inoculation (H), Mx1-Raptor cKO PKCαKR cells with (n=5) or without (n=7) 
poly(I:C) inoculation (I), and Mx1-Raptor control (no poly(I:C), n=11) and cKO PKCαKR cells given 
poly(I:C) (n=7) after disease development (J). Data are expressed as mean±SD/SEM (p *≤0.05, p 
**≤0.001, p ***≤0.0001, p ****≤0.00001).  
 194 
 
 
Figure 5.12 Mx1-Raptor cKO model is not completely efficient and causes disease relapse 
due to increased Raptor expression. 
Representative western blot (A) and densitometry showing protein expression ratios of 
pAKTS473/tAKT (B), RAPTOR/tAKT (C), p4EBP1T36/T47/t4EBP1 (D), pS6S235/S236/tS6 (E), and 
RICTOR/tAKT (F) in the spleen taken from host mice transplanted with 5x105 Mx1-Raptor control 
PKCαKR cells (n=3) and Mx1-Raptor cKO PKCαKR cells with 4 inoculation of poly(I:C) after 
disease development (n=4). Mice were sacrificed once health of the mice has been compromised 
due to disease. Cre-: Raptor-control, Cre+: Raptor-cKO. Data are expressed as mean±SEM (p 
*≤0.05). 
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Figure 5.13 Raptor-deficiency solely in CD19+ CLL-like cells does not affect CLL-like disease 
initiation in vivo. 
All NSG mice were transplanted with PKCαKR cells and developed disease. Representative flow 
cytometry plots showing proportion of GFP+CD45+CD19+ CLL-like PKCαKR cells in the blood of 
NSG mice transplanted with 5x105 CD19-Raptor control (A) or CD19-Raptor KO (B) PKCαKR cells. 
Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. Doublet cells were 
excluded (FSC-A/FSC-H) and positively selected for CD45 before assessing surface expression of 
GFP+CD19+ population. 
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Figure 5.14 Raptor-deficiency solely in CD19+ CLL-like cells increases survival in CLL-like 
disease in vivo. 
All NSG mice were transplanted with PKCαKR cells and developed disease. Spleen weight (mg) 
(A) and BM and spleen (B) organ cellularity of NSG mice transplanted with 5x105 CD19-Raptor 
control (n=6) or KO PKCαKR cells (n=6). C. Weekly blood samples were taken and assessed for 
percentage of GFP+CD19+ CLL-like disease in mice transplanted with CD19-Raptor control or KO 
PKCαKR cells. D. Kaplan-meier survival graph comparing the percentage of survival between NSG 
mice transplanted with CD19-Raptor control (n=4) or KO (n=7) PKCαKR cells. Cellularity of 
GFP+CD19+ cells in the BM and spleen (E) and percentage of GFP+CD19+ cells in BM, spleen, LN 
and blood (F) of mice transplanted with CD19-Raptor control (n=6) or KO PKCαKR (n=6) cells. 
Representative western blot (G) and protein expression ratio of RAPTOR/GAPDH (H), 
pAKTS473/tAKT (I), and pS6S235/S236/tS6 (J) in the spleen of mice transplanted with CD19-Raptor 
control (n=4) or KO PKCαKR cells (n=2). Data are expressed as mean±SD/SEM (p *≤0.05, p 
**≤0.001). 
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Figure 5.15 CLL-like disease is reduced with a combination treatment of AZD2014 and 
ibrutinib in vivo.  
NSG mice were transplanted with PKCαKR cells and established disease. Representative flow 
cytometry plots showing proportion of GFP+CD45+CD19+ CLL-like PKCαKR cells in the blood of 
mice which were transplanted with 5x105 PKCαKR cells derived from B6.SJL BM and were treated 
with either the vehicle control (captisol+0.5%methylcellulose) (A), AZD2014 (15 mg/kg) (B), 
Ibrutinib (12 mg/kg) (C) or a combination of AZD2014+Ibrutinib (D) once daily for 14 days by oral 
gavage. Plots are live and size (FSC-A/SSC-A) gated prior to the gating shown. Doublet cells were 
excluded (FSC-A/FSC-H) and positively selected for CD45 before assessing surface expression of 
GFP+CD19+ population. 
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Figure 5.16 Combination therapy does not reduce CLL-disease load more efficiently than 
single agents in vivo.  
NSG mice were transplanted with 5x105 PKCαKR cells and disease was established prior to 
commencement of drug therapy. A. Representative picture of spleens from NSG mice with 
established CLL-like disease and treated with either vehicle control (Veh; captisol+0.5% 
methylcellulose, n=5), ibrutinib (Ibr, 12 mg/kg n=6), AZD2014 (AZD, 15 mg/kg, n=5) or a 
combination of AZD2014+ Ibrutinib (Com, n=5). Ratio of spleen weight/total body weight (B) and 
cellularity of BM and spleen (C) in mice with established disease and treated with either the Veh 
(light pink bar), AZD (orange bar), Ibr (turquoise bar) or Com (purple bar). D. Weekly blood 
samples (representative n=3) were taken and were assessed for percentage of GFP+CD19+ CLL-
like disease in mice, treated with Veh, AZD, Ibr or Com. Cellularity (E) and percentage (F) of 
GFP+CD19+ CLL-like cells in the BM, and cellularity (G) and percentage (H) of GFP+CD19+ CLL-
like cells in the spleen of mice treated with either Veh, AZD, Ibr or Com. I. Cellularity of 
GFP+CD19+CD5+ cells in the BM and spleen of mice treated with either Veh, AZD, Ibr or Com. Data 
are expressed as mean±SEM (p *≤0.05, p **≤0.001, p ***≤0.0001). 
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Figure 5.17 Secondary transplants of CLL-like disease are responsive to rapamycin 
treatment in vivo.  
Secondary transplants were carried out with NSG or NRG mice transplanted with PKCαKR cells 
isolated from the spleen of mice with ≥95% CLL-like disease. Representative flow cytometry plots 
showing the proportion of GFP+CD45+CD19+ CLL-like PKCαKR cells in the blood of mice treated 
with either vehicle control (captisol) (A), AZD2014 (15 mg/kg delivered by OG) (B), or rapamycin 
(4mg/kg, delivered intraperitoneally) (C) given once daily for 3 wk. Plots are live and size (FSC-
A/SSC-A) gated prior to the gating shown. Doublet cells were excluded (FSC-A/FSC-H) and 
positively selected for CD45 before assessing surface expression of GFP+CD19+ population. 
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Figure 5.18 Rapamycin is a more potent agent for decreasing CLL-disease load in vivo.  
Secondary transplants were carried out with NSG and NRG mice transplanted with PKCαKR cells 
from the spleen of mice with ≥95% CLL-like disease. A. Picture of spleens from mice with 
established disease and treated with either vehicle control (Veh; captisol, n=8), rapamycin (Rapa, 4 
mg/kg delivered intraperitoneally, n=7) or AZD2014 (AZD, 15 mg/kg, n=9) given once daily for 3 
wk. Percentage of spleen/body weight (B) and total cellularity of BM and spleen (C) in mice with a 
CLL-like disease and treated with either Veh (light pink bar), Rapa (green bar) or AZD (orange bar). 
D. Weekly blood samples (representative, n=3) were assessed for percentage of GFP+CD19+ CLL-
like disease in Veh, Rapa or AZD treated mice. Cellularity (E) and percentage (F) of GFP+CD19+ 
CLL-like cells in the BM and spleen together with the percentage (G) of GFP+CD19+ CLL-like cells 
in the LN and blood of mice treated with either Veh, Rapa or AZD. Data are expressed as 
mean±SEM (p *≤0.05, p **≤0.001). 
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Figure 5.19 A potentially different mechanism of rapamycin in decreasing CLL-like disease 
load compared to AZD2014 in vivo.  
Secondary transplants were carried out where all NSG and NRG mice were transplanted with 
PKCαKR cells from the spleen of NSG mice with ≥95% CLL-like disease. Representative western 
blot (A) and densitometry of protein expression of ratio of RAPTOR/GAPDH (B), RICTOR/GAPDH 
(C), pAKTS473/tAKT (D), and pS6S235/S236/tS6 (E) of the spleens of mice treated with either Veh 
(n=3), Rapa (4 mg/kg delivered intraperitoneally, n=3) or AZD (15 mg/kg delivered by OG, n=2) 
given once daily for 3 wk. Gene expression (log fold change) of Ccnd1, Ccnd2, Ccnd3 (F) and Bid 
and Prkcb (G) in the spleen of mice treated with either Veh (n=3), Rapa (n=3) or AZD (n=2). All 
gene expression data is relative to the vehicle control with Actb as the endogenous reference gene. 
Data are expressed as mean±SEM (p *≤0.05). 
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General Discussion and Conclusions 
Although much is known about the mTOR signalling pathway and its role in 
metabolism and diseases such as diabetes, the exact role of the individual 
complexes, mTORC1 and mTORC2 in normal B cell development and in B cell 
malignancies was not well known. Therefore, my thesis addressed the individual 
roles of mTORC1 and mTORC2 in normal haemopoiesis and in CLL initiation/ 
maintenance and the potential for mTOR as a valid therapeutic target in CLL. 
Using the well-developed cre-loxP KO systems, KO mouse models were generated 
for mTORC1 and mTORC2 excising either Raptor or Rictor respectively at 
different haemopoietic stages giving rise to Vav- (KO at HSC stage), Mx1- (cKO in 
haemopoietic organs) or CD19-cre (KO in B cells) mouse models. Furthermore, 
utilising the PKCαKR retroviral construct which enables the generation of a 
murine CLL-like disease(230), combined analysis of the role of the individual 
mTOR complexes was carried out during leukaemogenesis in vitro and in vivo.  
Generation of mTORC1 KO mouse model confirmed the previous findings that 
mTORC1-deficiency at the HSC stage is lethal at the perinatal stage due to its 
fundamental role in regulating erythropoiesis (97). mTORC1-deficiency leads to a 
block in erythropoiesis at the MEP stage. In agreement with previous literature, 
the results demonstrate the potent role of mTORC1 in B cell development(109), 
as deficiency of mTORC1 (in Vav- or Mx1- mice) leads to a block in B cell 
development at the LSK stage (Chapter 3). While mTORC1 plays a role early in 
development, mTORC2 plays a subtle opposite yet complementary role to 
mTORC1 regulation in haemopoiesis giving both the complexes a yin-yang 
undertone. mTORC2-deficiency leads to aberrations in late B cell populations. 
Where mTORC1 plays a positive role in erythropoiesis, our results suggest a 
suppressive role of mTORC2 as Rictor-deficiency leads to an increase in RBC 
colony capacity. mTORC2 has also shown to play an important role in T cell 
development, as our results demonstrate a drastic decrease in DP T cells and an 
increase in DN T cells suggesting a block in T cell development, which is in 
agreement with previously published data (115)(Chapter 4). 
Whilst assessing the role of mTORC1 and mTORC2 in CLL-like disease initiation 
and/or maintenance, the PKCαKR retroviral construct was used to induce a CLL-
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like disease in the BM of the KO models and their respective controls. Our results 
showed that although mTORC1 and mTORC2 have distinct roles in haemopoiesis 
and leukaemogenesis, both the complexes regulate CLL and normal 
haemopoiesis in a similar manner: mTORC1 plays a fundamental role in CLL 
initiation (due to its role in B cell lineage commitment) in vitro and in vivo, 
whereas mTORC2 plays a role at later stages of B cell development and 
leukaemia alluding to a role in B cell and leukaemia maintenance in vitro. 
Induced Raptor-deficiency in established CLL-like disease led to a decrease in 
migration, proliferation and trends towards decreased cell cycling in vitro with 
an abrogation or a delay in disease maintenance in vivo. While the results 
showing an extension in survival in the PKCαKR CD19-cre mouse model in vivo 
was interesting, we concluded that the CD19-cre mouse models are not ideal as 
a KO model due to the reduced efficiency of cre-recombinase excision in this 
model(208). Therefore, it would be interesting to assess leukaemia maintenance 
in vivo using other efficient KO models such as Mb1-cre KO model (Chapter 5).  
CLL-like disease with Rictor-deficiency led to an increase in migration and trends 
in increase in cell cycling. Although there were trends showing a decrease in 
disease load at later stages of disease in vitro, we did not look into this in great 
detail due to time restrictions of this project. Additionally, the role of mTORC2 
in disease maintenance was not assessed in vivo also due to time restrictions. 
These experiments would be very beneficial in further assessing the exact 
mechanisms by which mTORC2 plays a role in disease maintenance. These 
processes allude to a role of mTORC2 in enhancing microenvironmental signals. 
However, as this cannot be assessed in vivo in NSG mice (highly 
immunocompromised), it would be of great interest to assess whether mTORC2 
maintains CLL by modulating the microenvironment in vitro. 
The opposing trends observed in a leukaemic setting between Rictor- and 
Raptor-deficient PKCαKR cells in vitro was interesting as there are other 
functions that have been assessed that the mTOR pathway regulates such as B 
cell development and erythropoiesis which are also differentially regulated by 
the two complexes where mTORC1 is fundamental for haemopoiesis and mTORC2 
either regulates haemopoiesis at a later stage (B cells) or dampens the 
generation of haemocytes (erythropoiesis)  (Chapter 3)(282). These trends 
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between the two complexes in disease initiation/maintenance, disease migration 
and trends in cell cycling alludes to the feedback loop in the mTOR pathway 
between mTORC1 and mTORC2(66) thereby highlighting the importance of both 
the complexes in the maintenance of both normal haemopoiesis and 
leukaemogenesis. 
Lastly, to test CLL-disease maintenance by using clinically relevant compounds 
targeting the mTOR signalling pathway, we transplanted NSG mice with the 
PKCαKR CLL-like disease to induce a CLL-like disease in vivo. Subsequent 
treatments with AZD2014, ibrutinib, or a combination resulted in a potent 
reduction of disease maintenance with both ibrutinib and AZD2014 suggesting 
dual mTOR inhibition could prove a valid therapeutic target for CLL. Moreover, 
combination therapy on CLL was not additive and did not confer synergy 
suggesting dual mTOR inhibition to be as potent as combination therapy (Chapter 
5). 
As mTORC1 has shown to play a fundamental role in disease initiation and 
maintenance, it was important to address the role of rapamycin in disease 
maintenance. To test this, secondary transplants were carried out to generate a 
more aggressive CLL-like disease in host mice which were subsequently treated 
with either rapamycin or AZD2014, to test whether only mTORC1 inhibition is 
sufficient for disease attenuation as opposed to using the dual mTOR complex 
inhibitor AZD2014. Despite the known role of rapamycin in partially inhibiting 
mTORC1 (partially inhibits 4EBP1 activity, but a potent inhibitor of S6K), 
rapamycin was superior to AZD2014 in reducing disease load in host mice 
(Chapter 5). This suggests that an aggressive disease is more mTORC1 
dependent, as our previous studies comparing rapamycin and AZD8055 (dual 
mTOR complex inhibitor with the same pharmacophore as AZD2014) in disease 
maintenance resulted in a superior effect of AZD8055 in primary 
transplants(128). This has led us to consider that another target of rapamycin in 
the mTOR pathway could potentially regulate disease: S6K. Previous research 
has shown the role of S6K in driving colorectal cancer through the mTOR-S6K-
EF2K axis in regulating translational elongation and thus disease 
maintenance(333). It would be interesting to test the mTORC1-substrate profile 
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in this aggressive CLL-like disease and compare the sensitivity of rapamycin and 
AZD2014/AZD8055 on these targets. 
Therefore, future directions would be to re-examine the role of mTORC1 in CLL-
like disease initiation/maintenance by using an alternative B cell promoter for 
the cre-LoxP mouse model. Instead of utilising the CD19-Raptor KO model, 
assessing another promoter which is more effieinct at Raptor deletion such as 
the Mb1-Raptor KO model would give a clearer insight into the role of mTORC1 
in disease progression. Moreover, perfoming secondary transplants of a WT CLL-
like disease led to the finding that Rapamycin is more superior than AZD2014 in 
decreasing disease load in NSG mice suggesting a more aggressive CLL-like 
disease is mTORC1 dependent. Therefore, re-performing this experiment to 
assess further downstream mTORC1 targets such as EF2 and EF2K by IHC on 
spleen and assessing the expression levels of these targets at the protein and 
message level on the haemopoietic organs (BM and spleen) of these mice would 
help answer whether translation events are attenuated in this more aggressive 
CLL-like disease. 
Future directions further assessing the role of mTORC2 in CLL would include 
performing transplants of PKCαKR CLL-like cells transformed from Vav-Rictor KO 
BM into NSG mice and assessing disease maintenance by evaluating survival and 
assessing downstream mTOR targets by IHC on the spleens which include 
pAKTS473, pS6S235/S236. Additionally, at the end of the project, RNA-sequencing of 
MIEV and PKCαKR cells (transformed from Vav-Rictor control or KO BM) was 
performed after co-culturing these cells till D21 (mimicking later stages of 
disease progression). Initial sequencing results showed the intriguing 
downregulation of Proopiomelanocortin (POMC) in Vav-Rictor KO PKCαKR 
datasets compared to controls. Therefore, future directions would include 
further assessing these results by qPCR via assessing various POMC variants in 
PKCαKR cells, and with dual mTORC inhibition. This could also be assessed in 
human CLL patient sample cells treated with AZD8055/AZD2014. It has recently 
been known that POMC is expressed in B lymphocytes(334), and therefore would 
be an interesting experiment to further determine the exact role of mTORC2 in 
the maintenance of late stages of CLL. 
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Taken together, we highlight the opposite and complementary roles of mTORC1 
and mTORC2 in haemopoiesis and in leukaemogenesis where mTORC1 playing a 
fundamental developmental role and mTORC2 regulating later stages of B cell 
lineages and leukaemia. Additionally, we demonstrate a synergistic effect of the 
dual mTOR inhibitor AZD2014 and ibrutinib in decreasing CLL-like disease in vivo. 
Lastly, although dual mTOR inhibition has previously shown to be more potent at 
reducing disease load compared to rapamycin in vivo, our results showed a 
significant superior role of rapamycin in reducing disease load in a more 
aggressive form of leukaemia suggesting that the disease becomes more 
dependent on mTORC1 for the maintenance on disease. 
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